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Summary
Over 600 chronic hepatitis B virus (HBV) carriers were identified in The Gambia. 142 families 
with multiple affected siblings were recruited for this study. The prevalence of HBsAg carriage 
in siblings of the carriers was significantly higher than in normal population with the same 
exposure rate to the HBV infection, which could be considered as the sign of the family 
clustering of the disease. Significant correlation between birth order of a sibling and the risk of 
becoming a carrier was found. Relatively low prevalence in mothers of HBV carriers in these 
families was suggestive that mother to child HBV transmission did not play a major role. The 
index cases have been assumed to come from within a family unit or from sources outside an 
immediate family, such as other families or inhabitants of the same compound or village. I have 
attempted to define these routes of HBV transmission by phylogenetic analysis of sequences 
from the entire HBV pre core/core and surface gene regions. Pre core/core gène sequences were 
found to be more informative for this purpose. Despite the overall conserved nature of the pre- 
core/core sequences, distinct clusters with high bootstrap support were easily defined at the 
family and village level, but not on the wider geographical distribution level. Over one third of 
the families studied had a strong evidence of intrafamilial HBV transmission. Therefore 
clustering of HBV infection in the Gambian families was confirmed with epidemiological data 
and the hypothesis on horizontal HBV transmission between West African children for the first 
time was supported by sequencing data and phylogenetic analysis. A large number of unique 
Gambian HBV core promoter/pre-core/ core and surface gene sequences were obtained and their 
molecular characteristics described. The analysis also revealed for the first time that HBV 
genotypes A and E circulate in The Gambia, with the clear predominance of the latter.
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1 Summary
Over 600 chronic HBV carriers were identified during my work in The Gambia. 142 
families with multiple affected siblings were recruited for this study. The prevalence of 
HBsAg carriage in siblings of the carrier was significantly higher than in a normal 
population with the same exposure rate to the infection, which could be considered as the 
sign of the family clustering of the disease. The transmission of hepatitis B virus (HBV) in 
West Africa was previously shown to occur during the first two years of life. Relatively 
low prevalence in mothers of the carriers in these families was suggestive that the mother 
to child transmission did not play a major role. The index cases in such events have been 
assumed to come from within the family unit or from sources outside the immediate 
family, such as other families or inhabitants of the same compound or village. I have 
attempted to define these routes of transmission by phylogenetic analysis of sequences 
from the entire pre-core/core region of the virus and sequences from the surface gene 
region. With surface gene sequences analysis did not seem feasible because of the highly 
conserved nature of the sequences. Precore/core gene sequences were found to be more 
informative. Despite the overall conserved nature of the sequences, distinct clusters with 
high bootstrap support were easily defined at the family and village level, but not on a 
wider geographical separation. Over one third of the families studied had a strong evidence 
of intrafamilial transmission.
Therefore the family clustering of HBV infection in Gambian families was confirmed with 
epidemiological data and the hypothesis on horizontal transmission of the virus in West 
Africa was for the first time supported by sequencing data and phylogenetic analysis. A 
large number of unique Gambian HBV S and C gene sequences were obtained and their
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molecular characteristics described. The analysis also revealed for the first time that 
genotypes A and E circulate in The Gambia, with the latter predominating.
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2 Introduction
2.1 General background o f the s tu d y
Hepatitis B is one of the most common, serious infectious diseases in the world More than 
350 million people worldwide are chronic carriers (Lee, 1997). The World Health 
Organisation estimates that the infection leads to more than one million deaths every year. 
Each year approximately 300 000 people will become infected with the Hepatitis B virus 
(HBV). HBV is believed to cause as much as 80% of the global hepatocellular carcinoma 
(HCC) cases and to be second to tobacco as an environmental carcinogen.
Although there is an effective vaccine for the prevention of HBV, it is of no value to those 
already infected. Evidence for usage of the conventional HBV vaccine for treatment is 
inconclusive. While treatments are currently available for the chronic infection, these have 
considerable limitations in terms of treatment efficacy. The cost, patient compliance and 
administration of both the treatment and preventative therapy for HBV infection can make 
attainment of lower prevalence rates using present resources, an expensive and difficult 
project. The aim now must be to develop more cost effective vaccines and treatment that 
can be used in developing countries.
The work carried out for this thesis is part of a larger collaboration between Professor 
Adrian Hill’s group in Oxford University, Professor Howard Thomas group in Imperial 
College School of Medicine at St.Mary’s, London and Roche Discovery Ltd ( 
Welwyngarden City). The aims of this collaboration were to investigate the genetic 
determinants of susceptibility to persistent infection and disease with HBV. For these 
genetic family studies a cohort of sibling pairs who were persistently infected with
17
hepatitis B were recruited. The thesis focuses on the epidemiological, serological and 
molecular aspects of family clustering of HBV infection in The Gambia
2.2 Hepatitis B virus
2.2.1 Viral genome
HBV belongs to a group of hepatotropic DNA viruses (hepadnaviridae) that include the 
woodchuck, ground squirrel, Peking duck and heron hepatitis viruses.
The infectious Dane particle has a diameter of about 42 nm and is composed of a lipid 
bilayer envelope containing hepatitis B surface antigen (HBsAg) and an internal 
nucleocapsid. The nucleocapsid, which consists of the core protein, contains the DNA 
genome of the virus, which is between 3182 and 3221 bases long and partially double
i 1 ■
stranded with ah associated DNA polymerase/reverse transcriptase (Tiollais et al, 1981). 
The numbering of the bases starts in most publications at the cleavage site for the 
restriction enzyme EcoRI or at homologous sites if a particular genome type does not have 
such an EcoRI site.
The HBV genome has four opening reading frames (ORFs), which are encoded by the 
same DNA strand. The genomes of hepadnaviruses seem to have evolved towards minimal 
length. The genome is not much longer that it’s longest ORF P, which encodes the viral 
DNA polymerase and its accessory functions. ORF S encodes the three HBsAg proteins. 
ORF C encodes the HBeAg protein and HBeAg protein, whilst ORF X encodes the X 
protein.
18
2.2.1.1 Viral proteins
2.2.1.1.1 Envelope proteins (HBsAg, Pre-S 1, Pre-S2)
The envelope proteins ( pre-S 1, pre-S2 and S) are encoded by the PreS/S gene. The 
HBsAg proteins are synthesised and assembled at the membrane of the endoplasmic 
reticulum and bud into the lumen . From the ER the particles are transported to the cell 
membrane where they are released by vesicles. Excess HBsAg occurs abundantly in serum 
as small (22nm) spherical or filamentous, non-infectious particles. In natural infection, the 
ratio of non-infectious HBsAg particles to virions is about 1000 to 1. Three different 
HBsAgs are synthesised: the large HBsAg (encoded by the pre-S 1, pre-S2 and S genes), 
the middle HBsAg (encoded by the pre-S2 and S genes) and the major HBsAg (encoded by 
the S gene) (Tiollais et al, 1985). The S gene region, encompassing roughly codons 124 to 
147 encodes the highly immunogenic “a” determinant. This epitope induces virus 
neutralising anti-HBs response after natural infection (Waters et al, 1992) or vaccination 
(Halliday et al, 1992).
2.2.1.1.2 HBeAg and HBeAg
The C ORF contains two in-frame initiation codons. Initiation of translation of the first one 
results in the production of the PreC/C protein from which the soluble HBeAg protein is 
derived, following proteolytic processing of its amino and carboxyl termini. The first 19 aa 
of the precore constitute a signal peptide, which is removed by signal peptidases at the ER 
membrane. The remainder of the protein is released into the lumen where it undergoes 
further processing of its carboxyl end and what remains is the HBeAg, which is released 
into the serum.
Initiation of translation at the second AUG results in protraction of the nucleocapsid 
protein of the virus of HBeAg.
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2.2.1.1.3 Viral DNA polymerase/reverse transcriptase
ORF P overlaps with ORF C and ORF S and covers almost the entire length of the 
genome. This encodes the DNA polymerase of the viruses, which fulfils several functions: 
reverse transcription, priming of DNA synthesis, DNA polymerase activity, and RNase H 
activity.
2.2.1.1.4 HBxAg .
The fourth ORF encodes the small protein X. The main function of X is thought to be as 
transcriptional activator and it has been shown to transactivate a number of cellular and 
viral promoters (Rossner et al, 1992). The X region overlaps'with the Enhancer II/ core- 
promoter region, which directs the transcription of precore/core sequences and is essential 
for the production of pregenomic RNA.
2.2.L2 Genotypes and subtypes
Seven genotypes A-G of HBV, which differ by more than 8% in protein homology, have 
been identified (Okamoto et al, 1988; Norder et al, 1994; Stuyvef et al, 2000). A difference 
in protein sequence of 4% at the level of the S gene is considered to be sufficient to 
differentiate between genotypes (Norder et al, 1992).
At present the clinical value of genotyping and subtyping is uncertain, but there are 
indications suggesting that genotyping may be of clinical importance. A Japanese study 
showed that severe liver disease is more common in carriers with subtype adr (genotype 
C) than in those with adw (mainly genotype B in Japan) (Shiina et al, 1991). Swedish data 
associate C-1858 strains with more severe liver damage (Lindh et al, 1996). Another study 
showed that patients infected with genotype A responded better to interferon therapy
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(Zhang, 1996). A Spanish study found that patients with genotype D are more likely to 
have persistent HBV infection by selection of pre-core mutants (Rodriguez-Frias et al, 
1995). Genotypes B and C, which are dominant in high-prevalence areas in East Asia, may 
be associated with prolonged HBeAg carriage and vertical transmission. In contrast, 
horizontal transmission is more important in sub-Saharan Africa and the Mediterranean 
area where genotypes A, D and E are common. Finally, a recent study associated genotype 
C with more severe liver disease and genotype B with the development of HCC in young 
Taiwanese (Kao et al, 2000).
LOOP
137
139 ( tT ) 124
122
d —► K w —► K
? R r R
/ - - i :  .
Figure 1. Structure of the a determinant of the HBsAg . (Karayiannis, personal 
communication)
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HBsAg cames a group-specific determinant a, common to all subtypes of this antigen; and 
two additional subtypic determinants, d 01 y  and w or r, depending on the amino acids in 
position 122 and 160 (See figure 1)., As a result,-four major subtypes of HBsAg are 
recognised; adw{¥. in positions 122'and 160), adr (K in 122, R in 160), ayw{R in 122, K 
in 160) and ayr (R in 122, R,in 1601 (Le Bouvier et al, 1971; Bancroft et al, 1972). With 
the description of 4 sub-determinants,(Sandler et al,, 1978) of w and with identification of 
the g determinant (Magnius et al, ; 1975) the number of subtypes increased to nine: 'aywl, 
ayw2, ayw3, ayw4, ayr, adw2, adw4, adrq- and adrq+. , v  -
Little is known about the distribution of HBV genotypes and subtypes in West Africa. A 
vaccine escape mutation from Lys to Glu at position 141 has been reported from West 
Africa (Devi-Karthigesu et al, 1994). This mutant has only been found in association with 
ayw4 subtype and genotype E. Other viral genotypes apart from E from West Africa have 
not been described (Lindh et al, 1997), but there are many reports about high prevalence of 
genotypes A (serotype aywl) and D in other parts of Africa (Norder et al, 1993).
Sequencing of the a determinant region of the S gene is sufficient for determining viral 
genotype and subtype. Classification of HBV genomes on the basis of the sequence of the 
S gene alone is feasible, because such results are in agreement with the previous 
classification based on the complete genome (Norder, 1993).
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Genotype Subtype Geographical
distribution
A adw2 Europe, USA
A aywl Africa
B adw2 Asia, Pacific
B aywl Asia, Pacific
C adr/ayr Asia, Pacific
C adrq- Asia, Pacific
D adrq- Mediterranean
D ayw2/3 India
E ayw4 West Africa
F adw4q- America
G Adw2 America, Euçope
. Tablel. Geographical distribution of HBV subtypes versus genotypes.
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2.2.1.3 HB V mutants
The accumulation of viral mutants depends on their generation rate and on the advantage 
granted to the virus. HBV, in spite of high replication efficiency with daily production of 
1 0 11 circulating virus particles per day, shows the rate of mutant generation lower than 2 x 
104 base substitutions/site/year (Girones et al, 1989). The structure of the HBV genome 
with multiple overlapping ORFs reduces the number of viable mutants and the fate of their 
production. Mutations occur randomly along the HBV genome, and the selection of one 
over the others warrants a biological advantage to the prevalent mutation during the 
replication cycle of the virus or a selective advantage to the mutant over wild type virus in 
host-virus interactions (Oldstone et al, 1991). *
2.2.1.3.1 Surface gene mutants. '
The envelope proteins of HBV are targets of both humoral and cellular immune responses 
that are involved in viral clearance, and anti-HBs antibodies show neutralising activity. As 
a consequence, envelope proteins have been used in the prophylaxis of HBV infection for 
preparation of the vaccines. However, HBV infection in children after receiving full 
vaccination has been described.
Most of the described vaccine escape eases had a mutation from glycine to arginine at 
aminoacid positions 145 of the HBsAg, within the second loop of the a determinant 
(Carman et al, 1990). This mutation has also been found in liver transplant patients given 
monoclonal anti- HBs (McMahon et al, 1992). Another mutation in residue 141 associated 
with breakthrough infection has been described in The Gambia (Fortuin et al, 1994). Both 
these mutations occur at the second loop of the a determinant (see figure 1). Other 
mutations have been seen in the a determinant in positions aa 124, 129, 131, 137, 140
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(McMahon et al, 1992), but they do not seem to have clinical importance, though 
substitutions T126S and Q129H have also been shown to exhibit various degrees of altered 
binding of HBsAg to several monoclonal antibodies (Chiou et al, 1997; Coleman et al, 
1999; Seddigh-Tonekaboni et al, 2000). There is a limited information about the 
prevalence of these escape mutations in the population at large. It is not clear whether the 
changes arise during the course of breakthrough infections or whether the original 
inoculum consists of a pool of HBVs that includes the HBV variant. A recent study from 
Taiwan showed that after mass vaccination the prevalence of a determinant mutants in 
HBV-DNA positive vaccine escape children increased from 7,8% in 1984 to 28*1% in 
1994 (Hsu et al, 1999).
Recently vaccine escape mutants with changes located outside the a determinant have been 
identified in 6 immunised Singapore infants (Chong-Jin et al, 1999). The significance of 
these mutants is suggested by the decreased binding of some of them to a determinant- 
specific monoclonal antibodies.
Detection of HBV unable to produce pre-S2 protein is not a rare event in chronic HBsAg 
carriers. Double nucleotide mutation in the start codon of the PreS region prevents the 
synthesis of the protein (Pollicino et al, 1995). One study also showed frequent association 
of pre-S2 defective virus with fulminant hepatitis (Pollicino et al, 1997).
Truncated integrated pre-S2/S gene sequences have a transcriptional transactivator 
function and appear to be associated with the development of HCCs (Kekule et al, 1990).
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A few patients have been identified who have mutations in the S gene sufficient to prevent 
normal production of HBsAg despite detectable DNA levels. Insertions of six and nine 
nucleotides that prevented HBsAg production were also reported (Hou et al, 1995).
In iimiiunosupprcsscd virus carriers deletions in the pre-Sl region removing the pre-S2 
initiation codon and creating a premature termination codon in the pre-Sl and S region 
were described (Preikschat et al, 1999).
2.2.1.3.2 Mutations in core promoter regain
The core promoter region of the HBV genome regulates transcription of the pre-core and 
pregenomic mRNAs encoding HBeAg and HBcAg. The ntl?62 A to T and ntl764 G to A 
double mutation in the basal core promoter (BCP) of the HBV genome appears to arise 
during chronic infection (Kaneko et al, 1995; Kidd-Ljunggren et al, 1995; Laskus et al, 
1995) and to become the dominant quasispecies, indicating that there may be a selective 
advantage for it over wild type viruses, possibly due to enhanced viral replication. This 
mutation has been observed regardless of the HBeAg status and clinical presentation, in 
chronic infection and has been associated with fulminant hepatitis (Laskus et al, 1995; 
Nagasaka et al, 1998) and hepatocellular carcinoma (Baptista et al, 1999).
Further mutations in the core promoter region affecting nt 1766 C to T and nt 1768 T to A 
were described in a cluster of cases of fulminant hepatitis B. These mutations led to a 15- 
fold increase in replication as a result of enhanced viral encapsidation of pregenomic RNA 
into the core particles (Baumert et al, 1998). These mutations were found also in 12 out of 
14 Chinese patients with HCC (Fang et àl, 1998). One patient had a deletion in this region.
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2.2.1.3.3 Pre-core and core mutants and deletions
The presence of HBeAg in the serum of hepatitis B surface antigen- positive patients is 
conventionally considered to be an indicator of active viral replication and indicate high 
levels of infectivity. Pre-core mutations that abolish HBeAg expression without a 
concomitant cessation in viral replication have been described. A guanine to adenine 
transition at nucleotide 1896 of the pre-core region, resulting in translation stop codon, is 
the mutation that most often prevents HBeAg expression (Carman et al, 1989). This 
mutation is present in almost all patients with anti HBe-positive HBV DNA-positive 
chronic hepatitis in Italy, Greece, Bulgaria, Spain and Japan and is thought to be associated 
with more severe disease (Dienes et al, 1995). Less often it has been described in North 
America, France, UK and China. Pre-core mutations have been associated with fulminant 
hepatitis. Epidemics of fulminant hepatitis caused by hepatitis B virus pre-core mutants 
have been described (Liang et al, 1991; Stemeck et al, 1998), but other similarities of these 
viral strains in different epidemics have not been observed, so it is difficult to say that 
certain mutants cause fulminant hepatitis. De novo infection with variant showing a defect 
in HBeAg and pre-S2 protein synthesis, but not a high replication competence has been 
described in fulminant disease in infants (Stemeck et al, 1998).
There are no data available on prevalence of pre-core mutations in West Africa, but South 
African study suggests a large variety of HBV genomes in Africa (Kramvis et al, 1997). 
Out of 57 HBV-DNA positive samples (42 HBeAg-negative, 15 HBeAg-positive) 10 
carriers had virus with mutations preventing HBeAg synthesis. The 1896 stop codon 
mutation occurred alone only in 1 HBeAg negative carrier. One HBeAg-negative and 3 
HBeAg-positive patients carried mixed populations of wild type virus and 1896 mutant. 
Mutations of the pre-core initiation codon (1814-1816) were found in 4 HBeAg negative
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carriers and 1 HBeAg-negative carrier had a nonsense mutation at position 1874. It 
remains possible that these findings were associated with viral genotype. Genotype A is 
common in Africa and it is known not to be associated with the 1896 stop codon 
mutations. In genotype A, the 1896 mutation mutation coexists with a second mutation (C- 
->T at position 1858 in codon 15), and both mutations are paired in the secondary structure 
of the RNA encapsidation signal, which can explain the rare presence of pre-core mutants 
in this genotype (Rodriguez-Frias et al, 1995).
HBc mutations are found rarely in HBeAg positive patients with asymptomatic disease. 
Changes in amino acid sequences away from consensus are. most frequent in anti-HBe 
positive persons or patients with severe chronic or fulminant hepatitis. Core genes in 
HBsAg-pocitivc Japanese chronic hepatitis patients had more amino acid substitutions or 
deletions than those without disease (Ehata et al, 1992).
The core gene possesses both humoral and cytotoxic T cell (CTL) epitopes (Bertoletti et al, 
1991). Mutations within a cytotoxic T-cell epitope of the viral nucleocapsid protein have 
been shown to abrogate or antagonise the T-cell response to HBV and lead to viral 
persistence (Bertoletti et al, 1994). In cross-sectional studies, representing accumulated 
variability over time and many different clinical situations, mutations were found 
significantly more frequently in known HBc T helper cell and B cell epitopes (Carman et 
al, 1995) than in interepitope regions, implying that they can be result of immune selection 
or have some growth advantage. New dominant variants with changes within B and CD4+ 
cell epitopes occurring during the course of disease were detected during occasional 
exacerbations in a chronic carrier (AJexopoulou et al, 1997). In another follow up study of 
anti-HBe seroconverters who went into remission, mutations occurred in the CD4+
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epitope, but for patients with ongoing disease mutations were most likely to be found in B 
cell epitopes (Carman et al, 1997). In those who remit, mutations in the major CD4+ cell 
epitope may allow immune escape, thus minimising immune-mediated hepatitis (Carman 
et ai, 1997). Whether mutations in B and Th cell epitopes are a cause or an effect of disease 
are entirely unresolved.
Deletions in the HBV core gene have been described and often were associated with severe 
liver damage (Ehata et al, 1992). HBV variants with core gene deletions are thought to 
inhibit HBV replication, do not persist in preference to wild-type HBV and do not confer 
resistance to interferon-alpha treatment (Marinos et al, 1996). Recently, a number of 
deletions in core region were described in immunosuppressed patients (Preikschat et al, 
1999). »•
2.2.1.3.4 Polymerase gene.mutants
The HBV genome encompasses four overlapping ORFs with the polymerase gene 
overlapping the envelope gene in its entirety. As a result, mutations in the catalytic domain 
of the polymerase gene can affect the aminoacid sequence of the HBsAg and vice versa. In 
particular, the genetic sequence for the a determinant (Carman et al, 1997), actually 
overlaps the major catalytic regions of the viral polymerase protein from amino acid 454 to 
524 and known as domains A and B (Aye et al, 1997). Surface gene mutants associated 
with mutations in the polymerase gene after treatment with lamivudine or famciclovir have 
been described. .
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2.2.2 Molecular evolution of HBV genome
2.2.2A  Evolution in different populations and phylogenetic analysis 
The evolutionary origins of HBV are unclear. The long infectious period and transmission 
routes do not require large host populations to establish an infection. It has been suggested 
that the divergence of the viral genotypes may reflect the migration of human population 
over the last 100000 years (Norder et al, 1994).
The most recent studies on the origin of HBV have employed the phylogenetic tree 
approach. Analysis using the neighbour-joining method and the unweighted pair-grouping 
method was done on 27 samples from different HBV subtypes (Mizokami et al, 1997). 
Phylogenetic trees for five regions: PreS, S, X, C, and P were constructed. The most 
frequent synonymous substitutions per nucleotide site were observed in the non- 
overlapping parts of the P and C genes. The hypothesis that the evolution of HBV was 
constrained by the overlapping genes was suggested, and thus the rate of evolution of HBV 
is slower than in other viruses.
Similar observations were made earlier by another group (Yang et al, 1995), using the 
maximum likelihood method on 13 complete HBV genomes. The variation in nucleotide 
conservation was not random around the HBV genome. Interestingly, genetic relatedness 
between serotypes was not observed.
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A New World origin of HBV was first suggested in 1997 (Bollyky et al, 1997), A 
subsequent study using phylogenetic analysis with maximum-likelihood (ML) and 
neighbour-joining (NJ) bootstrap analysis on 39 complete genome sequences supported 
this hypothesis (Bollyky et al, 1999). It also showed, that African primates may have 
acquired infection from humans.
Phylogenetic trees can also be used to trace the dynamics of viral transmission within 
small populations. Several point source outbreaks of other viral infections have been 
investigated using these methods. For example, phylogenetic tree analysis of HCV 
sequences obtained after transmission of anti-rhesus D immunoglobulin (Ig) in Ireland 
provided conclusive evidence that certain infected batches of the preparation were 
responsible for the cluster of cases seen (Power et al, 1995). An epidemiological 
investigation indicated that six patients treated in a haematology unit who developed acute 
hepatitis B may have been infected as a result of contamination of a liquid nitrogen bone 
marrow storage tank This hypothesis was supported by analysis of nucleotide sequences 
(Hawkins et al, 1996). In another study, phylogenetic trees of HIV sequences were used to 
show that a group of patients was possibly infected by a dentist in Florida (Ou et al, 1992). 
As far as I know, phylogenetic studies on outbreaks of HBV infection have not been done.
It is well known that the Pre-core/Core regions are the most variable in the HBV genome. 
In this respect, phylogenetic analysis of these regions would be most appropriate. ML and 
NJ bootstrap analysis are the currently recommended tools for phylogenetic analysis 
(Bollyky et al, 1999).
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2.2.2.2 Evolution of the genome within the host
Unfortunately, very few longitudinal studies of molecular sequences in HBV carriers have 
been reported so far. The limited data that is currently available suggest that most of the 
mutations occur during periods of increased immune pressure, around the time of HBeAg 
seroconversion and during exacerbations of chronic hepatitis.
During chronic HBV infection, patients with HBeAg frequently seroconvert to anti-HBe 
(Realdi et al, 1980). This has been associated with the occurrence and prevalence of 
precore-defective mutants. Several years are required for complete replacement of wild- 
type viruses by mutants (Aye et al, 1994; Uchida et al, 1994). A study of 26 Japanese HBV 
carriers showed that the number of amino acid changes in the core region in HBeAg 
negative carriers (5.9+/-3.S) was significantly higher than that in the HBeAg positive 
carriers (1.5+/-1.0) (Karasawa et al, 1997). 95% of HBeAg negative samples in this study 
contained pre-core stop codon mutations. Another group in Chinese patients reported 
similar findings over a period of four years (Bozkaya et al, 1996).
In HBeAg positive samples a very high degree of conservation of the pre-core/core region 
can be maintained for a long time period. Completely identical nucleotide sequences were 
present in Chinese family members over a 20-year period and after perinatal transmission 
(Bozkaya et al, 1997). Similar observations were made on Vietnamese and Turkish 
families (Hannoun et al, 2000). Some sequences did not change over 20-30 years. In one 
out of seven Japanese patients followed up for 7 years, the virus sequence remained the 
same during this time (Uchida et al, 1994),
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2.2.3 Vaccines
Prevention of HBV infection is the most effective weapon for its control.
The first licensed hepatitis B vaccine consisted predominantly of purified 22-nm particles 
derived from plasma of chronic carriers. This vaccine was shown in a controlled trial in 
American homosexual men to be at least 95% effective (Szmuness et al, 1980).
The limited availability of infected human plasma and the possible risk of HIV infection 
led to the development of a recombinant vaccine prepared from antigen expressed in the 
yeast Saccharomyces cerevisiae. This vaccine was shown to be equally effective (Stevens 
etal? 1987).
Currently both types of vaccine are available and plasma vaccine cost is down to 60 cents 
per injection. Vaccination against hepatitis B is shown to be cost effective in prevention of 
HCC and chronic liver disease and it is recommended by WHO.
New DNA vaccination approaches are still under development for both prevention and 
treatment of chronic HBV infection (Encke et al, 1999).
2.3 Transmission of hepatitis B virus
2.3.1 Modes of transmission
Percutanous exposure to blood, sexual transmission, perinatal transmission and horizontal 
transmission through close physical contact account for almost all HBV infections in 
humans. Studies in animals support these observations. Primates have been experimentally 
infected with HBV by inoculation of blood, semen, and saliva (Alter et al, 1977; Bancroft 
et al, 1977}. Intranasal or peroral administration of saliva failed to infect chimpanzees and
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gibbons. Infection by faeces, urine, tears and breast milk has never been demonstrated 
although HBsAg or HBV particles have been detected in such fluids
2.3. L I  Percutaneous and parenteral transmission
Transmission of the infection may result from accidental inoculation of small amounts of 
blood or contaminated fluid during medical, surgical or dental procedures, immunisation 
with inadequately sterilised syringes and needles (Seeff et al, 1987), intravenous and 
percutaneous drug abuse, tatooihg, ear piercing, and accidental inoculation with razors that 
have been contaminated with blood. Infected health care workers can also be a significant 
source of infection (Rimland et al, 1977).
\ . . ■ • ■
Before blood screening was introduced, in developed countries disease was thought to be 
acquired mostly by transfusion of blood or other contaminated blood products. Prevalence 
rates of hepatitis B were highest in haemophilic patients who previously received blood- 
clotting components.
2.3.1.2 Sexual transmission
HBV infection in spouses of carriers has been described (Henigst et al, 1973; Berris et al, 
1973). In one study six (18%) of 34 spouses of HBsAg positive carriers observed for at 
least 4 months developed clinical hepatitis, and asymptomatic infection was detected in an 
additional 16% followed for 7 months or longer. In only two of 136 other family members 
subclinical infection was detected (Mosley et al, 1975). Exposure to infected semen and 
menstrual blood during sexual intercourse is suspected to be the source of infection (Alter 
et al, 1977; Inaba et al, 1979).
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The sexually promiscuous, particularly male homosexuals are thought to be at higher risk 
of infection with HBV (Fulford et al, 1973; Coleman et al, 1977; Szmuness et al, 1975). In 
a study of 3816 homosexual males who attended sexually transmitted diseases clinics, 
61.5% were positive for serological markers and 6% became chronic carriers, a 
significantly higher rate than in other group of patients (Schreeder et al, 1982).
There are remarkably few studies of sexual transmission in Africa. However, since most of 
the population is infected in early childhood, it may play a limited role in overall 
transmission rates. A study in Tanzania has shown that sexual transmission occurs in 7,2% 
in men and 3% in women if the partner was known to be a carrier (Jacobs et al, 1997).
2.3,1.3 Maternal- neonatal transmission
t
Perinatal exposure to maternal blood is highly efficient mode of HBV transmission. During 
the perinatal period infants are exposed to maternal blood through placental tears, trauma 
related to birth and contact of conjunctiva and mucous membranes with blood and other 
fluids during labour and delivery.
The incidence of perinatal transmission depends primarily on the prevalence of carrier 
mothers and the risk of transmission of the virus from a carrier mother to her infant 
(Edmunds et al, 1996). The risk of perinatal transmission is far greater from HBeAg 
positive mothers than from HBeAg negative mothers (Beasley et al, 1977; Schweitzer et al, 
1973; Tong et al, 1981).
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In Eastern Asia around 70-85 % of children bom to HBeAg positive mother become 
HBsAg positive during the first 3 months after birth (Beasley et al, 1977). A greater 
proportion of carrier mothers in east Asia appear to be HBeAg positive and have higher 
levels of circulating HBV DNA compared to African mothers (Greenfield et al, 1986). 
Even when mothers in Africa are HBeAg positive, their babies do not become HBsAg 
positive until 6 months to 1 year later (Marinier et al, 1985).
•.
2.3.Ï.4 Horizontal transmission
Most hepatitis B virus infections in sub-Saharan Africa are acquired through horizontal
transmission in early childhood (Whittle et al, 1983; Tabor et al, 1985), but the exact
, , ’ ■ ’i
mechanisms of spread have not been documented. Study in North America found an 
association between intra-familial transmission and skin sores (Bernier et al, 1982). In 
West Africa virus was found in exudates from tropical ulcers (Foster et al, 1984).
> . *
The possibility of transmission by blood-feeding arthropods has been of concern but never 
proven. Experimental feeding of HBV- contaminated blood to mosquitoes revealed that the 
virus was digested within 48 hours. Because mosquitoes tend to feed every 72 hours 
transmission this is unlikely. Bedbugs retain virus up to 30 days after a single blood meal 
(Ogston et al, 1979) and virus is detectable in their faeces for up to 6 weeks (Ogston et al, 
1980).
The hypothesis of bedbug transmission was tested in The Gambia. Risk factors for 
hepatitis B virus transmission were examined in 973 Gambian children aged 6 months to 5 
years. Skin disease and presence of bedbugs in the bed were found to be associated with
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transmission (Vail Mayans et al, 1990). Later, a controlled trial of bedbug elimination in 
several villages failed to reduce the risk of HBV infection (Vail Mayans et al, 1994).
In a large study enrolling 1385 persons performed in Ghana (Martinson et al, 1998), the 
behaviour most strongly associated with prevalence of HBV was sharing of bath towels, 
sharing of chewing gum or partially eaten candies, sharing of dental cleaning materials and 
biting of fingernails in conjunction with scratching the backs of carriers.
Horizontal transmission is known to be common in tropical parts of South America, where 
the environment is quite similar to that in Africa. In a study in Brazil of families that were 
moved 1500 km to the Amazon region, a significant rise in acute infections was described 
soon after arrival. An incidence rate of 7.2 new infections per 100 exposed subjects per 
month was found (Outra et al, 1998). All the main known transmission factors such as 
tattooing ear piercing, circumcision, surgical or dental procedures, immunisation with 
inadequately sterilised syringes and needles were excluded and unknown environmentally 
related factors were suggested.
Recently, in the study on 54 chronic HBsAg carriers HBV DNA was found in urine in 82% 
of HBeAg positive patients and in 24% of HBeAg negative patients (Knutsson et al, 2000). 
Therefore urine should be regarded a potential route of transmission and therefore be 
investigated further a means of horizontal transmission of HBV.
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2.4 Natural History of HBV infection
2.4.1 Clinical presentations
2.4.1.1 Acute hepatitis
Hepatitis B infection can be divided into acute and chronic hepatitis. The course o f acute 
hepatitis B  can be divided into four clinical phases: (a) the incubation period; (b) a 
prodromal or preicteric stage; (c) the icteric phase and the convalescent period (Fields BN, 
1997).
Usually the incubation period ranges from 45 to 120 days (Mosley et al, 1975). The 
incubation period can be influenced significantly by the size of inoculum (Allen et al, 
1970). Coinfection with other hepatitis viruses, chemical or physical factors, age, 
immunosuppression or other unusual viral- host interactions can shorten the incubation 
period. Late administration of specific antibody in some cases is not protective but can 
delay the development of clinical disease (Grady et al, 1975).
t
In symptomatic patients a short prodromal and preicteric phase, varying from several days 
to more than a week, precedes the onset of jaundice in more than half of the adult patients. 
Usually it is characterised by mild fever, easy fatigability, malaise, anorexia, myalgia, 
nausea and vomiting. Hepatomegaly usually precedes jaundice and patients can feel pain 
or discomfort in the right upper quadrant. The icteric phase usually starts with appearance 
of dark urine due to bilirubinuria followed by pale stools and jaundice, which becomes 
clinically apparent when the total bilirubin level exceeds 2 to 4 mg/dl. On physical 
examination the liver is usually enlarged. Usually clinical symptoms subside in a few 
months and full clinical recovery occurs. Clinical signs associated with poor prognosis, are
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rapid decrease of a liver size, prolongation of protrombin time to greater than 50 seconds, 
an elevated bilirubin level of greater than 17,5 mg/dl, often a presence of a rapidly 
declining ALT value and encephalopathy developing within seven days of the onset of 
jaundice (O’Grady et al, 1989). The severity of disease is proportional to increasing age of 
the patient. Infants usually have asymptomatic disease.
Fulminant hepatitis has been designated as acute hepatitis which in first 8 weeks of illness 
leads to severe impairment of hepatic synthetic processes and other functions causing 
sudden onset of high fever, abdominal pain, vomiting, and jaundice, followed by hepatic 
encephalopathy associated with coma and seizures (Berk et al, 1978). Ascites, bleeding, 
renal dysfunction and decerebrate rigidity lead to death in more than half of the patients. 
Mortality is highly correlated with increasing age.
2.4.L2 Chronic hepatitis
Some chronically infected patients may have no clinical or biochemical evidence of liver 
disease. This group is often categorised as asymptomatic hepatitis B carriers or simply 
HBsAg carriers. Disease can be histologically classified as chronic persistent, chronic 
active, and chronic active hepatitis with cirrhosis, but this classification is rather 
approximate and often does not reflect the dynamics of the disease. •
The main method of classifying chronic viral hepatitis is by cause and the old histology- 
based classification is no longer considered appropriate. The concepts of grading and 
staging, borrowed from tumour pathology, have been introduced (Scheuer, 1996).
Patients with moderate to severe chronic hepatitis may have no symptoms, but may also be 
significantly incapacitated. Easy fatigability, anxiety, poor sleep, anorexia, and malaise are
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the most common complaints: During follow-up, a series of remissions and relapses are 
usually observed. Remissions may last a few months or years. Patients may have jaundice 
and elevated transaminases, especially during the relapse of disease. Ascites and pedal 
oedema may be present., Encephalopathy or -variceal bleeding can be 'occasional 
presentations of the disease and usually this is associated with progression to cirrhosis.
Survival rates at 5 years in chronic .persistent hepatitis are thought to be around 97% of 
patients with chronic persistent hepatitis, 86% for those with chronic active hepatitis and 
55% for those with active hepatitis and cirrhosis (Weissberg et al,’1984). Age is the most 
important factor for survival. Prognosis for,the .elderly is worse because of decreased 
function of other organ systems. , , . . - ’
2.4.2 Pathogenesis and pathology
Both CD8+ and CD4+ cells are thought to be crucial in immune response against HBV. 
Patients who successfully clear acute HBV infection characteristically mount a strong, 
polyclonal, multispecific GD4+ and CD8+T lymphocyte responses to several epitopes in 
the HBV envelope, nucleocapsid and polymerase proteins, (Ferrari et al, 1990; Ferrari et al, 
1991; Jung et al, 1994, Rehermann, 1995). HLA class I restricted CTLs have a key role in 
the control of HBV infection by destroying infected cells. This process leads to direct cell 
killing by the CD8+ cytotoxic T lymphocytes (Chisari et al, 1995). The polymorphic 
nature of die MHC binding sites and differences in the-T-cell repertoire among people , 
leads to highly variable binding affinity for the immunodominant HBV peptides, which 
can determine outcome after acute HBV infection (Carman et al, 1997). The different 
immune responses in patients in whom the virus is cleared successfully and those, in whom 
it is not, depend on the match between the HBV peptides presented by host MHC
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molecules and the specific T-cell repertoire of the host. Highest frequency of circulating 
HBV-specific CD8 cells was also shown to coincide with the clinically acute phase of 
hepatitis (Maini et al, 1999). If there is sufficient recognition and activation, the immune 
response is carried to completion, infected cells are destroyed, viral replication is aborted 
and antibodies to HBsAg prevent the reinfection of hepatocytes are produced. Some 
studies indicate that long lasting immune response can be maintained by traces of virus 
that persist indefinitely after clinical and serological recovery (Penna et al, 1996). 
Following this reasoning, HBV-specific CD8+T lymphocytes contribute to chronic 
inflammatory liver disease by destroying some of the infected hepatocytes, but they remain 
quantitatively ineffective in eliminating infected hepatocytes or mediating viral clearance. 
CD8 cell response differs in patients with active liver disease and active viral replication 
and in patients without liver inflammation and HBV replication. High frequency^xif 
intrahepatic HBV specific CD8+ cells was found in the liver of patients from both groups, 
but in patients with active disease these cells were more diluted among liver infiltrates of 
other non-specific cells (Maini et al, 2000). Inhibition of HBV replication was also 
associated with the presence of a circulating reservoir of CD8+ cells able to expand after 
specific virus recognition that was not detectable in highly viremic patients with liver 
inflammation.
Some other important mechanisms of clearance of infection have been suggested. T 
lymphocytes may directly inhibit viral gene expression and replication and thus inactivate 
HBV without killing the infected hepatocytes (Cavanaugh et al, 1997; Chisari et al, 1997; 
Guidotti et al, 1997). HBV DNA was even shown to nearly disappear from the liver and 
the blood of acutely infected chimpanzees long before the peak of T cell infiltration 
(Guidotti et al, 1999). That has lead to suggestion that HBV infection can be primarily
controlled by a noncytopathic, cytokine dependant curative mechanism, named viral 
purging (Guidotti et al, 1999). ■ This effect was found to be mediated by gamma interferon 
(INF-y), tumor necrosis factor alpha (TNF-a) and other interferons in transgenic; mice 
model (McClaiy et al, 2000). The cytokine-inducible downstream events that exactly 
inhibit HBV replication have not been well defined. ' Nitric oxide (NO) was shown to 
mediate the ability of.INF-y but not IFN-o/p to inhibit HBV replication (Guidotti et al,' 
2 0 0 0 ). : • . . : v .
The pathology in HBV infection usually does not differ from the pathology of hepatitis 
from other causes. It is difficult to distinguish acute hepatitis from exacerbation of chronic 
active hepatitis. Early events in viral hepatitis are not well described, but occasionally an 
increase in liver-cell mitoses or a proliferation of sinusoid- lining cells is seen..
Fully developed hepatitis is characterised by degeneration and death of liver cells 
accompanied by proliferation of Kupffer cells and.an infiltrate composed mainly of 
mononuclear cells. Portal tracts are the main sites of such infiltrates. The liver-cell changes 
are apparent throughout the lobule, but vary in intensity and are most severe, in . 
centrilobular areas. Liver cells are commonly swollen (ballooning degeneration), but they * 
can shrink (acidophilic change) (Bianchi et al, 1970).
Tn the later stage of evolution of the lesion there is often a variable degree of collapse and 
condensation of reticulin fibres, and accumulation of ceroid pigment and stainable iron in • 
large phagocytic cells. Portal- tract enlargement may lead to linking of portal tracts without 
interference with lobar architecture. .
In chronic disease the portal and periportal alterations are often more prominent. When 
confluent necrosis links vascular structures, it is called bridging necrosis. Piecemeal 
necrosis is the death of hepatocytes at an interface between parenchyma and the inflamed 
connective tissue of a portal tract or fibrous septum.
Immunohistochemical staining is often helpful. The presence of HBsAg in hepatocytes is 
an indicator of chronicity -in HBV infection, and HBcAg in these cells is a marker of 
active viral replication, especially when it is abundant and located in hepatocyte cytoplasm 
as well as in nuclei (Scheuer et al, 1996).
The stage of chronic hepatitis is related to its time course. Its histological evaluation is 
based on the extent of fibrosis and development of fibrosis. Connective tissue stains are 
essential for staging. In chronic hepatitis, fibrous tissue is deposited in and around portal 
tracts, usually in association with periportal necroinflammatory activity. Perihepatocellular 
fibrosis may lead to the formation of hepatocyte rosettes. Extensive piecemeal necrosis 
may extend to portal tracts and result in development of portal-portal septa. Then fibrous 
septa extend from the portal tracts into hepatic lobules for varying distances and eventually 
reach the central hepatic venules. Portal septa are thought to be more important in the 
development of cirrhosis.
Cirrhosis is the final and irreversible stage of chronic hepatitis. It is characterised by 
presence of parenchymal nodules, which are surrounded by fibrous septa. This leads to 
functional alterations of blood flow with increase of portal pressure.
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2.4.3 Serological findings during HBV infection .
A number of serological assays are available to differentiate acute from chronic or past 
infection. In an acute case HBsAg is present for some days to 2 weeks before the onset of 
symptoms and is at maximum titre at the height of liver damage. In most cases HBsAg 
cannot be detected beyond 3-4 months. In 5-10% of patients antigenemia is of short 
duration and may not be detectable at the onset of clinical symptoms. In such cases the 
presence of antibodies, especially IgM ariti-HBc, and ànti-HBe may be the only indications 
of HBV infection. - . \ *
Methods, such as reverse passive haemagglutination (RPA) and enzyme 
immunoassay/radioimmunoassay (EIA/RIA), are highly sensitive and specific and allow 
detection of HBsAg at 100-200 pg/ml serum, that is, aboüt 3 x 107 particles/ml 
(Schmilovitz-Weiss et al, 1993). These assays are used most commonly for the detection 
HBsAg in serum and plasma. In RPA, fixed erythrocytes coated with anti-HBs are added 
to test samples, and haemagglutination patterns are read. In RIA a sandwich method, with 
anti-HBs as both absorbed reagent and as tracer have been employed. RPA is marginally 
less sensitive than the other two serological methods on Gambian elderly but not in young 
children (Whittle, personal communication). -
The immunoglobulin class of anti-HBe can differentiate between acute and chronic HBV 
infection: Patients with acute hepatitis develop high titres of IgM-specific anti-HBe 
antibody commencing with aminotransferase abnormalities (Cohen et àl, 1978; Lemon et 
al, 1981). These titres gradually decline over a 6- to 8- month period regardless of whether 
the disease resolves or becomes chronic. Low concentrations of IgM-specific anti-HBe 
have been detected up to 2 years in patients whose disease has resolved successfully and in
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many; chronic carriers (Sjogren, 1983; Tsuchié* 1984; Tsuda,L 1984). Among- HBsAg 
carriers the predominant component is a 7S IgM fraction versus a 19S component in aciite 
disease. Fewer than 15% of chronic hepatitis . B. patients- haver an IgM-specific anti-HBe 
titer that is. high enough to be detected in thé conventional IgM anti-HBe assay; but the 
reactivity of the test is relatively low when compared with that observed in acute "disease. 
IgM anit-HBc is detectable during reactivation of chronic disease or especially after steroid 
withdrawal. So the presence of IgM-specific anti-HBe at a dilution of 1:1000 or higher is 
presumptive evidence a recent acute infection.
Detection of anti-HBe and anti-HBc in HBsAg negative specimens normally indicates a *
1:
I . ,previous infection and ; confirms ; immunity^ against ;reinfection.?However such serological
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anti-HBe can be very helpful. t
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Anti-HBs is the principal neutralising antibody/bf hepatitis^, and its appearance usually 
signifies recovery from infection. Patients with pre-existing anti-HBs are usually protectee 
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infectious or contain a relatively small concentration of infectious virions, assays for 
detection of HBeAg, anti-HBe, or HBV DNA can be used. Most acutely infected patients 
are HBeAg positive. HBeAg positive specimens contain high concentrations of infectious 
particles and HBV DNA (van Ditzhuijsen, 1985). The presence of HBeAg shows active
viral replication. In contrast, in anti-HBe positive samples, the number of hepatitis B 
virions is markedly reduced. However, a subset of anti-HBe- positive carriers may be HBV 
DNA positive, especially those with pre-core mutations. The clinical course of the disease 
can be very aggressive. HBeAg testing for HBsAg positive pregnant women identifies 
those of them, whose infants are at risk of becoming infected.
Incubation period Prodrome, acute disease Convalescence
MTA p o ly n m s i. •
Anti-HBe
Months after M tetion
Mpârei k w  hue bom 
Clijrieal symptoms
Figure 2. Serological findings during the typical course of acute HBV infection.
Stage of the 
infection
HBsAg HBeAg Anti-
HBe
Anti- IgM 
HBc
Anti- IgG 
HBc
Anti-
HBs
Incubation period + + - - - -
Acute hepatitis + + - + + -
Chronic carriage + +/- +/- - + -
Recovery - - - - + ' +/-
Immunisation - - - - - +
Table 2. Serological findings for the different stages of HBV infection. ;;
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2.4.4 Polymerase chain reaction and sequencing.
Detection of HBV DNA is a useful tool for evaluating virus load in serum and assessing
j .
efficacy of antiviral treatment. The most sensitive assay for HBV DNA detection is the 
polymerase chain reaction (PCR) (Carotenuto et al, 1995).
PCR products can be cloned and sequenced afterwards or sequencing can be done directly. 
Cloning and sequencing could give much better insight into the presence of quasispecies in 
the sample. It is widely accepted that sequencing of PCR product directly will reveal tjie 
dominant sequence (Akarca et al, 1994). From longitudinal studies, it has become 
apparent that by direct sequencing of PCR products it is difficult to tell whether changes 
in sequences represent true mutations or changes in the proportion of different 
quasispecies.
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2.4.5 Levels of aminotransferases as a diagnostic test
Alanine-aminotranserase (ALT), an enzyme present in liver cells, with lesser amounts 
in the kidneys, heart, and skeletal muscles, is a relatively specific indicator of acute liver 
cell damage. When such damage occurs, ALT is released from the liver cells into the 
bloodstream, often before jaundice appears, resulting in abnormally high serum levels that 
may not return to normal for days or weeks.
ALT levels by a commonly used method range from 10 to 40 U/L. The normal range 
for infants is twice that of adults. Very high ALT levels (up to 50 times normal) suggest 
viral or severe drug-induced hepatitis, or other hepatic disease with extensive necrosis 
(death of liver cells). (AST levels are also elevated but usually to a lesser degree.) 
Moderate-to-high levels may indicate infectious mononucleosis, chronic hepatitis, 
intrahepatic cholestasis or cholecystitis, early or improving acute viral hepatitis, or severe 
hepatic congestion due to heart failure. Slight-to-moderate elevations of ALT (usually with 
higher increases in AST levels) may appear in any condition that produces acute 
hepatocellular (liver cell) injury, such as active cirrhosis, and drug-induced or alcoholic 
hepatitis. Marginal elevations occasionally occur in acute myocardial infarction (heart 
attack), reflecting secondary hepatic congestion or the release of small amounts of ALT 
from heart tissue.
Aspartate-aminotransferase’s (AST) levels measured by a commonly used method 
range from 8 to 20 U/L although some ranges may express a maximum high in the 40s. 
AST levels fluctuate in response to the extent of cellular necrosis (cell death) and therefore
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may be temporarily and minimally elevated early in the disease process, and extremely 
elevated during the most acute phase. Depending on when the initial sample was drawn, 
AST levels can rise- indicating increasing disease severity and tissue damage- or fall- 
indicating disease resolution and tissue repair. Thus, the relative change in AST values 
serves as a reliable monitoring mechanism. Maximum elevations are associated with 
certain diseases and conditions. For example, very high elevations (more than 20 times 
normal) may indicate acute viral hepatitis, severe skeletal muscle trauma, extensive 
surgery, drug-induced hepatic injury, and severe liver congestion. High levels (ranging 
from 10 to 20 times normal) may indicate severe myocardial infarction (heart attack), 
severe infectious mononucleosis, and alcoholic cirrhosis. High levels may also occur 
during the resolving stages of conditions that cause maximal elevations. Moderate-to-high 
levels (ranging from 5 to 10 times normal) may indicate chronic hepatitis and other 
conditions. Low-to-moderate levels (ranging from 2 to 5 times normal) may indicate 
metastatic hepatic tumours, acute pancreatitis, pulmonary emboli, alcohol withdrawal 
syndrome, and fatty liver (steatosis).
2.5 HBV and HCC
The geographical distributions of HCC and the HBV carrier state, at both global and local 
levels, are remarkably similar (Szmuness et al, 1978). Even though carriers may represent 
5% to 10% of the population, they account for 50% to 80% of the HCC patients in 
endemic areas. The size of the risk is best illustrated by the cohort study on 3454 
Taiwanese carriers of the virus which showed that 5% of these carriers died from HCC 
(Beasley et al, 1981). HBV carriage was associated with a 100-fold increase in the risk for 
HCC development in relation to non-carriers (Beasley et al, 1988). Patients with HCC had
a significantly higher prevalence of markers of current HBV infection in serum and liver 
tissue than matched controls (Szmuness et al, 1978). HBV carriage usually precedes the 
onset of HCC by many years; an interval consistent with a cause and effect relationship, 
and the chance of neoplastic transformation rises progressively with increasing duration of 
the infection. From the age distribution of Taiwanese hepatoma cases, it can be inferred 
that most tumours arise after 30 or more years of persistent infection; relatively few cases 
occur in children or adolescents. Sequences of viral DNA are integrated in most of the 
HBV related HCC cancers.
Woodchuck hepatitis virus induces HCC in eastern woodchucks with a frequency of 100% 
within 2 years of infection, whilst 30% of ground squirrels infected with ground squirrel 
hepatitis virus develop HCC within 6 years (Popper et al, 1987).
Not only HBsAg carriage but also presence of antibodies to HBsAg after infection was 
found to be associated with a 4,7-fold increased risk for HCC (Yu et al, 1997) in non- 
Asians of Los Angeles, but other researchers have never repeated these observations.
50
2.6 Chronic HBsAg carriage
2.6.1 Definition
A chronic HBV infection is defined as the presence of HBsAg in serum for 6 months or 
more. This definition is based on a study of patients in hemodialysis units whose 
seroconversion from HBsAg negative to HBsAg positive was observed. In the patients 
with persistent HBsAg detection for 6 months was associated with a 90% probability of 
remaining positive indefinitely (London et al, 1977).
2.6.2 Risk factors
2.6.2.1 Influence of age at exposure
The major determinant of chronicity of HBV infection is age at exposure (Edmunds et al, 
1993; Coursaget et al, 1987; McMahon et al, 1985). In vertically acquired infection, 
chronic infection establishes in 75-90% of cases (Beasley et al, 1983). In horizontal 
transmission in early childhood, chronic infection occurs in 10-15% of infected cases 
(Ryder et al, 1992). When infection is acquired in adulthood, the rate of chronic infection 
is around 5% (Nielsen et al, 1971; Tassopoulos et al, 1987).
2.6.2.2 Concurrent infection.
A large increase was observed in the rate of persistent infection in homosexual men who 
acquire HBV infection in the early phases o f  HIV infection (Bodsworth et al, 1991; Hadler 
et al, 1991). Coinfection also may contribute to higher levels of HBeAg expression and a 
lower degree of inflammation (Goldin et al, 1990).
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2.6.23 Alcohol v
Alcohol is a well-known hepatotoxic agent and may exacerbate HBV-related liver damage 
through the development of cirrhosis. Persons chronically infected with HBV and who 
drink alcohol regularly might be expected to be at higher risk of both cirrhosis and HCC 
(Oshima et al, 1984).
2.6.2.4 Aflatoxin
Exposure to aflatoxin-Bl (AFB1) in several areas of the world has been positively 
correlated with high mortality rates for HCC. In a prospective study in Shanghai, urinary 
excretion of aflatoxin metabolites increased the risk of development of HCC fourfold. 
HBV infection alone increased the risk about seven times, but persons who both excreted- 
aflatoxin metabolites and were HBV carriers had 60 times higher risk than HBV 
uninfected, AFB1 unexposed individuals (Ross et al, 1992).
2.6.2.5 Human genetic factors
Family associations. The outcome of viral hepatitis infection depends on a number of 
variables in both the host and the infecting virus. Early studies suggested an autosomal 
recessive mode of inheritance for chronic HBsAg carriage (Hann et al, 1982), but this 
seems to be an oversimplification. The same group showed that fathers of patients with 
chronic HBV infection have significantly lower rates of anti-HBs antibodies after 
infection. It was suggested that genetic control of anti-HBs production can play a role in 
development of chronic infection. One report clearly demonstrates that the same virus 
isolate may lead to two different clinical outcomes in different hosts (Karayianms et al,
1995). A small study of Chinese twins shows that the outcome of HBV infection is very 
much influenced by the host genotype (Lin et al, 1989). Monozygotic twins in this study
52
were chronic carriers in 50% of family cases but dizygotic twins were carriers in 20% of 
families. No difference was observed in infection rates between both groups.
MHC Class I  Associations. Intracellular HBV is eliminated by the CD8+ cytotoxic cells, 
which are able to recognise viral antigenic peptides presented by MHC class I 
glycoproteins. In patients with chronic HBV infection the CTL response is decreased 
(Chisari et al, 1995). Results of MHC association studies comparing the distribution of 
MHC class I alleles in patients with chronic hepatitis, asymptomatic HBsAg carriers and 
controls are not very consistent. Moderate and severe hepatitis has been associated with an 
increased frequency of HLA-B35 and a decreased frequency of HLA-DQwl (Mota et al, 
1987; van Hattum et al, 1987). Asymptomatic carriage has been associated with HLA-B15 
(Gianietal, 1979).
MHC Class I I  associations. Variations in MHC class II amino acid sequences determines 
which viral antigenic peptide fragments are presented to CD4+ helper cells. Observations 
show that Th cell responses in patients with chronic HBV. infection are reduced in 
comparison to those in patients with acute infection (Ferrari, 1990). The DR2 locus has 
been associated with clearance of infection and DR7 with persistent infection in a study 
performed in Qatar (Almarri et al, 1994). Analysis of MHC class II allele frequences in 
The Gambia showed an association of the allele DRB1M302 with clearance of HBV 
infection (Thursz et al, 1995). The association has been confirmed in a European study 
(Hohler et al, 1997).
In patients, who seroconvert from HBeAg- positive to antibody to HBeAg (anti- HBe) 
after therapy with interferon, Th and CTL responses have increased substantially (Jung et
al, 1995). In a small study DR6 and DR3 alleles were associated with viral clearance after 
interferon therapy (Scully et al, 1990).
Mûnnose-binding proiein associations.lt was discovered that patients with chronic HBV 
infection have a defect in opsonization that is not seen in other patients with chronic liver 
disease (Munoz et al, 1987). HBV has a mannose-terminated carbohydrate chain on the 
middle envelope protein (pre-S2 region), which can be a potential target for mannose- 
binding protein (MBP). MBP is a known opsonizing protein. Binding of HBV to MBP can 
enhance the clearance of HBV from peripheral blood (Gerlich et al, 1993). MBP codon 52 
‘mutant’ allele has been found more frequently in patients with persistent HBV infection 
(Thomas et al, 1996), but this was not confirmed by further more extensive studies 
{M.Thursz, personal communication}.
TNF-a associations TNF-a being a proinflammatory cytokine may help to control the 
replication of HBV. Suppression of HBV antigen expression by TNF-a has been 
demonstrated in HBV transgenic mice (Gilles et al, 1992). TNF-a levels are higher in 
chronic carriers, who are successfully treated with interferon (Daniels et al, 1990). The 
rarer TNF2 allele has been shown in functional studies to be associated with increased 
TNF-a production (Wilson et al, 1993). The same allele is associated with cerebral 
malaria and may be weakly associated with clearance of HBV infection (Thursz et al,
1996).
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Gender differences. It has been shown that males after getting infected in childhood and 
adulthood are more likely to develop a persistent infection than females and in patients 
treated for persistent HBV infection females are better responders (London et al, 1977; 
Realdi et al, 1990}. In an Alaskan population-based study of 1400 carriers, women were 
significantly more likely to clear HBsAg than men (McMahon et al, 1990). One study 
comparing sex to clearance of HBeAg showed that clearance was higher in women than in 
men (McMahon et al, 1985).
In chronic hepatitis the major sequelae, such as fibrosis and cirrhosis, are more common in 
men than in women. A large prospective Taiwanese study showed that the age-specific 
incidence of hepatocellular carcinoma was threefold greater in men than in women over 
the age of 45 (Beasley et al, 1982).
Explanations for the sex difference have not been found, but it is known that replication of 
HBV is sensitive to sex hormones (Almog et al, 1992). HBsAg clearance by phagocytic 
cells in inbred mice was achieved more quickly in females than in males (Craxi et al, 
1982).
2.6.3 Theoretical background fo r  sample collection fo r  genetic studies in The Gambia.
Recently molecular genetic tools have increased our ability to discover variations 
(polymorhisms) and correlate them with human disease. Investigators can scan a large 
number of subjects and identify multiple associated alleles. Approach used on Gambian 
samples was genome wide scan, where densely distributed markers- microsatellites were 
used to identify areas of interest in the genome. Distortions in the frequencies of these
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markers were compared between a cohort of patients with a specified outcome (e.g. 
chronic HBsAg carriage) and those without the outcome or in a group of families with the 
disease phenotype (Dib et al, 1996).
This approach was used successfully previously to detect genetic associations for 
development of infectious disease- tuberculosis (Bellamy et al, 1998). If a disease- 
associated polymorphism and a marker are linked, then the marker will be found 
significantly more frequently in those with the disease. In diseases without previously 
known genetic associations, distortions in frequencies of microsatellite markers can focus 
the search for the associated gene or group of genes. It was estimated that for studies like 
this on families with multiple affected siblings DNA samples from at least 200 sibling 
pairs should be obtained and screened in order to get significant associations. These were 
the reasons why the study on chronic HBV carriers was initiated in The Gambia. My main 
task was to recruit sufficient number of sibling pairs for the human genetic study.
After associations are found by genome wide scan the candidate genes can be chosen from 
disease associated area of the genome. Later, in disease association studies, a candidate 
gene polymorphism is studied in a group of individuals exposed to a particular infection. 
The frequencies of the polymorphism are then compared between those with or without 
outcome. Very large patient groups have to be recruited for this type of case- control 
studies. For example, for an allele with a frequency of 10%, 307 case-control pairs are 
needed to have an 80% chance of detecting a twofold disease association (Thio L, 2000).
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2.6.4 HBsAg carnage in The Gambia
2.6.4.1 Studies in The Gambia
I shall review in more detail the studies that have been conducted in The Gambia, because 
the information from databases of these studies was used to find chronic HBV carriers, 
already known to be residing in The Gambia.
2.6.4.2 Chronic carriers in Keneba and Manduar
These two villages, Manduar and Keneba, are situated 8 km apart in The West Kiang 
District of The Gambia along the river Gambia. Accurate demographic data for these two 
villages have been kept since 1951 (Billewicz et al, 1981). The ages were known for 
individuals bom later than 1951 and annual surveys have revealed the seasonal pattern and 
prevalence of infectious disease. Between March, 1972, and March, 1973, sera from 1317 
people of these two villages were tested for HBsAg. 174 (13%) were positive with the 
majority of cases in the 10-14 years group (McGregor et al, 1976).
f
Year 1980
All mothers and children under the age of 15 were asked to participate in the study. 
Attendance ranged from 73% for those aged 10-14 to 100% for those aged 5-9. 63 out of 
174 HBsAg positive people in 1972 were tested again.
The prevalence of HBV infection was found to be markedly different in the two villages. 
62 % of cliildien in Manduar aged 2-4 years were infected whereas in Keneba only 27% of 
this age group were infected- none under 6 months of age and only 2 of 58 between the
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ages of 6 and 12 months. The carriage of HBsAg was high, reaching à peak of 36% in the 
5-9 age group in Manduar and 17,8% in the 2-4 age group in Keneba. Infection clustered in 
families, transmission from sibling to sibling was suspected to be of major importance. 
From 4 HBeAg positive mothers 10 out of 11 children became HBsAg carriers. 63% of 
those carrying HBsAg in 1972 were still positive in late 1980.
Age
(Years)
M anduar Keneba
HBsAg
+ve
% Proportion 
HBeAg +ve
HBsAg
+ve
% Proportion 
HBeAg +ve
0-1 5/39 - 12,8 3/3 4/85 4,7 • 4/4
2-4 15/60 25,0 9/11 18/102 17,6 9/11
5-9 26/72 36,0 14/21 18/164 10,9 8/12
10-14 9/26 35,0 0/5 12/72 16,4 3/12
Mothers 20/58 34,5 4/20 11/111 9,9 0/11
75/255 30/60 63/534 24/50
Table 3. Prevalence of HBsAg and HBeAg in two Gambian villages (All HBsAg positive 
samples were not tested for HBeAg).
(Whittle et al, 1983)
The prevalence of HBsAg and HBeAg carriage in persons bled during the survey in 
Keneba and Manduar is shown in table 3.
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Year 1984
All children in the villages <20 years of age were asked to participate in the study. 306 
children in Manduar and 602 children in Keneba were tested. 172 (85%) of 207 Manduar 
children and 326 (77%) of 424 Keneba children who were tested in 1980 were tested again 
in 1984.
Number of HBsAg positive 
children per family
Number of families in 
Keneba(n=142)
Number of families in 
Manduar(n=108)
0 88 50
1 35 32
2 13 11
3 6 9
4 6
142 108
Table 4. Family clustering of HBsAg carriage in Keneba and Manduar 
(Whittle et al, 1990)
The rate of HBV infection in the 2-4 years age group differed markedly again: in Manduar, 
68%(46/68) of children became infected in contrast to Keneba 29 %(41/140). Male 
children were more frequent carriers of either HBs or HBeAg than were female children. 
Significant clustering of hepatitis B surface antigenemia within siblings was shown in both 
villages (p< 0,001). This clustering remained apparent when only HBV-infected children 
were considered (p<0,01). Regardless of HBsAg status, HBV infection was found to
59
cluster in Keneba but not in Manduar. The chance of the youngest child in a household 
being a earner of HBsAg was strongly related to the number of antigen positive siblings. 
Four years later, 53% of children who were, initially positive for HBsAg and 33% who 
were positive for HBeAg still carried these antigens. All non immune children under the 
age of 5 years were vaccinated against HBV. .
In May 1989, blood was also taken from- individuals less then 20 years old and their 
mothers, who had not been previously tested for HBV infection (Whittle et al, 1991). 94% 
of those between the ages 0-4 years were tested compared with 85% of those aged between 
15 and 19 years. Out of 433 vaccinees who were vaccinated with 4 different vaccination 
regimens since 1984 358 were traced and bled.
This study has shown that the dose, route and schedule of vaccination were of little 
importance in protecting children from persistent infection. Only 1 vaccinee became a 
earner, despite variation of peak antibody concentration from zero to over 10 000 mIU/ml. 
9% (32 out of 358) were found to be positive for anti-HBc antibodies and were thus 
defined as having a breakthrough infection. The number of infections after vaccination 
varied according to endemicity in the two villages: Manduar, which has twice the HBV 
infection rate of Keneba, had a fourfold higher rate of breakthrough infections. Vaccinated 
children of HBsAg positive mothers were at increased risk of infection, but this was not a 
case for children whose older siblings were HBsAg positive. The study also showed that 
the mother’s HBsAg status was contributing to family clustering of HBV infection, 
probably by increased circulation of the virus in these families.
60
The decline of anti-HBs following vaccination was rapid, and the rate of decline was 
constant and independent of peak antibody concentration.
Year 1991
In May 1991, 32 children with breakthrough infections in 1989 were bled and serological 
tests were performed (Fortuin et al, 1994). 2 of them were still HBsAg positive. 15 
children out of 32 lost their anti-HBc antibodies. 7 out of these 15 in 1989 were 1-2 years 
old. Three samples were PCR positive. One virus had a mutation at residue 141 (lysine to 
glutaminic acid) of the S gene.
Year 1993
Again all children, younger than 20 years, were bled (Whittle et al, 1995). Despite a rapid 
decline in anti HBs antibody titres the prevalence of breakthrough infections did not 
increase 9 years after vaccination. Between 1984 and 1993, vaccination reduced the 
prevalence of HBV infection in 1-14 year old children from 50% to 9% in Keneba and 
from 80% to 9% in Manduar. In 1993, there were only 3 chronic carriers among vaccinated 
children in Keneba and 2 in Manduar compared with expected numbers (form 1984 data) 
of 42 and 52, respectively. The prevalence in unvaccinated groups over the age of 14 years 
did not change significantly in either village.
186 chronic carriers aged 4-60 years in Keneba and Manduar and 75 younger carriers, aged 
3-4, from other villages were tested for HBeAg and HBV DNA by dot blot hybridisation 
using phosphorus-32 as label. The prevalence of these markers of infectivity declined with 
age.
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Age HBeAg +ve (%) HBV DNA+ve 
(%)
Total number of 
carriers
0-4 70 95 ,75
5-9 40 45 17
10-14 38 45 50
15-24 22 26 52
25-34 22 16 25
35-44 15 10 22
>44 20
Table 5. Prevalence of HBeAg and HBV DNA in chronic HBsAg carriers according to 
their age. (Whittle et al, 1995)
I  followed up 184 chronic HBV carriers identified in above-mentioned studies in Manduar
. ’ •
and Keneba.
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2.6.4.3 Studies on risk factors fo r  transmission
In 1988 risk factors for hepatitis B virus transmission were examined in 973 Gambian 
children aged 6 months to 5 years in seven neighbouring villages: Kolior, Massembeh, 
Genieri, Kaiaf, Jiffin, Toniataba, and Sikunda (Vail Mayans et al, 1990). A total of 867 
adults were tested. Villagers lived in well-defined compounds consisting of a variable 
number of households. In each compound the mean number of households (1.9) and people 
(20.5) were recorded.
33% of children were found to be infected. 4% were acute, 10% were HBsAg carriers, and 
18% had evidence of infection. Of 140 HBsAg positive children 103 (73%) were HBeAg 
positive, and 71% were positive 6 months later.
In sera from parents, 90% (532/592) of mothers and 93% of fathers (181/192) were anti- 
HBc positive. Carriers more commonly had HBsAg positive mothers (25% (18/73)) than 
non-carriers (12 (20/167)). Significant clustering of HBsAg carriage (p<0.01) was found 
both within compounds and within households). There was no association of malaria 
parasitaemia and any hepatitis marker. A significant association was found between 
infection and tropical ulcer scars, and between e antigenemia and the presence of bedbugs 
in each child’s bed. There was no association between infection and traditional scarring, 
circumcision, or injections.
Between 1990-92 an intervention study was done over two years in the same villages to 
determine the contribution of bedbugs to hepatitis B transmission. In addition fortnightly 
questionnaires were completed for each child to assess other possible routes of 
transmission.
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Children found to be uninfected (hepatitis B core antibody negative for children aged 12 
months or older and hepatitis B surface antigen negative for those younger) were 
randomised into an intervention or control group. Randomisation was by compound. 
Intervention compounds were sprayed with insecticide. . •
There were 641 children in the survey who were uninfected .(320 to sprayed and 321 to 
unsprayed compounds). Infection with hepatitis B occurred in 30% of the children over the 
2 years. The intervention, insecticide spraying of the children’s dwellings, was highly 
effective in reducing exposure to bedbugs but there was no effect on hepatitis B infection. 
No other risk factor for transmission was identified despite consistent village to village 
variation in the rate of childhood transmission. 1
Ifollowed up 43 o f  carriers identified during this study.
2.6.4.4 Vaccination follow up studies
2.6.4.4.1 Study in Keneba and Manduar
The Gambia Hepatitis Intervention Study was a large-scale intervention study to examine 
the efficacy of vaccination against HBV in preventing chronic carriage of the virus, 
chronic liver disease and liver cancer.
In 1984, children under the age of 5 years in Keneba and Manduar villages, who possessed 
no serum HBV core antibody, were randomly allocated to one of three regimens of 
vaccination (Whittle et al, 1987).
Three trials of intradermal HBV vaccine were carried out in Gambian children. In the first 
trial HBV vaccine(lpg) was given to neonates in the same syringe with BCG, followed by
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two further doses of the vaccine. The trial was a failure, since 19 of 32 subjects had HBV 
surface antibody response less than 10 m.i.u./ml.
In the second trial in young children two different regimes were used: either two doses of 
2pg HBV vaccine given intradermally after a 20pg intramuscular dose or three doses of 
2pg given intradermally. In both cases geometric mean antibody titres were significantly 
lower than in the control group who were given 20pg HBV intramuscularly followed by 
two lOpg doses intramusculary. Vaccine failures, defined as presence of HBV surface 
antigen or core antibody or absence of surface antibody, were also significantly higher in 
the intradermal groups.
In the third trial 4pg of vaccine were given intradermally to 20 young children with a 
multiple orifice head fired by a jet gun: all had a good HBV surface antibody response > 
100 m.i.u/ml in serum.
2.6.4.4.2 The Gambia Hepatitis Intervention study (GHIS)
In 1986 a national hepatitis B vaccination program of young infants was initiated gradually 
over a 4-year period. The country was stratified into four geographical zones of 
approximately equal populations. Each new team beginning vaccination was selected 
randomly from teams not yet vaccinating against HBV, until national coverage was 
achieved in February 1990. The randomisation was stratified by zone to ensure that the 
introduction was balanced geographically. All children attending for vaccination were 
registered for this period, providing two cohorts of about 60,000 children each; one
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rece iv ed  ro u tin e  v acc in a tio n s  and  th e  o th e r rece iv ed  H B V  v acc in a tio n  too  (A n o n y m o u s,
1987).
1990. To assess the response to the vaccine and the durability ot vaccine-induced 
immunity, 1041 children from the cohort that received the HBV vaccine were followed up 
annually for 4 years (Fortuin, 1993). Blood samples for the 4 years of follow-up were 
available for 720 of these children. 33(4,6%) showed evidence of infection, 4(0,6%) of 
these had become chronic carriers. 9 (31%) of the mothers of children with uncomplicated 
infections were HBsAg positive and 5(17%) were also HBeAg positive. Only 78 (11%) of 
687 mothers of uninfected children were HBsAg positive and 6(1%) were also HBeAg 
positive. Of 4 children who were chronic carriers, 3 had HBsAg positive mothers, 2 of 
who were also HBeAg positive. Overall, vaccine was estimated to be 84% effective against 
infection and 94% effective against chronic carriage.
To assess vaccine efficacy* a single cross-sectional study was undertaken from September, 
1990, to July, 1991, in 3-4 year old children in the cohort that did not receive the vaccine 
(Fortuin et al, 1993). Twenty clusters, each containing 10 children, were selected from an 
area within each of the four geographical zones. 816 children were bled. 71% were 
uninfected, 29% had anti HBc, and 103 (13%) were also positive for HBsAg. Those 
HBsAg positive were traced a year later and 13 (14%) had become HBsAg negative.
Another cross-sectional study was carried out from September 1995 to September 1996 on 
unvaccinated children to determine vaccine efficacy against HBV chronic carriage and 
infection (Viviani et al, 1999). At nine years of age, 675 (65%) children originally 
recruited were traced and bled. In children 9 years of age, eight percent of the vaccinated
children had primary HBV infection compared to 50% of the unvaccinated control group; 
HBV carrier status was 0,6% and 10% respectively, resulting in vaccine efficacy of 83% 
against infection and 95% against chronic carriage. Among the vaccinated children, 
induced surface antibody had declined to geometric mean concentration of 19 IU/1, with 
32% of the vaccinees now having undetectable antibody levels.
159 o f  the carriers identified in 1990 and 117 o f  the carriers identified in 1995 were 
followed up by me and used as index cases.
2.6.4.5 E-study
The study was designed to investigate factors which determine prolonged HBe 
antigenemia and also effects of prolonged antigenaemia (Hall, personal communication). 
Using data from previous GHIS studies 38 HBeAg positive women of childbearing age 
were selected, as well as the same number of HBeAg negative chronic HBsAg carriers and 
non-earners. Subsequently, all family members of these women who could be found were 
included in the study.
The prevalence of HBV infection was found to be higher in mothers of HBeAg positive 
women (17%) than in mothers of HBeAg negative (9%) and non-carrier woman (4%), but 
this difference was not statistically significant. None of the mothers was HBeAg positive. 
In the siblings of the index woman, the prevalence was similar. The prevalence of HBsAg 
was significantly higher in siblings of HBeAg positive (34%) and HBeAg negative (35%) 
than siblings of non-carriers (13%). In fathers and husbands, no difference was found. The 
Humber of siblings in each family had an effect on the risk of the HBsAg carriage. For 
every extra sibling, the risk of the carrier state increased by 40%. The risk for index
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women being an HBeAg positive or HBeAg negative carrier was higher,in first bom 
women and decreased with increasing birth order rank.
The prevalence of HBV carriage was significantly higher in children of HBeAg positive 
women (54%) than in HBeAg negative (26%) and non-carriers (19%).
26 o f  the carriers identified, during this study were followed up by me and used as index 
cases.
6%
2 7 Molecular epidemiology of the intrafamilial transmission and clustering 
of HBV infection.
So far, only a few studies have addressed the question of intrafamilial transmission and 
clustering of HBV by sequence analysis or DNA hybridisation with synthetic 
oligonucleotides. Neither classical subtyping nor genotyping is applicable to 
epidemiological tracing of transmission because of their dominance in particular 
communities. Finer divisions can be achieved by sequence analysis constructing 
phylogenetic trees or looking for distribution of specific point mutation within the family.
Two Chinese families carrying the same point mutant from C to T at position 2735 for 
three generations, have been described (Lin et al, 1990) and this observation was at that 
time considered as direct proof of intrafamiliar spread of this virus.
A different selection of precore defective mutant virus between members of a Turkish 
family has been described (Barlet et al, 1994). The predominant strain in the mother and 
one of the children was the precore mutant type. In the other three children, the wild-type 
virus represented the major or exclusive population. The presence of an X gene deletion in 
the mother and three of her children was also detected.
In Taiwan, a family cluster carried immune escape variant of HBV infecting the mother 
and her two fully immunised children (Ho et al, 1995).
69
In .another study, 59 Chinese families with at least two PCR positive family members 
showed that most of the same family members shared the same precore mutations (Akarca 
et al, 1994).
Extensive intrafamiliar clustering of HBV variants with,mutations in the pre-C and pre-S 
regions and long term persistence of some mutants as stable strains (Santantonio et al,
1997) have also been reported. The ethnic,origin of these families was not stated.
Sequence analysis of HBV surface and core genes of 34 DNA positive members of 22 
Asian new immigrant families in Australia described evidence of mainly vertical 
transmission and a few cases of possible horizontal transmission (McIntosh et al, 1998). 
Distal X and pre-Core sequence data provided better discrimination between different 
family groups than S gené sequences.
A study of 42 HBsAg positive subjects from 11 Chinese families, where perinatal, 
transmission was thought to be predominant, showed a higher,degree of homology within 
families than between families. Within all families, core sequence homology was higher 
than 97.5%. In two families, all family members had completely identical sequences over 
the 20-year period after infection Two identical pairs were found in other families as well. 
In other families, the increased divergence of the sequences was associated with age and 
HBeAg status.
A study of 19 Italian families showed that most of the infected family members shared the 
same virus strain with very high homology (Karayiannis, personal communication). For
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detection of viral strains infecting each particular family sequencing of the pre-core/core 
genes was found to be the most informative.
2.8 Phylogenetic methods
Phylogeny studies convert information from nucleotide and amino acid sequences into an 
evolutionary tree for those sequences. Several methods have been developed and are 
classified into distance and discrete methods. The division is based on how the data are 
treated; distance methods first convert aligned sequences into a pair wise distance matrix, 
then input the matrix into a tree building method, whereas discrete methods consider each 
nucleotide site directly.
,
The most commonly used distance methods are the neighbour joining (NJ) and unweighted 
pair group method with arithmetic means (UPGMA). The NJ method is more commonly 
used, because it is very fast and is considered the best heuristic method for a small number 
of substitutions but it does not differ substantionally from more conventional methods. 
The NJ tree can give sufficient insight into what the final tree will look like and help in 
deciding which more advanced methods should be used.
The main discrete methods are maximum likelihood (ML) and maximum parsimony. ML 
is considered by many to be the current method of choice for tree reconstruction (Clewley,
1998).
The phylogenetic analysis of molecular sequence data using explicit evolutionary models, 
and the maximum -  likelihood approach has been used since 1981 (Felsenstein et al,
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1981). This approach is now widely used and has seen many applications, from looking at 
viral divergence within a single patient (Holmes et al; 1992) to examining the relationships 
between mammalian orders (Novacek et al, 1992). The maximum likelihood approach has 
not been used for evolutionary analysis of HBV until very recently (Bollyky et al, 1999). 
The tree that makes the most probable evolutionary outcome is the maximum likelihood 
estimate of the phylogeny. Likelihood says nothing about the probability of the model 
itself. Given a model that specifies probabilities of observing various events, the likelihood 
can be computed. This can be written as:
L=Pr(D/H)
where Pr(D/H) is the probability of getting the data D given hypothesis H. As L is often a 
very small number, likelihoods are often expressed as natural logarithms and referred as 
log- likelihoods. This mathematical expression makes likelihood a powerful tool for 
hypothesis testing. Also it provides a mathematical tool to see which of the chosen 
nucleotide substitution models results in a greater increase in likelihood (Huelsenbeck, 
1997).
Given that observed distances may underestimate the actual amount of evolutionary 
change, there has been a considerable amount of research in developing methods of 
converting observed distances into measures of actual evolutionary distance. These 
techniques are termed distance correction methods, which use different substitution 
models. Transition/transversion bias and unequal base frequencies have to be taken into 
account in order to obtain higher likelihoods. The relative degree of fit between each 
model and the data can be evaluated by computing for each model (see table 6) the
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likelihood of obtaining the observed data. For HBV infection, the HKY 85 substitution 
model seems to be the most appropriate and commonly used (Bollyky et al, 1999).
Substitution
model
Base frequencies Transversion/transition ratio
Jukes-Cantor
(JC)
Equal All substitutions equally likely
Kimura 2 (K2P) Equal Transversions and transitions 
have different substitution rates
Felsenstein (FBI) Unequal All substitutions equally likely
Hasegawa et al 
(HKY85)
Unequal Transversions and transitions 
have different substitution rates
General
reversible (REV)
Unequal All six pairs of substitutions have 
different rates
Table 6 . Interrelationships among the five best-known models for estimating the number 
of nucleotide substitutions among a pair of DNA sequences.
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Different sites have a range of probabilities of . substitution. It was difficult. to develop 
tractable models of this rate variation. The most widely•. used approach makes use of the 
gamma distribution. This distribution has ‘shape’parameter a, which specifies the range of 
rate variation among sites. Small values of a  result in an T-shaped distribution with 
extreme variation of rates. Conversely, the larger the smaller the range of rates. These a  
values on different genes of HBV are relatively small reflecting quite different rates of 
substitution in different parts of the genome (Bollykyn et al, 1999).
One reason for a poor estimate of a phylogeny may not be the method used, but limitations 
in the data themselves. Estimates of phylogeny based on samples will always be 
accompanied by sampling error. Trees are complicated structures and it is extremely 
difficult to develop equations for confidence intervals around a phylogeny. An approach 
called bootstrap mimics a multiple sample approach with resampling from the sample. 
Each resampling is a pseudoreplicate. Bootstrapping can be applied to phytogenies by 
generating pseudoreplicates from the sequence data. Pseudoreplicates will resemble the 
original data set in that they contain only sites found in the data set, but will differ in 
frequencies at different sites. From these pseudoreplicates it is possible to build trees using 
conventional methods. The process can be repeated in a large number of times (up to 1000 
fold) resulting in a set of bootstrap trees. This set of trees contains information on the 
sampling error associated with our sample. The most common splits found among the 
bootstrap tree can be assembled into a bootstrap consensus tree. These are often drawn 
with each node labelled with its frequency of occurrence among the bootstrap trees. 
Originally it was suggested that only nodes with bootstrap values above 95% should be
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accepted and well supported (Sanderson, 1995), but currently values higher than 70% are 
considered as having a statistical significance (Holmes E, personal communication).
Maximum likelihood provides a natural means for hypothesis testing. Likelihood ratio tests 
(LRTs) are known to be optimal when comparing simple hypotheses and the same time 
they often perform well for cases in which no optimal test is known. The likelihood ratio 
provides a measure of the support of the data for one hypothesis versus another.
Null distributions.can be generated by using computer simulation (Felsenstein, 1988).. 
parametric bootstrapping or Monte Carlo simulation of phylogenetic trees has been
previously described (Huelsenbeck, 1997). Program package PAUP 4.0 has a tree
!
simulation option and generation of-simulated trees fiom the given phylogenetic tree is 
easy to perform. ML logarithmic values fiom each simulated tree can be obtained and then ,
compared to other logarithmic values obtained from the real ML trees.
!
I . ‘ ;
Explicit model-based methods are a recent innovation in phylogenetics and published 
information is very limited, but it is clear that these approaches allow a much broader ! 
evolutionary analysis.
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2.9 Geographical setting of the study
2.9.1 The country
The Gambia lies on the west coast of Africa, between latitudes 13 ° W and 17 ° W. The 
country forms a narrow band on either side of the River Gambia and is almost entirely 
surrounded by the Republic of Senegal (see figure3). The Gambia averages about 24 km in 
width and extends along both banks for about 487 km. The total area of The Gambia is 
10367 km2.
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Figure 3. Map of the Gambia
The Gambia a population of is 1038145 inhabitants according to the 1993 Census. The 
highest concentration of the population is in the periurban areas of Banjul, Serekunda and 
Brikama. The main ethnic groups are Mandinka (40%), Fula (19%), Wollof (15%), and 
Jola (10%). Other ethnic groups as Manjago, Sere re, Sarahule are in minority. The annual
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population growth rate is 4,1% and the population density is 46 people per square 
kilometre. The vast majority of Gambians are Muslim.
Administratively, The Gambia is divided into 5 Divisions and 2 Municipal Areas. The two 
municipal areas are Banjul and Kanifing, each including the periurban areas around the 
coast. The divisions are the Western Division, the Lower River Division, the Central River 
Division, the Upper River Division and the North Bank Division.
The climate of the Gambia is tropical with two distinct seasons: a dry season from 
November to June, and the wet season from June to October.
2.9.2 Geographical distribution of villages involved in study
The study referred to in this thesis was carried out throughout all Gambia. The main MRC 
laboratories in Fajara and Basse, and the Farafenni field stations were used to access 
known carriers from each village.
2.9.3 Ethnic groups participating in the study
The main ethnic groups represented in the study are Mandinka Wollof, Fula, Jola, Sarahule 
and Serere. Some refugees from countries such as Sierra Leone, Guinea Bissau were 
occasionally included in the study.
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2.10 Study Objectives
To characterise the family clustering of HBV carriage in Gambian families by analysing 
the prevalence of HBV serological markers in siblings according to their age, birth order, 
sex, and serological status of their parents.
To characterise predominant genotypes and subtypes of HBV in The Gambia by obtaining 
consensus sequences of HBV surface, core promoter, and pre-core/core genes and confirm 
or exclude the presence of HBV mutations with clinical significance.
To employ phylogenetic and statistical methods of HBV sequence analysis to confirm 
hypothesis on horizontal transmission of HBV within Gambian families by combining it 
with epidemiological data.
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3 Methods
3.1 Field work
The field work was done with the help of two field workers- Mr.Lamin Giana and Mr. 
Joseph Bass. Patients were usually visited three times by the field worker and once by me 
for the bleeding.
3.1.1 Finding of carriers, getting consent from family members and making 
appointments
Data about carriers were taken from the databases of previous studies in The Gambia. 
Information about the carrier’s name, surname, name of their parents and village of 
residence were usually available. The field worker had to find the carrier and talk to his/her 
parents. All siblings of the index case older then 10 years (not vaccinated against Hepatitis 
B) and parents were asked to take part in the study and give a blood sample. The consent 
form was completed for every blood sample taken.
In some families all family members were bled during the previous surveys (Keneba and 
Manduar), so siblings carriers were already identified. On such occasions only those 
known to be positive and their parents were bled.
Following verbal explanation the consent form was signed by the field worker on behalf of 
every person participating in the study.
Example of the consent form shown as Appendix I
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At the same time, a questionnaire was completed to document the family status, how many 
siblings were vaccinated, how many were not present and where they could be found.
An example of the family field questionnaire shown as Appendix II.
After the first visit, consent was obtained and appointments were made for bleeding on the 
next occasion.
3.1.2 Bleeding
5-10 ml of blood usually was taken through venepuncture from each patient. 1ml of the 
specimen was stored in a serum separator (Becton Dickinson) and the rest of the blood in a 
10ml EDTA tube. Specimens were stored in a cool box until arrival to the laboratory. 
Before bleeding the questionnaire was completed for every person bled. The field worker 
completed the left side of the questionnaire and I filled the right side later in order to check 
for mistakes. Example of field questionnaire shown as Appendix III
Immediately after arrival from the field, both tubes were spun at 3500 rev/min for 10 min. 
Serum in microseparators was stored at -20°C. Plasma from EDTA tubes was immediately 
separated and stored at -70°C.
3.1.3 Delivery of preliminary results
Serum was tested for HBsAg status and the field worker delivered the form shown in 
Appendix IV to parents or to every family member separately. He explained the
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consequences of a positive result and also informed them why they will be visited later 
again for follow up studies.
3.1.4 Data entry and statistical analysis of epidemiological data and 
laboratory results
All information from the field questionnaires and laboratory sheets were entered into EPI 
INFO version 6.02 program package. The same package was later used for statistical 
analysis.
3.2 Laboratory work
3.2.1 Hepatitis B serology
3.2.1.1 HBsAg detection
Reverse passive agglutination (Hepato-test, Wellcome Diagnostics) was used to detect 
HBV surface antigen. Positive tests were confirmed by neutralisation reaction, according 
to the manufacturer’s instructions.
Despite RPA being less sensitive than other conventional methods (RIA, ELISA) it was 
decided, that the shortfall in study like this would not be substantial in achieving the m ain  
aim; collection of families with multiple affected siblings. The other consideration was that 
we had to bring preliminary results as soon as possible back to the families bled. The RPA 
for field conditions was much more convenient and the number of samples tested can be 
very small. Previous studies in The Gambia showed that the difference in sensitivity 
between RPA and RIA is around 3-5% (Whittle H, personal communication).
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All negative samples were later retested fo r : hepatitis B surface antigen with an* 
immunoradiometric assay (Sorin Biomedica) to achieve highest possible sensitivity.
3.2.1.2 Other H BV serology
An HBeAg/anti-Hbe immunoradiometric assay kit (DiaSorin) was used according to the 
manufacturers instructions for detection of HBeÀg, anti-HBe, Total anti-Core; and anti- 
Core IgM . '
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3.2.2 PCR and sequencing
3.2.2.1 Buffers and solutions
Ethidium bromide 10mg/ml ethidium bromide solution in sterile deionised distilled 
water
1% Agarose gel 
solution
Ig of Agarose to 100 ml TBE
TBE buffer 0.9 M Tris, 0.9 M Boric Acid, 25mM disodium EDTA (pH=8,3)
dNDPs 20 pi for each dNTP (lOOmM solution) 
320 pi of water
Chloroform Chloroform/isoamyl alcohol (25:1) equilibrated pH 8
Phenol Saturated with 0.1M citrate buffer pH 4.3, equilibrated with water 
(pH adjusted to 7.5)
Loading buffer for
automated
sequencing
99.5% deionized formamide and 25 mM EDTA containing 
50mg/l dextran blue in a ratio of 5:1 formamide to EDTA/ dextran 
blue
2.5X sequencing 
buffer
200mM Tris/HCl pH=9, 5mM MgCl
6X agarose sample 
loading buffer
0.25% bromophenol blue, 0.25% xylene çyanol FF, 40% sucrose 
in deionised distilled water
Table 7. Buffers and solutions
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Films and photographie reagents
Kodak instant films were used for photographing of gels.
Molecular weight markers
lOObp DNA ladder consisting from . 11 double-stranded fragments with sizes of 100, 200, . 
300, 400, 500, 600, 700, 800, 900, 1000, 1500 (Promega) was used in all agarose gels as a 
molecular weight marker. . .
S.2.2.2 DNA extraction
HBeAg
positive
HBeAg
negative
Stock solution
- - * -
Serum dr 
Plasma
50 pi 150pl
1 OX buffer 20 pi 40 pi 250mM NaCl/25mM 
EDTA
Proteinase
K
20  pi 40 pi 20  mg/ ml
t-RNA 2,5 pi 5 pi 8 mg/ ml
10% SDS 20  pi 40pl 10 g /100ml (10%)
Water 87,5 pi 175 pi
Table 8 . DNA extraction mix
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The mix was incubated at 37° C overnight, extracted twice with Phenol/Chloroform and 
once with chloroform, before precipitation of the DNA by adding 1/10 of the volume 3 M 
Na Acetate and 2 volumes of 100% ethanol at -70° C for one hour. Following 
centrifugation the pellets were washed with 70% ethanol and dried before resuspending the 
pallet in 2 0 pl of distilled water.
3.2.2.S PCR amplification o f HB VDNA
3.2.2.3.1 PCR reaction
The following reagents were mixed in eppendorf tube for the amplification of the target 
region by PCR.
Stock Final concentration
DNA 5pl
Buffer lOpl 1 OX PCR 
buffer
lOOmM Tris-HCl 
500mM KC1 
0,8% Nanidet P40
MgCl 6 jjl 25 mM 1,5 mM
dNTP 4pl 100 mM 10 mM (mix)
Primer 1 Ipl . 0 .2  pmol
Primer 2 Ipl 0 .2  pmol
Water . 73 pi -
Taq 0 ,2 pl 5 U/ ml
Total 1 0 0 ,2 pl
Table 9. PCR reaction mix.
85 ,
The thermo- cycling conditions for both the first and second round reactions
Time Temperature Number of Cycles
4 min 95°C 1
Imin 95°C
Imin 53°C 40
2,5 min 72°C
10min 72°C 1
Table 10. Thenno-cycling parameters of PCR
Negative samples after first PCR round were subjected to heminested PCR using another 
set of primers.
3.2.23.2 PCR of the pre-core/core gene
Oligonucleotides
M3
S’-CTGGGAGGAGTTGGGGGA Position 1732-1755 (sense)
6C
5 ’-GGCAAGCCATTCTTTGCTGGGG Position 2070-2092 (sense)
SC
5’-CCCACCTTATGAGTCCAAGG Position 2466-2486 (anti-sense)
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Pol8
5’- AGG AT AG AAT CT AGC AGGC Position 2649-2667 (anti-sense)
8C
5*-GTCCCTGGAI GCTGGATCTTGCT Position 2130-2154 (anti-sense)
PCR reactions
a) M3-POL8 for the first round 
Length of product, 935 bp
b) M3- 5C for the second round 
Length of product, 754 bp
Other combination of primers were tried later to improve the sensitivity of the reaction
a) M3-5C for the first round
Length of product, 754 bp
b) M3-8C and 6C-5C for the second round (heminested PGR)
Length of product 420bp with primers M3-8C
Length of product 416bp with primers 6C-5C
2 pi of the first round PCR product were used as template for the second round PCR.
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3.2.2.33 Surface gene 
Oligonucleotides
53
5’ CAAGGTATGTTGCCCGTTTG Position 457-476 (sense)
54
5’ GGGTTTAAATGTATACCCAGAGAC Position 817-838' (antisense)
Reaction S3-S4 ■ '
Length of product, 381 bp
i  , * ■
3.2.23.4 Analysis of PCR products
PCR products were analyzed by agarose gel electrophoresis in TBE buffer. 7 pi of the PCR 
sample was run on a 1% agarose gel by adding 2 pi of 6X loading buffer. 4 pl of lOObp 
DNA ladder was also added to each gel run. The gel was stained by shaking in a solution 
of 10 fig/ml ethidium bromide and bands were visualized under UV illumination and 
photographed.
3.2.2.4 DNA purification
A  QIAquick purification kit was used to extract the DNA fragment from the 1% agarose 
gels, after running 50pl of the PCR product. To the excised gel slice 400pl of Buffer QG 
were added and incubated for 10 min at +50°C, the mix was poured into spin column and 
centrifuged for Imin, and the immobilized DNA was washed with 500pl of QG buffer and 
subsequently with Buffer PE, before centrifuging again. Finally, 25pl of elution buffer was 
added and the DNA was stored at -20° C.
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After purification 5pi of the product were run in 1 % agarose gel to assess the quality and 
size of the purified product.
3.2.2,5 Sequencing
Automatic sequencing was done on an ABI PRISM 377 DNA sequencer (Perkin-Elmer) 
and sequences read with supporting software for line extraction and analysis.
Sequencing reaction
Purified PCR product 2  pi
2,5X Sequencing Buffer 4 pi
Big Dye Terminator 4 pi
Primer (l.Spmol solution) 2  pi
Distilled water 8 pi
Total 2 0 pl
Thermo cycling parameters of sequencing reaction
Imin 96°C
0 .5min 50°C 25cycles
3min 60°C
Extension 4 °C
Sequencing gel . ' j
Acrylamide gel:
18 g Urea
5,3 ml Acrylamide solution
. . * ' , . . . 1 , ■ ■ ' 1 ' ■' "
5 ml 10X TBE buffer
250^1 10% Ammonium Persulphate
. -  ■ -  - v :  .
35|il TEMED
27,5ml Water
' . •
After thermoGyclings the products were precipitated by adding 50pl of 95% Ethanol and 2
pi 3M Na Acetate solution. This was allowed to stand for 10 min and then centrifuged. The
;  ' ,  ■ ,
pellets were washed with 70% Ethanol, centrifuged again, vacuum dried and then stored at 
-20  °C .
Before sequencing 6  pi of sequencing loading buffer were added to the pellet and the DNA 
denatured at 95 °C for 2 minutes. 2pl of this solution were loaded onto the sequencing gel.
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3.2.3 Analysis and editing of the sequences
Editing and translating sequences to protein sequences- programme package DNASIS 
Sequences obtained by automatic sequencing were edited by comparing with the published 
ayw subtype sequence (Norder et al, 1993).
Afterwards sequences were exported to Notepad format document and aligned in FASTA 
format for further phylogenetic analysis.
Protein sequences were translated from nucleotide sequences using DNASIS programme. 
Editing and comparing protein sequences
Programme package PROSIS was used for editing and alignment of amino acid sequences.
3.2.4 Phylogenetic analysis 
Sequence alignment
All sequences were aligned in FASTA format (see appendix 6). Afterwards they were 
changed to NEXUS format (see appendix 7) by using programme SeqVerter (downloaded 
from www.genestudio.com/seqverter.html). This alignment can be afterwards used by the 
PAUP 4.02b programme package.
Pictures of alignments used in the thesis were produced using Multalin program Web 
interface (http://www.toulouse.inra.fr/multalin.html) (Corpet).
Neighbour joining trees.
NJ trees on S gene sequence fragments and Precore/core gene seqeunces were constructed 
by using PAUP 4.02b programme package.
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Maximum likelihood trees.
Two genotypes A and E were analysed separately in order to reduce sample size and.make 
mathematical calculation more efficient. Later sequences were devised according to their 
HBeAg status. This resulted in four different sequence data sets; (I) all available genotype 
A sequences (n = 14), (II) all available genotype E sequences (n = 99), (III) HBeAg 
negative samples from genotype E (% = 30), (IV) HBeAg positive samples from genotype 
E (tz = 53). Note that the sum of the E antigen negative and positive samples is less than 
the total number available for this genotype because, in both of these cases, sequences, 
which were the sole representatives from a village, were also excluded. It was not possible 
to subdivide the genotype A sequences by E antigen status because of the small number of 
samples available.
Phylogenetic relationships among the HBV sequences sampled were reconstructed 
using a maximum likelihood (ML) method. This method incorporated the Hasegawa- 
Kishino-Yano (HKY85) model of nucleotide substitution with a gamma distribution of rate 
variation among sites. Both the transition/transversion (Ts/Tv) ratio and the a  shape 
parameter of the gamma distribution, which determines the extent of rate variation, were 
estimated during tree reconstruction. To assess the robustness of this phylogeny, and 
particularly whether viruses were clustered according to the family and village from which 
they were sampled, a bootstrap resampling analysis was undertaken (1000  replications), 
although computational constraints meant that this analysis was based on replicate 
neighbour-joining trees reconstructed using the ML substitution model.
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A maximum likelihood approach was also used to determine whether sequences were 
clustered by family and village more than might be expected by chance alone. First, for 
each of the four data sets, 200 random tree topologies were constructed. The log 
likelihood of each of these replicate trees was then estimated, again using empirical Ts/Tv 
and a  values. As these trees represent random assortments of the data, they effectively 
constitute a null distribution of log likelihoods. Next three “model” trees, representing 
clustering at different levels of population structure, were constructed using the TreeView 
programme: (I) one in which only sequences from the same family were grouped together, 
with all other branches left unresolved, (the “family” tree) (II) one in which only sequences 
from the same village were grouped together, with all other branches left unresolved and 
ignoring what family they came from (the “village” tree) and (III) one in which sequences 
from the same family and village were grouped together (the “family+village” tree). The 
log likelihoods of these model trees were then estimated under the data as before. If these 
likelihoods fall outside the null distribution then we could conclude that the HBV sequence 
data shows more clustering by family and village than might be expected by chance. It 
should be noted that this randomisation test was highly conservative because most 
branches are left unresolved, particularly when the data were only partitioned by family, 
and therefore ignored any other phylogenetic signal in the data. All phylogenetic analyses 
were undertaken with PAUP 4.02 package (Swofford).
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4 Human epidemiology of HBV and characteristics of the 
chronic HBsAg carriers
4.1 Introduction
Hepatitis B virus (HBV) infection is endemic in the Sahel area of West Africa (Barin et al, 
1981; Whittle et al, 1983), where high rates of hepatocellular carcinoma (HCC) associated 
with chronic carriage of the virus are reported (Bah et al, 1990). Chronic infection with 
HBV acquired early in life is the major risk factor for development of HCC in humans. 
HCC is the major cause of cancer mortality in males in the African continent (Pisani et al, 
1997). Mass vaccination against HBV, introduced in The Gambia in 1986, was very 
effective in preventing chronic infection in children (Viviani et al, 1999; Fortuin et al, 
1993) but disease burden still remains high in the adolescent and adult population.
Epidemiology of HBV infection in The Gambia was discussed in detail in the main 
Introduction (see 2.6.4). It was shown previously that most of the HBV infections in The 
Gambia are acquired in early childhood and mother to child transmission is not a 
predominant route of transmission, because majority of babies do not become positive until 
6 months to 1 year after birth (see 2.3.1.3). Possible horizontal transmission between 
children has always been suggested but the exact mechanisms of the transmission were 
never found. It is also known that males in The Gambia are more likely to become chronic 
HBsAg carriers and to develop I ICC than females. Significant clustering of HBsAg 
positivity among siblings on the village and compound level was previously described in 
two Gambian villages (Whittle et al, 1983 and 1990).
The main original aim of the sample collection was to investigate the genetic determinants 
of susceptibility to persistent infection and disease with HBV. A large number of affected
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sibling pairs was recruited for this study in order to perform the whole genome scan (see 
2.6.3). ■
4.2 Results
1180 people from different areas and ethnic groups of The Gambia were bled during the 
study. Samples were taken from 351 previously known chronic HBsAg carriers and in 181 
cases their family members whose HBsAg status was unknown were also bled. Children 
younger then 9 years were not tested because they were assumed to be vaccinated.
95
Previous
study
Number of 
carriers
Sex Age group (years)
M F 9-19 20-29 30+
E-study 26 13 13 9 6 11
Keneba and 
Manduar 
study (2.6.4.2)
184 88 96 79 57 48
The Hepatitis 
Intervention 
study 
(2.6.4.4.2)
207 91 116 139 26 42
Studies on 
risk factors of 
transmission 
(2.6.4.3)
45 29 16 45
Total 462 221 241 272 89 101
Table 11. Known index carriers bled in previous studies and their sex and age distribution.
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Fathers Mothers Sons Daughters
Bled 92 (51%) 107 (75%) 321 (58%) 308 (62%)
Not bled 87 74 234 190
Total 181 181 555 498
Table 12. Proportion of family members found and bled in families where only one carrier 
was identified previously.
29% (125/424) of the siblings not bled were under 9 years of age and therefore vaccinated 
and most likely protected against the HBV infection. The rest of them were not present at 
the time of bleeding or refused to take part in the study. Fathers who were not bled usually 
were travelling or refused to take part in the study.
624 samples tested were HBsAg positive and anti Core IgM negative. Two samples were 
found to be anti-HBc IgM positive and therefore not defined as chronic HBV carriers. 439 
(93%) out of 473 HBsAg negative samples tested for total anti-Core antibodies were found 
to be positive. Other 82 HBsAg negative samples were not tested because the amount of 
the plasma sample was insufficient (2 0 0 pl was needed for each serological reaction).
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Ethnic group Total bled Prevalence in bled Prevalence in 
Gambian 
population
Mandinka 765 65% 40%
Wollof 95 8 % 15%
Jola , 63 ;» ' ' 4  ’ 5% ; 1 0%
Fula 85 7% 19%
Sarahule 81 7% 7%
Other 93 8 % 9%
Total 1180
Table 12. Prevalence of the ethnic groups in study subjects in comparison to the overall 
prevalence in The Gambia.
The proportion of Mandinka ethnic group is higher because most of the persons were bled
. .* ■ • •
in Basse, Brikama and Keneba areas where the Mandinkas are the predominant ethnic 
group.
Family clustering of HBV infection
Family clustering was defined as present if at least one sibling of the known carrier or 
parents were found to be chronic HBV carriers.
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In 181 families HBsAg status was known only in one sibling and the rest of the family 
members were bled and tested. In 142 (78%) of these families at least one more sibling 
was found to be a chronic HBsAg carrier. In 34 families family clustering was already 
previously confirmed and only known earners were re-bled. In 55 families only one 
previously known carrier and only one sibling with an unknown HBsAg status were bled. 
In 27 (49%) of families that another sibling was found to be a chronic carrier.
Chronic HBsAg carriers Siblings bled
Number of 
carriers in 
the family
Number of families 
with chronic HBV 
carriers
Number of 
siblings bled in 
each family
Number of families
1 64 1 70
2 85 2 36
3 51 3 49
4 10 4 22
5 5 5+ 22
Total 215 222
Table 14. Numbers of siblings bled, number of HBsAg carriers found and the number of 
families tested. In some families the only sibling bled was found to be HBsAg negative 
that could be the explanation why some families did not have chronic carriers.
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Prevalence of HBsAg positivity in family members of previously known carriers
Families with multiple HBsAg 
carriers
Families with at least one 
carrier
HBsAg positive Tested HBsAg positive Tested
Fathers 8 (1 1 %) 72 14 (12%) 114
Mothers 24 (24%) 99 33 (23%) 144
Table 15. Prevalence of HBsAg positivity in parents from all families with at least one 
sibling carrier and from the families with multiple siblings. (11 mothers from E study 
(2.6.4.5) are excluded because they were already known HBeAg carriers 6  years ago and 
their children were bled in order to characterise mother to child transmission).
Mothers were more likely to be the carriers than fathers (p=0.01, % 2 test) (see Table 15) in 
the families with multiple affected siblings and in the families of single carriers (p=0 .0 2 , % 
2 test). The HBsAg prevalence in the fathers was similar to the rate reported in the normal 
population.
In this study only four mothers of the carriers were found to be HBeAg positive. That was 
not enough to do any statistical analysis on the influence of HBsAg status of the mother.
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Siblings HBsAg prevalence in tested Tested Not tested
Sisters 37% 203 204
Brothers 57% 201 248
Table 16. HBsAg status according to sex of the siblings of the chronic carrier. (Data from 
21 families where HBsAg status of family members was known previously are excluded).
These data (see table 16) show clearly that chronic Gambian HBsAg carrier has a very 
high chance of having a sibling carrier, which is much higher than overall prevalence of 
the chronic carriage (10-15%) in The Gambia (Whittle, 1990).
Brothers of the carriers were statistically more likely to be carriers (p<0.001% 2 test) than 
sisters of the carriers. The relative risk of being a carrier if you were a male sibling versus 
a female one was 2,1 (1,4- 3,1). After adjustment for age using logistic regression approach 
this was completely unchanged i.e. age made no difference.
HBsAg carriage according to the HBsAg status of other family member
From the family data available it was very difficult to analyse carriage rates according to 
the birth order, family size and HBsAg or HBeAg status of the mother, because too many 
family members were not bled or were vaccinated and therefore protected against 
infection. However, it was possible to see the distribution pattern of the infection within 
the families with multiple chronic HBsAg carriers.
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If we assume that transmission from mother to the. child occurs, then we expect that 
children bom first are more likely to become chronic HBsAg carriers, because at the 
younger age mothers are more likely to be HBeAg positive with higher viral loads. Only 
two mothers from families with multiple HBsAg carriers were HBeAg positive, but their 
status at the time of actual transmission of the infection was not known. The prevalence of 
HBsAg positives in the mothers of multiple carriers is significantly higher than in fathers 
or at the population at large. That indicates a possible link between mother’s and child’s 
HBsAg status. . - . ,
Birth order HBsAg carrier 
mother (N=13)
Non-carrier mother 
(N=44)
Mother’s status 
unknown (N=153)
1 1 1 1
2 0.4 (0.1-2.5) 2.4 (0.8-7.0) 1.5 (0.8-2.8)
3 2.8 (0.5-173) 3.0 (1.0-8.5) 2.7 (1.4-53)
4 0.8 (0.1-73) 5.5 (1.7-17.9) 1.7 (0.8-3.5)
5 - 5.0 (13-19.5) 1.9 (0.8-4.5)
6 1.6 (0.1-38.0) 6.0 (1.2-29.2) 6.6 (1.5-27.9)
7 7.0 (1.4-35.5) 4.9 (1.2-20.1)
Test of trend p=0.4 P=0.003 PO.OOl
Table 17. Relation of birth order adjusted to family size and HBsAg status of mothers.
If we assume that children became infected from older HBeAg positive siblings then the 
carnage rate in younger siblings should be higher, because they are getting exposed to the 
virus earlier and therefore are in higher risk of becoming carriers. Many families were
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clearly following this pattern where several first siblings were HBsAg negative and their 
younger siblings were carriers (see Appendix V, families 40, 108), but this was not enough 
to draw a conclusion that in the families with multiple affected siblings younger children 
were in higher risk of developing a chronic infection. Also, I did not know whether 
siblings had grown up in the same compound or had travelled during childhood.
Analysis in Table 17 shows that birth order was not a significant risk factor for the chronic 
HBsAg carriage in families with a carrier mother, but the difference was significant for the 
trend in families where mothers were non-carriers or their carrier status was unknown. 
The number of families was small but these data indirectly indicated that acquisition of the 
HBV from older siblings takes place in families with multiple chronic HBsAg carriers.
Clustering of the HBeAg in Gambian families
I defined a clustering of the HBeAg in the family as a presence of two or more HBeAg 
positive family members in the family. In 24 families clusters of the HBeAg positive 
siblings were identified. They were not always the youngest siblings. Some HBsAg 
carriers already seroconverted to anti-HBe but their older siblings remained HBeAg 
positive. For example, in family 174 only oldest and youngest out of three sisters HBsAg 
carriers bled were HBeAg positive (see Appendix V).
Extremely interesting were families 141, 61 and 217 (see Appendix V) where all siblings 
tested were found to be HBeAg carriers. These families are of special interest for future 
molecular epidemiology and human genetic studies.
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Age
(Years)
Males Females
HBeAg
positives
(%)
Total HBeAg
positives
(%)
Total
10-14 48 70/147 30 25/84
15-19 37 21/56 21 9/42
20-29 12 5/43 13 8/63
30-39 15 2/13 5 3/55
40+ 10 2 /2 0 3 1/33
Total 36 279 17 277
Table 18. Prevalence of HBeAg positives in HBsAg carriers adjusted to their age and sex. 
Selection of these age groups better reflects the dynamics in age group 10 to 20 where the 
most of the seroconvertion occurs.
The sex difference in the HBeAg carriage was significant for the trend adjusted for age. 
Therefore boys remain as potential reservoirs of infection for longer. It is also evident that 
most of the patients become HBeAg negative at the age of 15-20 when most of 
séroconversions occur.
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Surface gene 
(% positives) 
First PCR
Core promoter/pre-core/core gene (% positives)
First PCR Second PCR 
on 1-st 
negative
Total with 
core primers
HBeAg
positives
83%(83/99) 54% (54/100) 80% (37/46) 91%(91/100)
HBeAg
negatives
27% (44/160) 14% (21/155) 48% (60/124) 52%(81/155)
Total 50 % (127/259) 33% (75/255) 57% (97/170) 73%(186/255)
Table 19. PCR positivity according to HBeAg status
The PCR on pre-core/core genes was performed with different primer sets. Though 
sensitivity of the assay at the first PCR varied from 20 to 85 % during the optimisation of 
reactions the total sensitivity of both reactions was acceptable in comparison with other 
studies (Karayiannis, personal communication). The surface gene PCR worked better from 
the very beginning and hemi-nested PCR was not performed. This means that the overall 
sensitivity of this assay is lower than on pre-core/core reaction. PCR on pre-core/core and 
surface genes were not always performed on the same samples so the data shown in table 
19 should be interpreted cautiously.
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Age PCR positives in 
males
PCR positives in 
females
Total
prevalence
10-14 73/87 (84%) 38/51 (74%) 111/138 (80%)
15-19 34/50 (6 8 %) 11/32 (34%) 45/82 (55%)
20-29 19/36 (53%) 20/40 (50%) 39/76 (51%)
30-39 2/9 (22%) 10/24 (42%) 12/33 (36%)
40+ 4/11 (36%) 6/16 (37%) 10/27 (37%)
139/200 (69%) 86/166 (51%) 225/366 (61%)
Table 20. Prevalence of the PCR positivity adjusted to age and sex (PCR results of surface 
and core genes are combined).
PCR positivity could also serve as a good marker for high viral load. Table 20 cannot give 
a completely objective picture, because the sensitivity of PCR assay improved significantly 
during the optimisation. The purpose of this study was not to get higher sensitivity, but to 
get sequences from affected siblings and their parents. The high prevalence of PCR 
positives in the group of women aged 20-39 could be biased, for 11 of them were part of 
the mother to child transmission study (E-study) and 6 years ago were already known to be 
HBeAg positives. The PCR on pre-core/core gene was started on samples from the 
younger age group and HBeAg positives and then after optimisation it was done on the 
older age groups. Therefore the sensitivity of the assay performed on older age group was 
higher.
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The decline of the PCR positivity according to age is still obvious. There is a statistically 
significant difference between the rates of PCR positives in males and females in the age 
group from 10 to 19 years, corresponding to the sex difference in rates of HBeAg carriage.
Levels of aminotransferases
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Figure 4. ALT levels in HBsAg positive and HBsAg negative patients.
ALT (lU/ml) HBsAg negative HBsAg positive
0-39 439 385
40+ 3 (1%) 27 (7%)
Total 442 412
Mean age (Years) 30 21
Table 21. Levels of ALT in HBsAg positive and HBsAg negative persons
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Internationally accepted upper limit of the assay is 40 lU/ml. The difference between a 
HBsAg positive group and HBeAg negative group is statistically significant (p=<0,001, %2 
test).
ALT Total HBsAg 
positive
HBeAg positive HBeAg negative HBsAg negative
Males Females Males Females Males Females Males Females
0-39 197 188 67 32 124 147 184 255
40+ 19 (9%) 8 (4%) 11(14%) 4(11%) 8(6%) 4 (3%) 2 (<1%) !(<!%)
Total 212 196 78 36 132 151 186 256
Mean
age
19 25 13 17 20 26 34 28
Table 22. ALT values and patients HBsAg and HBeAg status in relation to the gender of
t h  ,  ,  'the patients.
ALT values are more often elevated in male carriers (p=0.05, % 2 test). But HBsAg 
positive males bled were on average younger then females and probably have higher viral 
replication, which could lead to elevated enzyme levels. This has not been reported before.
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Figure 5. AST levels in HBsAg positive and HBsAg negative patients
AST HBsAg negative HBsAg positive
0-39 382 291
40-59 48 (11%) 83 (20%)
60+ 16 (4%) 41 (10%)
Total 446 415
Mean age (Years) 30 21
Table 23. Levels of AST in HBsAg positive and HBsAg negative persons
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40 lU/ml is widely accepted as cut off value for the test, but Mean +2SD can also be used 
(ter Borg, 1998). Out of 300 HBsAg negative Gambian samples it was calculated to be 
60IU/ml.
AST elevations are significantly higher in HBsAg positive patients (p<0,001,%2 test). 
Interestingly, mildly elevated ASTs are quite common in HBsAg negative persons. 
Possibly other diseases (malaria) or environmental factors (aflatoxin) could explain this 
observation. The prevalence of elevated AST in HBsAg carriers is quite high.
AST
lU/ml
Total HBsAg 
positive
HBeAg positive HBeAg negative HBsAg negative
Males Females Males Females Males Females Males Females
0-39 139 151 45 19 89 126 159 223
40-59 50
(23%)
25
(13%)
21
(26%)
11
(30%)
26
(20%)
12
(8%)
24
(13%)
28
(11%)
60+ 25
(12%)
16
(8%)
13
(16%)
7
(20%)
12
(9%)
9
(6%)
5
(2%)
7
(3%)
Total" 214 198 79 37 127 147 188 258
Table 24. AST levels and HBsAg and HBeAg status in relation to the gender of the patient. 
Prevalence of elevated AST was similar in HBeAg positive patients of both genders
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Clearance of the HBsAg carriage
10% of chronic HBV carriers bled after interval of 6 to 10 years were found to have 
cleared the HBsAg (see Table 25). All 351 previously known carriers bled during this 
study were previously confirmed as chronic carriers by double bleeding after a year’s 
interval. No sex difference in this clearance was observed.
Sex Cleared HBsAg (%)
Males 10 (17/169)
Females 9,3 (17/182)
Total 9,6 (34/351)
Table 25. Relation of sex and clearance of HBsAg over 6-10 year time period
Age at the time 
of the bleeding
Cleared 
HBsAg 
carriage (%)
10-19 8 (18/238)
20-29 9 (5/57)
30- 18 (10/55)
Total 10 (33/351)
Table 26. Relation of age and clearance of HBsAg over 6-10 year time period.
At the time of previous testing, when they were found positive, patients were 6-10 years 
younger. Data in this table shows that the clearance is increasing after 20 years of age.
I l l
4.3 Discussion
The main aim of this study was the collection of human DNA for further genetic studies on 
families with multiple HBV carriers. In many families a large proportion of the siblings 
were not bled, because they were vaccinated or not available at the time of bleeding. 
Children up to 10 years old were not bled, because presumably they were vaccinated. 
Mother HBeAg status at the time of the actual infection could not be established since the 
children were bled at least 10 years after the actual infection. Considering all these factors, 
this study cannot give a complete insight on HBV transmission in The Gambia, but can 
shed light on the clinical course of the chronic carriage and the epidemiology of infection 
in families with multiple carriers.
The prevalence of the HBV carriage in siblings of chronic carriers was found to be 
significantly higher than in the normal population; 37% in sisters against 10% in the 
normal population and 57% to 15% in brothers. The risk that the first sibling of a chronic 
carrier will also be a carrier was 45%. The prevalence of the HBsAg carriage in mothers of 
the carriers was higher than in the normal population (25% to 10%), but the prevalence in 
fathers was the same, indicating that a mother was possibly responsible for occasional 
transmission. These data support previous observations of significant clustering of chronic 
HBV infection in Gambian villages (Whittle et al, 1983 and 1990; Vail Mayens et al, 
1990).
The prevalence of anti-HBc, which is a recognised marker of present or past infection, in 
the Gambian population is higher than 90%, which shows very high risk of exposure and 
infection (Whittle et al, 1983; Vail Mayens et al, 1990). In our study, the prevalence of
anti-HBc was found to be 93%, suggesting that nearly every person was infected at some 
stage and therefore was at the risk of becoming a chronic carrier.
Findings of my study suggest that the overall prevalence (10-15%) of the HBV carriage 
reported in previous studies does not exactly depict the actual situation in the population. 
Most of the carriers seem to be concentrated in the families. Members of these multiple 
affected families are obviously at higher risk of developing serious complications. 
Identification of these families at risk would be an important measure in reducing the costs 
of the possible therapeutic interventions.
The HBeAg carriage is associated with an increased viral replication, higher viral load, and 
HBeAg positive patients are more likely to be infectious than HBeAg negative. In the 
majority of patients, if an infection was acquired in childhood, seroconversion of HBeAg 
to anti-HBe occurred in adolescent years. This was also apparent in this study, where by 
the age of 20 to 29 only 10% of the carriers remained HBeAg positive. If we assume that 
HBeAg positive patients are more infectious then it is clear that in a case of horizontal 
transmission, infection was acquired from HBeAg positive children or adolescent siblings. 
That was already suggested previously (Whittle et al, 1983).
This study showed the remarkable difference in HBsAg and HBeAg carriage rates between 
brothers and sisters of carriers that would mean that brothers of the chronic carrier are at 
much higher risk of becoming carriers than sisters. The prevalence of HBeAg positives 
was also found to be significantly higher in adolescent males than in females. The 
explanation for this difference could either be different X chromosome encoded genetic 
predisposition or simply hormonal differences. Another less likely explanation could be
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that the boys got infected earlier for some unknown reason and therefore have developed 
HBsAg and HBeAg carriage more often. Rituals such as circumcision and scarification 
were always considered, but never confirmed as the risk factors (Martinson et al, 1999). 
Recently published evidence about the high prevalence of HBV DNA positivity in the 
urine of the chronic carriers (Knutsson et al, 2000) should be considered seriously. 
Different urination habits for boys and girls could make the difference in transmission 
pattern.
Another good marker of viral replication is detection of viral DNA in serum by PCR. 
Although the sensitivity of this assay was improved by optimisation and the data has to be 
interpreted cautiously, a trend for PCR positivity to decline with years has been observed. 
Sex difference was very significant at the age group of 15-19, again suggesting that boys 
clear viremia later than girls.
The high number of vaccinated siblings and siblings not bled did not allow proper analysis 
of the influence of birth order and family size on the development of carriage. Because of 
these reasons it is possible to talk only about a trend. In families with carrier mothers the 
first and the second siblings seemed more likely to become chronic carriers, but that was 
found not to be statistically significant. In families with multiple affected siblings the 
prevalence of HBV chronic carriage in younger siblings was significantly higher for the 
trend when the mother was HBsAg negative or her HBsAg status was unknown, indicating 
that they could get infected from their older siblings in a very young age. This is 
consistent with previous reports on birth order as the risk factor for development of chronic 
carriage and hepatocellular carcinoma (Ryder et al, 1992; Hsieh et al, 1992).
The prevalence of elevated activity of aminotranferases was shown to be significantly 
higher in HBsAg carriers than in non-carriers. 7% of HBsAg positive patients had elevated 
ALT and 10% had elevated AST. In HBeAg positives this proportion was higher (13% 
and 17% respectively). It could be speculated that these persons have more active liver 
disease but measurements were done only once and the value of single measurement of the 
aminotransferase levels is uncertain. A rather high proportion of HBsAg negative patients 
had elevated AST levels (4%). Overall, AST levels in HBsAg negatives were higher than 
the normal value for the test system (40IU/ml) and a new normal upper value had to be 
established (60IU/ml =Mean+2SD). Whether the test system was at fault or the Gambian 
population in general has constantly elevated AST activity remains subject of further 
exploration. Other factors such as malaria or chronic aflatoxin exposure could possibly 
cause constantly elevated AST.
The spontaneous clearance of HBsAg has been described previously (McMahon et al, 
1990). Our cohort of 351 previously confirmed chronic carriers was followed up over 6- 
10 years. Overall, 10% percent of the carriers cleared the HBsAg and there was no sex 
difference in the clearance contrasting with previous reports (McMahon et al, 1990). In the 
older age group, clearance was found to be higher probably because the majority of 
patients from this group had already seroconverted to anti-HBe.
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5 Molecular epidemiology of HBV in the Gambia.
5.1 Introduction
Over the past decade, increasing attention has been focused on the contribution of variant 
HBV strains to the clinical course of acute and chronic infection. Mutant HBV could 
display enhanced virulence with increased levels of HBV replication and resistance to 
antiviral therapies and vaccine escape.
HBV is a small virus with 4 overlapping open reading frames. The genes are core, surface, 
X, and polymerase, responsible for encoding core nucleocapsid protein and HBeAg, pre- 
Sl, pre-S2 and S protein, X protein, and protein with priming, RNA- and DNA- dependant 
DNA polymerase and RnaseH activities respectively.
Seven genotypes A-G of HBV have been identified so far with different geographical 
distributions (see 2.2.1.2) (Norder et al, 1992; Okamoto et al, 1988; Stuyer et al, 2000).
The envelope proteins are targets of both humoral and cellular response that are involved 
in viral clearance. Some of the envelope mutants determine the different subtypes of HBV 
and may also be selected over centuries perhaps under HLA pressure. Changes in amino 
acids 122 and 160 define the four subtypes: either lysine or arginine at amino acid position 
122 or 160 identify d/y or w/r determinants, respectively (see 2.2.1.2)
Little is known about the distribution of HBV genotypes and subtypes in West Africa. 
Only genotype E has been described so far (Lindh et al, 1997), but high prevalence of
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genotypes A and D has been reported from North, East and South Africa (Norder et al, 
1993).
Surface gene mutants are known to cause breakthrough infections in vaccinated infants and 
in patients receiving monoclonal antibodies or hyperimmune human immunoglobulin. 
Vaccine escape mutation from L to G at position 141 has been reported from West Africa 
(Karthigesu, 1994). A recent study from Taiwan reported increase in prevalence of the a 
determinant mutants in vaccinated population. Gambian mass vaccination was initiated 
approximately 10 years ago and similar changes in prevalence of mutant viruses could 
occur.
The core promoter region of the HBV genome regulates transcription of the pre-core and 
pregenomic mRNAs encoding HBeAg and HBeAg. A double mutation in the basal core 
promoter (BCP) of the HBV genome appears to arise during chronic infection and is 
thought to have a selective advantage over wild type viruses due to enhanced viral 
replication (Kaneko et al, 1995; Kidd-Ljunggren et al, 1995; Laskus et al, 1995).
The presence of HBeAg in the serum of chronic HBV carriers is considered to be an 
indicator of active viral replication and indicates high levels of infectivity. The frequent 
virological explanation for the HBeAg-negative profile of hepatitis B are mutations 
occurring within the pre-core region of HBV DNA which block the translation of the 
protein. Point mutation, G to A switch at nucleotide 1896 changes the tryptophane (UGG) 
codon into translation stop codon (UAG) in the corresponding mRNA, is usually 
responsible for defective HBeAg secretion in these cases (Carman et al, 1989). This
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mutation was described previously in South African patients (Kramvis et al, 1997), but has 
never been previously reported from West Africa.
As an alternative mechanism to abolish the secretion of a viral antigen, target of the 
immune response, the virus can use mutations within epitopes recognised by T cell 
response. The frequency of core gene mutations significantly correlates with pre-core stop 
codon mutation and active liver disease (Bozkaya et al, 1997; Ehata et al, 1992; Carman et 
al, 1992; Fujiwara, 1998).
In cross-sectional studies mutations were found significantly more frequently in known 
HBc T helper cell and B cell epitopes (Carman et al, 1995) than in interepitope regions, 
implying that they could be the result of immune selection or had some growth advantage. 
Few mutations are noted in the C-terminal portion of the core gene because this overlaps 
with the highly conserved polymerase gene. New dominant variants with changes within B 
and CD4+ cell epitopes occurring during the course of disease were detected during 
occasional exacerbations of the clinical disease in a chronic carrier (Alexopoulou et al, 
1997). In the follow up study of anti-HBe seroconverters in remission mutations occurred 
in the CD4+ epitope, but for patients with ongoing disease mutations were most likely to 
be found in B cell epitopes (Carman et al, 1997).
Pre-core/core genes from Gambian HBV have never been sequenced previously and 
prevalence of different variants is completely unknown.
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5.2 Optimisation of PCR for the surface and pre-core/core regions of HBV
In order to optimise the sensitivity of the PCR, different sets of primers were initially used.
5.2.1 Surface gene
High enough sensitivity was achieved with the primer combination S3 and S4 (see figure
9), which was shown to work on samples from other parts of the world (P.Karayiannis, 
personal communication). Hemi-nested PCR was not used, because the task was not to get 
as many PCR positives as possible, but only to get enough samples for genotyping of the 
amino acid sequences in The Gambia.
5.2.2 Pre-core/Core genes
With pre-core/core PCR products more problems were experienced.
Set of primers, which had been found to be most effective in studying Greek and Italian 
patients (P.Karayiannis, personal communication), was chosen.
Primers M3 and Pol 8 were used for the first PCR and primers M3 and
3C (5’- CT AAC ATT G AG ATT CCCG AG A, positions 2439-2460, antisense) for the
second round hemi nested PCR.
The sensitivity obtained with M3 and Pol8 (see figure 9) was rather low (20% on HBeAg 
positive samples) and the combination of M3 and 3C for hemi-nested PCR did not work at 
all.
A new primer, 5C, was designed (See 3.2.2.3.2) based on sequenced M3-Pol8 fragments 
from Gambian samples. The combination of M3-5C significantly improved the sensitivity 
of the hemi-nested PCR (80% on HBeAg positive samples), but it was still unsatisfactory.
119
The M3-5C (see Figure 9) combination was next used for the first round PCR. The 
sensitivity improved significantly (80% from the first PCR on HBeAg positive samples). 
At that stage it could be considered enough for the purposes of this study, but the 
proportion of PCR positives was very low in the HBeAg negative group, where viral load 
is known to be much lower and so hemi-nested PCR was employed.
The sequence required for study purposes was already restricted to the minimum with the 
primer combination M3-5C, so two additional primers 6C and 8C were designed so that 
both PCR products overlapped each other sufficiently to obtain the full sequence of the 
pre-core/core region (see Figure 6). Hemi nested PCR with primer set M3-5C (see Figure
10) and 6C-5C achieved 95% sensitivity on HBeAg positive samples and 30% sensitivity 
on HBeAg negative samples, similar to positivity rates obtained with other patient cohorts 
(P.Karayiannis, personal communication). M3-8C was less sensitive (25%) on HBeAg 
negative samples. Samples positive only with both primer sets were later used for 
sequencing.
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Figure 6. ORFs of HBV and positioning of primers used in this study. (Background 
picture from Nassal, 1999).
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5.3 Validation of PCR results.
DNA extraction and PCR were repeated on 8 samples and the products from both reactions
were sequenced to determine the variation of the sequences from two different reactions
and establish the probability of mistakes and the risk of possible nucleotide
misincorporation. Samples with surprisingly similar sequences from the first sequencing 
set were chosen. Phylogenetic analysis was also performed to see whether the positioning 
of the samples in the tree remained the same.
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1143
1143N
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Figure 7. Neighbour- joining phylogenetic tree on pair sequence sets from the same 
samples. Extension N indicates that sample is from the second PCR set.
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On sequencing of the second sample 1665 a small deletion was detected, which could 
explain the different positioning of (1665N) in the phylogenetic tree. Second PCR products 
from samples 1664 and 1660 were found to have one nucleotide mutation difference from 
the first PCR product but did not change their positioning in the tree. All samples were 
HBeAg positive. This analysis showed that direct sequencing of PCR products was reliable 
and did not significantly change the positioning of samples in phylogenetic trees (see 
Figure 7).
M 1 2 3 4 5 6 7
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Figure 8. 1% agarose gel with PCR products obtained with primers S3-S4 and stained with 
ethidium bromide. Legend: M-1,5 kb molecular weight marker, 1- negative control, 2 to 
7 -patient samples.
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Figure 9. 1% agarose gel with PCR products obtained with primers M3-Pol8 and M3-5C 
and stained with ethidium bromide. Legend: M-l,5kb molecular weight marker, 1- 
negative control for primers M3-Pol8, 2 and 3- PCR products with primers M3-Pol8, 5- 
negative control for primers M3- 5C, 6 and 7 -  PCR products with primers M3-5C.
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Figure 10. 1% agarose gel with PCR products obtained with primers M3-5C, M3-8C, C5- 
C6 and stained with ethidium bromide. Legend: M-lkb molecular weight marker, 1 -  
negative control with the primers M3-8C, 2 and 3- PCR with primers M3-8C, 4 -  negative 
control with primers M3-5C, 5- PCR product with primers M3-5C.
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5.4 Sequencing
5.4.1 Genotyping
5.4.1.1 Genotyping by comparing with already published sequences
HBV genotype was determined by comparing amino-acid sequences over the a 
determinant of the S genes of published isolates (Norder et al, 1993). Aligned a 
determinants were compared to published sequences in order to determine genotype and 
subtype (see Figure 11).
The 6 out of 38(16%) surface gene sequences were found to belong to genotype A. These 
38 patients were chosen randomly. Out of 144 precore/core sequences 18 (14%) were 
found to belong to genotype A. None of these sequences were from the West Region 
(Basse Area). The rest of the sequences were from genotype E.
Analysis of the genotype of the Gambian samples was first done on sequenced surface 
gene fragments and then confirmed on pre-core/core gene fragments. The consensus amino 
acid sequence of the S gene region from genotype A in The Gambia was similar to the 
published genotype A isolate {aywl subtype) from Cameroon (Norder et al, 1993). The ’ 
consensus amino acid sequence of the S gene region from genotype E was similar to the 
published ayw4 subtype, genotype E sequence from West Africa (country was not stated) 
(Norder, 1993).
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Geno­
type
Amino acid sequence
122 160
E R T C T T L AQGT S MP F S C CCS KP S DGNCT CI P I P S S WAF GK
A K P N  T T A
131 140 143 159
B K P T T A127
C K I P  T V R
126 " 160
D M T T125
F K L
158
Gambian
A
RT CTT P AQGNS MP F S CCCT KP T  D G NCTCI P I P S S WA FAK
Gambian
E
RT CTT L AQGTS MP F S CCCS KP S  DGNCT CI P I P S S WA FGK
Figure 11. Comparison of the Gambian consensus sequences from the a determinant from 
genotypes A and E to sequences of other genotypes.
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5.4A. 2 Phylogenetic analysis o f different genotypes and subtypes.
Phylogenetic tree of the S and Pre-core/Core fragments sequences was generated during 
the study by including already published sequences from different genotypes and subtypes. 
The clustering of the sequences into distinct genotypes and subtypes is demonstrated in 
Figures 12 and 13, constructed with the neighbour-joining (NJ) algorithm.
GenA Sweden
Gen A Gambia
GenE Gambia 
GenE Senegal 
GenE West Africa!
GenD France
GenO Latvia
GenG Columbia
GenB Japan 
GenB Indonesia
3enF Columbia
GenC Japan
GenC USA
GenF France
Figure 12. Neighbour joining phylogenetic tree representing sequences from pre-core/core 
regions from all known human genotypes and two Gambian consensus sequences from 
each genotype. Designation: Genotype and country of origin.
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B ayw l Vietnam
AadwSouth Africa
B ad w Jap in  C am eroon AaywGambia
0.01
Figure 13. Neighbour joing phylogenetic tree representing sequences from the S gene (nl 
509-810) from all subtypes, genotypes and the Gambian consensus sequences from each 
genotype. Designation: genotype, subtype, and country of origin.
Both figures clearly show, that genotyping can be done either on S or C gene sequences 
and the result is clear-cut. Separation in subtypes seems to be less significant than division 
in the genotypes, because the sequences from the S gene clearly cluster according to 
genotype, not subtype.
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5.4.1.3 Geographical distribution of HB Vgenotypes in The Gambia.
Genotype E seemed to be prevalent around the country, whilst genotype A was detected 
only in the Western part of the country (see Figure 14).
m m
North
Ocean
S a n t a  S ir
M  E  A  -  B  I $  S
Figure 14. Geographical distribution of genotypes A and E in The Gambia. Designation: 
green- genotypes A and E, violet- genotype E only.
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5.4.2 Mutations in amino acid sequences
5.4.2.1 Surface gene
Protein translation from nucleotide sequences encoding amino- acids 112 to 227 of the S 
gene was carried out in 35 patients. In 8 out of 35 samples single amino-acid substitutions 
were detected in the surface gene fragment under study (see Figure 15). In four samples 
amino acid substitutions in the a determinant were observed. In sample 1157, amino acid 
mutation 123 T to A or T123A was localised in the first loop of the a determinant, has not 
been reported previously in breakthrough infections in vaccinees or associated with any 
clinical observations. Mutations in samples 1285, 1144, 1486, 1487 were localised in 
genotype specific regions. Two genotype E samples, 1285 and 1144, had mutations at 
positions 140 and 143 and change was from S to T in positions which are normally found 
in the consensus sequences of genotype A in these positions (see Figure 15). In genotype 
A samples 1485 and i486 samples A in position 159 was substituted by G which is a 
normal amino acid in this position for E genotype.
Premature termination codons at position 216 of the S region preventing full expression of 
full-length S protein were found in three samples. These mutations had no effect on the 
amino acid sequence of the open reading frame of the polymerase gene.
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5.4.1.5 Core Promoter region
Primer M3 was chosen in order to include the core promoter area. In the 99 samples the 
sequence of core promoter area was available. In 7 samples (7%) double mutations at 
nt!762 A to T and 1764 G to A were detected. Four of these 7 samples were HBeAg 
positive. Two samples were from the mother and her child. This pair also shared the 
ntl 896 pre-core stop codon mutation.
In 31 (31%) samples a mutation from C to T at position 1768 was found. This mutation has 
never been reported before and did not lead to changes in amino acid sequence. Most 
likely, it represents the normal sequence of the regional wild type isolate.
5.4.1.6 Pre-core/core genes.
Nucleotide sequence o f pre-core region.
All nucleotide mutations found in this study in the pre-core region seem not to affect the 
secondary structure of the pregenomic HBV-RNA encapsidation signal (see Figure 16)
The association between HBeAg status and the number of mutations in the core region is 
given in figure 17 and 18. HBeAg positive samples in general did not have any amino acid 
mutations. Anti-HBe positives on the other hand more often had amino acid substitutions. 
12 out of 20 Anti-HBe positive patients were found to carry the 1896 pre-core stop codon 
mutation. Patients negative for both HBeAg and Anti-HBe who were possibly in a stage 
of seroconversion window period had an intermediate range of mutations.
All together 14 pre-core stop codon mutants were identified in this study. All these 
samples were HBeAg negative, 12 samples were Anti-HBe positive and two samples were
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4G44
1577
1159
1162
1453
1741
1824
1825
1827
1831
1456
1540
1461
1729
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1199
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1487
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S t e m
A genotype f E genotype
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RTGCfiflCTTTTTCflCCTCTGCCTflflTCHTCTCTTGTTCflTGTCCTRCTGTTCRflGCCTCCflflGCTGTGCCTTGGGTGGCTTTGGGGC
...........................................................................fl.........................................................................................................
...........................................................................fl.........................................................................................................
................................... *.......................................................................................................................R..A.
........................................................................... R..R.
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............................................................................................................................................................................ fl____
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  ....................... fl...... C...!...................................
.................................fl......C...C...................................
.................................fl...... C...C...................................
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Figure 16. Predicted secondary structure of the pregenomic HBV-RNA encapsidation 
signal showing the base paring in genotypes A and E. Below, the aligned nucleotide 
sequences are given of the pre-core gene from 24 out of 144 Gambian samples, in which 
changes were detected.
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not tested for HBeAg markers. In four of these samples an additional mutation at 1899 (G 
to A) leading to amino acid change from G to D was found.
A mother and her child were found to carry the pre-core stop codon variant. In another 
family, all three siblings tested were also found to carry the pre-core stop codon variant. 
Two other samples originated from the same village contained pre-core variants and these 
may have had a common source of infection.
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Genotype E Genotype A
HBeAg
status
Number
sequenced
Number 
having 
changes in 
amino- 
acid
sequence
Avarage 
number 
of
mutations
Number
Sequenced
Number
having
changes
in
amino-
acid
sequence
Avarage 
no of 
mutations
HBeAg
positive
74 14 (20%) 1.56 14 2 (14%) 1.5
Anti-HBe
positive
20 16 (80%) 4 2 0
HBeAg neg,
Anti-HBe
neg
20 8 (40% ) 2.3 2 0
HBeAg neg, 
Anti-HBe 
not tested
7 2 (29% ) 3
HBeAg and 
Anti-HBe 
not tested
5 0 1
Table 27. Relation between HBeAg markers and number of mutations in the Core gene.
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Most of the HBeAg positive samples did not have mutations leading to amino acid changes 
in the pre-core/core regions. Mutations were distributed over the entire core without an 
apparent concentration to certain regions, except positions 64 E to D, 93 M to V, and 113 
E to D where mutations were recorded more than in one sample. In HBeAg negative 
samples mutations occurred more frequently. Most of these mutations occurred in B cell 
epitopes (see Figure 17).
(Carman,
1995)
Chuang,
1993)
(Ehata, 1992) (Rodriguez- 
Frias, 1995)
Not
previously
reported
38 Y to F 49 S to C 49 S to E 12 T to S 5 P to S
46 E to Q 55 L to I 55 L to I 27 V to I 13 V to E
57 Q to H 60 L to E 591 to V 116 I to L 14 E to Q
64 E to D 130 P to Q 60 L to V 48 C to R or C
67 T to S or 74 V to G to H
T to N 113 E to D 51 H to Y
69 T to S or T 130 P to T 68 L to I
to G 100 L to F
74 V to G 125 W to C
79 P to Q 125 L to P
92 N to H 146 N to T
93 M to V
113 E to D or
E to Q
114 Tto I
130 P to Q
131 A to P
Table 28. Amino acid substitutions in the core gene found in this study and in relation to 
previous reports.
Mutation 64 E to D occurred quite often and it was much more common in HBeAg 
negative samples with the 1896 stop codon mutation than in HBeAg positive samples
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(71% (10/14) and 7% (5/74) respectively). It was also seen in 50% (2/4) of Anti-HBe 
positive samples without the pre-core stop codon mutation.
A similar distribution of 146 N to T or N to I substitution was found in 50% (7/14) of 
samples with the pre-core stop codon and in 3% (2/74) of HBeAg positive samples.
Mutations at position 67 from T to S or from T to N I were found only in 50% (6/14) of 
samples with the pre-core stop codon mutation. Another mutation from 116 I to L or from 
I to V was found in 29% (4/14) of samples with the pre-core mutation and was absent in 
the rest of the samples.
Interestingly, in some samples certain mutations diverging from the Gambian consensus 
sequence are present in other genotypes or subtypes as part of the normal sequence (see 
Table 30).
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Mutations compared to 
the Gambian consensus 
sequence
Genotype Subtype
E genotype (ayw4)
12 T to S B and C adw2, adw4
59 V to I C adrq-
64 E to D D ayw2, ayw3
66  M to I D ayw2,ayw3
67 T to N B,C adw2 , adr, adrq-
69 T to S D ayw2, ayw3
93 M to V A adw2
116 I to L D and E ayw3, ayw4
116 I to V D ayw2
130 P to T C adw
130 P to Q D ayw2
146 N to T A, B, C, D, F adw2 , adw, adrq-, ayw3 , ayw2
A genotype (aywl)
87 N to S B, C, D, E adw2 , adw, adrq-, ayw3 , ayw2
98 I to F D, E ayw4
Table 29. Relation of amino acid substitutions found in the Gambian samples to normal 
sequences in other genotypes or subtypes.
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D iscu ssion
A large number of core promoter, pre-core/core and surface gene sequences have been 
obtained from Gambian chronic HBV carriers. Only three genotype E sequences from 
West Africa have been published so far (Norder et al, 1993) and information provided by 
this study is very useful in assessing the predominant strains of the HBV in Gambian 
chronic HBV carriers.
Core primers, previously found to work on samples from all around the world 
(Karayiannis, personal communication), did not work satisfactorily on Gambian samples; 
this was an indirect indication that the nucleotide sequence of these isolates was different. 
A new set of primers was designed and at the end of the optimisation the sensitivity of the 
assay was 95% on HBeAg positive samples and 30% on HBeAg negative samples, which 
was considered as optimal and good for the study purposes.
Two predominant genotypes of HBV were identified in samples from Gambian patients. 
Genotype E was predominant and sequences from the surface and core genes showed that 
it was quite similar to previously published isolate from Senegal. Sequences of genotype 
A were also detected and represented 14% of the total sequenced and the consensus 
sequence was very close to previously published genotype A sequence from Cameroon. 
Genotype E was spread throughout the whole country, but genotype A was found only in a 
Western part (see Figure 14).
The double mutations at nt 1762 from A to T and at 1764 from G to A in the part of the X 
ORE that contains the core promoter were never previously described in West African
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population. In our survey 7% (7/99) of HBV carriers were found to carry this mutation. 4 
out of 6 patients with this mutation had elevated AST and ALT levels, significant in 
comparison to the prevalence of elevated aminotransferases in non-mutant population, a 
finding that indicates that they could have had higher viral replication rates, as it was 
suggested previously (Laskus et al, 1995).
The pre-core stop codon mutation also has not been reported previously in West African 
population. In this study 14 pre-core mutants were detected out of 141 sequences (10%). 
Pre-core variants were found only in genotype E. Nucleotide sequence substitutions in the 
pre-core gene were found in 24 out of 144 (17%) sequences. None of these could affect 
the secondary structure of the pregenomic HBV-RNA (see Figure 16) and therefore 
HBeAg production.
The findings of the present study indicate that the HBV genome is extremely stable unless 
exposed to host immune pressure. Analysis of the nucleotide sequences will be reviewed in 
detail in Chapter 6 , dealing with their phylogenetic analysis.
Most of the samples sequenced did not have any amino acid substitutions. Mutations were 
distributed over the entire core gene without an apparent concentration to certain regions. 
Slightly more amino acid mutations occurred in B cell epitope regions (see Figure 17). 
Mutations were more frequent in HBeAg negative samples than in HBeAg positive 
samples. Amino acid substitutions in core gene at position 64 from E to D, 69 from T to S 
and 146 from N to T were much more common in anti-HBe positive samples with the pre­
core stop codon mutation. Why these particular transformations occur mainly in anti-HBe 
positive patients is not clear.
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Although many families were bled, only few of the siblings were found to have the same 
amino acid mutation. Family clustering was only significant in patients with the pre-core 
stop codon mutation. Sample 1162 is the sample from a mother and 1158 was sample from 
her child. They both shared core promoter and pre-core stop codon mutations, but 
otherwise the amino-acid sequences were very different. Samples 1824, 1825, and 1827 
were obtained from siblings from the same family, and 4640, 4690 from non-related 
children from the same village. They all shared pre-core stop codon mutation, but the 
sequences had a lot of other different amino acid substitutions. This could reflect how a 
common variant was selected in different host genetic backgrounds.
In the surface gene only one amino-acid mutation 123 T to A was found which could 
potentially affect the structure of the first loop of the a determinant, but it has never been 
previously associated with any clinical significance. The previously published vaccine 
escape mutation at position 141 was not observed in chronic carriers studied. This 
indicates that if this mutation occurs, its prevalence is not high in the normal population. In 
four samples amino acid substitutions characteristic for other genotypes were observed. 
That was similar to findings in core gene and its clinical significance is not clear.
Premature termination codons at position 216 of the S region preventing full expression of 
full-length S protein were found in three samples. These mutations did not appear to 
change the amino acid sequence in the overlapping open reading frame of the polymerase 
gene. The mutation was previously described only in immunocompromised (Preikstat et al, 
1999). Clinical importance of this mutation in Gambian population remains to be 
investigated.
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6 Phylogenetic tree analysis of HBV sequences in Gambian 
families.
6 .1 Introduction.
Most HBV infections in sub-Saharan African infants and children are known to be 
acquired through horizontal transmission of the virus in early childhood (Whittle et al, 
1983, Tabor et al, 1985; Davis et al, 1989). However, the exact mechanisms of spread have 
never been documented (See Introduction). Significant clustering of HBsAg positive 
siblings was previously described in Gambian families and transmission of HBV in 
between them was suggested (Whittle et al, 1983 and 1990).
The organization of Gambian households is quite specific. An extended family is a 
predominant social structure. In the villages people tend to live in compounds. Usually 
families with their close relatives share a compound. The number of families in the 
compound can vary from 1 to 5 or even more in rare occasions. Polygamy is widespread, 
especially in rural areas. Polygamic families were also included in this study, but 
constituted only small part of the samples. Non-paternities were excluded by genetic tests 
during the human genetic study.
To date only a few studies have addressed the question of intrafamilial transmission and 
clustering of HBV by sequence analysis. In order to determine the extent of intrafamilial 
versus intracompound or intravillage transmission, I have applied extensive phylogenetic 
tree analysis to sequences of the pre-core/core and surface genes, obtained following 
amplification of HBV-DNA extracted from the sera of HBsAg carriers from Gambian 
families.
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6.2 Phylogenetic analysis of surface gene fragments
The NJ tree was constructed on 38 surface gene fragments in order to determine whether 
there was clustering according to genotypes, geographical area, villages or families (see 
figure 19).
Two larger clusters are obvious and they characterise two different genotypes. Larger 
cluster represents genotype surface gene fragments and smaller cluster contains sequences 
from genotype A. The difference between genotypes A and E are well defined and 
confirms my previous observation, that detection of different genotypes by using 
phylogenetic methods is easy and effective.
The sequences of this surface gene region were highly conserved and the difference 
between sequences was generally very small. 12 sequences were found to be completely 
identical, what makes more detailed phylogenetic analysis on certain clustering of 
sequences not feasible.
However, sequences from two siblings in the family 125 were positioned separately from 
other genotype A sequences. This shows that even surface gene fragments can be family 
or village specific. Both samples were known to be Anti-HBe positive and to have unique 
amino-acid mutations (see Samples 1486, 1487 in Figure 19).
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  1003Lamin Kombo fam1
  IISTDaraman NorthBasse
1073Damphakunda Basse fam18
1112Tambasang Basse 
1142Digiri Basse fam33
1374Sanchasulay Kombo
  151 GKartong Kombo
1143Digiri Basse fam33
1184 Basse
1247Nokunda Farafeni fam53
1249Nokunda Farafeni fam53
1328Geniri Sibanor
1352Jumasara BassefamQO
1371Bakoteh Kombo
1916Brikama Kombofam254
1917Brikama Kombofam2S4
4537M and uar
4640Manduar
4644Manduar
1461Sikunda Sibanor
1159Saresilli NBassechfam36
  4609Manduar
  1825Ngengie Essoe
— 1144Digiri Basse fam33
4692Manduar
 1213Sukuta Kombo
1194Bakoteh Kombo 
I 1199Bakoteh Kombo
1815Baianghar Farafeni
1486Farafenn'rfam125
1487Farafennifam125
1376Sabiji Kombo
1720Gunjur Kombo
— 1914Brikama Kombofam254
1162Saresilli NBassemothfam36
1174Basse
1285Bajaghar Sibanor
1349Jumasara Bassefam90
o.oi
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Figure 19. Phylogenetic tree analysis of 38 surface gene nucleotide sequences using the NJ 
method. Tree is rooted on sample 1003 because of convenience reasons. Taxa descriptions 
include sample number, village o f birth, geographical area and family number if sample 
was from a family with multiple affected siblings.
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6.3 Phylogenetic analysis on pre-core/core gene fragments.
The variability of the pre-core/core gene was found to be higher and therefore phylogenetic 
analysis for family clusters on the sequence of this gene seemed to be more feasible.
First, a phylogenetic tree was constructed using the simple NJ approach just to see the 
general trend and positioning of sequences in the tree (see Figure 20). In a case when 
differences between sequences are expected to be small, the NJ tree is considered to be 
quite informative and rather similar to the trees obtained with more complicated and 
perfect algorithms (Maximum likelihood, bootstrap).
The tree was rooted on sample 1199, which was found to be phylogenetically quite 
distinct. Information about the village of birth, area of the country, age and HBeAg status 
has been added to the phylogenetic tree in order to see whether there was clustering 
according to these variables.
Figure 20. Rooted NJ phylogenetic tree on 143 pre-core/core gene nucleotide sequences. 
Taxa information includes identification number, village of birth, area, age, sex (M or F), 
HBeAg status (E-HBe antigen positive, AntiE- Anti-HBe positive, Eneg-both E antigen 
markers negative), and family number, if siblings are from a family with multiple carriers.
148
1199BAKOTEH K0M B09FE
G e n o ty p e  E
1682M U N Y  A G E N  E S S O E 1 2 M N E G
i 1444SIK U N D A SIB A N O R 1 6 M E
H M 2 M M D U M 1 7 K H D EME 
I i 1862JE SW A M G  K 0 M B 0 1 9 M  E tam 231
_   4 6 9 0 M A N D U A R 1 4 M E n eg
lÔ Ü sYlJNDUM K O M B^ s f i ’F E fa m S * ^  U  " 0 * T H B A S 5 5 Fm O tM .n ,3 6  
1 6 6 0 K E R R N G 0 R R  E S S O E U M E fa m 1 7 3
!8gi®Mg|8li$ltoF5
s a m s r
n i H i ™ s r 2"E
1SS7 M A S S E M B E H  B E D  12 fa m 6 1
15 3 S ^ p ^  N O R T H  B A S  S E ^ 3 U Er  f  3 M efgm 6  f
■ S IB A N O R 1 7 F E fa m n 6 1
  4 6 4 SM A N D U A R 17M E nag
 4S27M A N D U A R 1 3 F E n eq
4S79M A N D U  A R 3 9 F E n e g
1831K A YIN E S S O E 2 8 F A n tiE m o tfa m 2 1
1741K E R R N G O R R  K O M BQ 21 A n tlE fa m 1 7  
4644M A N D U  A R 2 4 F E n e g
1824N G E N G IE  E S S O E 2 b M E n a g ia m 2 1 8
182SN G E N G IE  E S S O E 2 S M E n eg fa m 2 1 8
  1872K ITTY  K O M B 0 1 6 M  E
* S 9 7 K E N E B A 1 9 M A N D U A R E n eg
-  4607K E N E B A 28M  
1 143 D IG IR IB A S S E 1 3 M E fa m 3 3
r— 41 125 & A % ? B Â S S E F13M N E■E13M N G1am34
1 J4 9 J U M A S A R A K O T O  B A S S E 3 6 F N E G m o th fa m 8 9 c h fa m 9 0
1 S94N JO B E H  E S S 0 E 1 9  
I F A R  A FENII.TFE fa m 8 9
r 10S
Jfii
Tr~ 124
14 8 2 JÜ M A S A R A B A  F A R A H 1 0 M E fa m 8 9
' s a m s r "
-  1828M A C C A  E S S O E 1 1 M E sib fa m 2 1 9
■ÏÊÊË^S
------------------------------4SS0M A N D U A R 18F E
1003LAM IN  K O M B O S 1 2 F A n tlE fa m 1
^  I T T i
171S25KARTONGMfSMBofsMEfam137
1 7 2 0 G U N J U R K O M B O W M E 2F E  
 [ _ ________ 10 8 W A M P H A K U N D A  B A S S E  10F E fam 20
1181 B A S S E  16M E fam 41
SjfËËsmz.
1S 4 0 B A JA K U N D A  B A S S E 1 4M  A n tiE
^ E lE E E P ™ »
1307K A IA F  S IB  A N O R 12M A ntiE
-  1486F A R A F F E N I1 Ô M A ntiE fam  125  
J* 8 7 F A R A F F E N I1  IM A n tiE fa m i  25
------------------------------  ‘fa m 3 3
I i  1213N EM AK U N G K U N G  K 0 M B 0 9 M Eu I  1730G IB O R E H  K O M B O I 3 F fa m 2 0 2
1 1841SIN G H U M AG AL E S S O E 1 4 M E n a g fa m 2 2 2
G e n o ty p e  A
149
The phylogenetic tree in figure 20 revealed the following information:
Two major clusters emerged in the tree and they represent genotypes A and E. This tree 
clearly shows, that genotypes can be clearly defined by phylogenetic analysis on the pre­
core/core genes as well as surface genes (see Figure 19). Genotype E was predominant and 
variability and phylogenetic distances between several individuals in this genotype was 
found to be higher, probably due to the larger amount of samples examined. Other 
explanations, such as longer presence in a certain population or greater variability of the 
genotype E sequences due to higher prevalence of precode stop codon mutation, could be 
considered, but could not be proven with the information available.
The clustering of different sequences according to geographical area was not seen, except 
for genotype A was found only in eastern parts of the country (see Figure 14). Differences 
between the precore/core sequences were obviously too small to analyse the geographical 
circulation of the virus in The Gambia.
Definite family clustering of sequences in the phylogenetic was observed. More then one 
pre-core/core sequence from members of 32 families with multiple HBV carriers were 
included in this phylogenetic tree. In 22 families sequences from several family members 
were clustered in the same cluster, which could indicate a close evolutionary relationship. 
Also siblings from the same family and quite different ages clustered together (e.g. Fam 
217), a strong indication of intrafamilial circulation of the virus. Clustering according to 
village of birth was also obvious in some cases and needed further evaluation.
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6.4 Detailed analysis on family and village clustering.
After obtaining the NJ tree, which provided preliminary information, more detailed 
analysis was performed to confirm family or village clustering of the viral sequences. The 
presence of different genotypes and also the observation that HBeAg negative samples 
tend to mutate more due to increased immune pressure was taken into consideration.
To maximise the efficiency of data analysis, only samples with more than one sequence 
from each village of birth or samples representing families with multiple carriers were 
included and single samples not belonging to a family or being a sole representative from 
the village of birth were excluded. This resulted in four different sequence data sets; (I) all 
available genotype A sequences, (II) all available genotype E sequences, (III) HBeAg 
negative samples from genotype E, (TV) HBeAg positive samples from genotype E. 
Phylogenetic relationships among the HBV sequences sampled were reconstructed using a 
maximum likelihood (ML) method. More details çn construction of phylogenetic trees see 
in Methods section.
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Figure 21. Maximum-likelihood tree (Ts/Tv= 1,60; a=0.13) with NJ bootstrap values for 99 
genotype E precore, core gene sequences. Bootstrap values are shown for selected nodes 
only, where they were higher than 50%. Several examples of village and family clusters 
are marked with colours.
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Figure 22. ML tree (Ts/Tv=l,09; a=0.25) with neighbour-joining bootstrap values for 14 
genotype A pre-core/core gene sequences. Bootstrap values are shown for selected nodes 
only, where they were higher than 50%. Descriptions of taxa include sample number, 
village of birth, age, sex, E antigen status, family number, and compound name {comp) in 
some samples
The ML trees (with NJ bootstrap values) for the HBV genotype A and E sequences are 
presented in figures 21 and 22. The general pattern of clustering according to family or 
village is apparent, although only few nodes are supported by the high levels of bootstrap 
values as might be expected given the conserved nature of the sequences.
In the genotype A (see Figure 22) most of the nodes are supported by the sufficiently high 
bootstrap values. Bootstrap values higher than 50% are indicating that node could be of 
importance (Holmes E, personal communication). Nodes supported by 70% and higher 
values can be considered as statistically significant.
Families 125 and 214 are located separately with 95% and 6 8 % bootstrap support 
respectively. Sequences from family 222 cluster together but this cluster does not have 
sufficient bootstrap support. Of interest is a village cluster from Kaiaf, which has 82% 
bootstrap support. It is difficult to separate siblings from family 79 and family 80 
suggesting that the source of infection from these families was the same or they got 
infected from each other. Both families inhabited the same compound. Two sequences 
from the village Baniakang show strong relation with 65% bootstrap support and 
phylogenetic distances between these two sequences are not longer than distances within
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other families. These two sequences were obtained from persons living in different 
compounds.
In the genotype E the number of samples is much higher and clustering between families 
and villages is not so well pronounced, but several clusters are still supported with 
bootstrap values higher then 50% (see Figure 21). Families 231, 81, and 238 are positioned 
separately in the phylogenetic tree and are supported by high bootstrap values. Some 
families have very similar sequences to the families from different villages or even 
different areas, and this most likely is coincidental due to the conserved nature of the 
sequences in general. For example, families 18 and 42 are positioned in one cluster but are 
from geographically completely different villages.
In several families and even villages, viral sequences seem to be completely identical. In 
families 8 8 , 65, 18, 217, 174 sequences from the siblings of the same family are identical. 
In villages Kermgorr and Maccaomar members of the families 174 , 172 and one single 
sibling carry exactly the same viral sequence. These two villages are small and 
geographically very close, so communication between them cannot be excluded. PCR on 
these samples were repeated in order to exclude contamination artefacts and result was 
confirmed with the exception of only one nucleotide difference in some samples (see 
Figure 7). A sequence from family 5 was also identical to sequences mentioned above, but 
the villages of birth are located very far apart and I cannot imagine any possible 
relationship between them. Direct communication (travel) seems to be highly unlikely.
Two sequences from the village Manduar were also completely identical. They were 
obtained from HBeAg positive non-related subjects. Another large cluster of 6 sequences
from Manduar was evident and supported by a 67 % bootstrap value. Children from this 
cluster are not relatives and do not live even in the same compound. Sequence 1142 also 
belongs to the same cluster, but represents a completely different geographical area and 
possible connection between these subjects again seems very unlikely.
Many other families also cluster in family clusters, but these clusters do not have sufficient 
bootstrap support.
Interestingly, families 40 and 41 do not show any signs of clustering in villages and 
compounds at all. Samples from both of them were obtained in the regional town Basse, 
which cannot be considered as a village and has much larger population. Therefore the risk 
of contracting the infection from somebody outside could be higher.
6.5 Phylogenetic analysis according to HBeAg status.
It can be assumed, that most of the patients recruited in this study were infected in early 
childhood. Over a time period of more than 10 years, a number of new mutations could 
occur, especially in HBeAg negative subjects. An increased number of mutations and 
reverse mutations could significantly change the positioning of the sequence in the 
phylogenetic tree. Separate analysis of HBeAg positives and HBeAg negatives was 
performed in order to see whether it would make any difference.
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Figure 23. ML tree (Ts/Tv=l,10; a=0.24) on HBeAg positive samples. Taxon descriptions 
include sample number, village of birth and family number.
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Family and village clusters were more pronounced in the phylogenetic tree in figure 23 of 
sequences from HBeAg positive subjects than in the common tree in figure 20.
In HBeAg positive samples village and family clusters were definitely more distinct, but 
some sequences, for example from families 33, 40 and 82 were still scattered throughout 
the phylogenetic tree and did not show any signs of relatedness.
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Figure 24. ML tree (Ts/Tv=l,06; a=0.19) on HBeAg negative samples.
Taxon descriptions include sample number, village of birth and family number.
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Family and village clusters were not so well pronounced in the phylogenetic tree in figure 
24 of sequences from the HBeAg negative subjects. The branch length overall was longer 
than that o f HBeAg positive sequences, possibly because the increased number o f viral 
mutations in HBeAg negative samples. Interestingly, family 218, which carried pre-core 
stop codon variant still managed to cluster together in the phylogenetic tree despite large 
number of different amino acid mutations in the siblings (see Figure 18)
Tree Number of 
taxa
Ts/Tv a
All A genotype 14 1.60 0.13
All E genotype 99 1.09 0.25
HBeAg positive 53 1.10 0.24
HBeAg negative 30 1.06 0.19
Table 30. Summary of data and substitution parameters of the ML phylogenetic trees 
constructed.
Ts/Tv -  Transition/transversion ratio
a- Shape parameter o f a gamma distribution o f rate heterogeneity among sites
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6.6 Sequences from mothers and their children
Sequences from four mothers and their children were obtained. These were the only PCR 
positive mothers from those tested. Separate phylogenetic analysis was performed in order 
to see whether mother to child transmission could possibly occur it this limited number of 
families.
In the phylogenetic tree shown in figure 25 of positive mothers and their children, only one 
family (219) did not seem to share similar sequences. In families 137 and 89, phylogenetic 
clustering was also demonstrated in the main phylogenetic tree (see Figure 20). A mother 
and her child in family 36 shared both the core promoter mutations and precore stop-codon 
mutations. Both mother and sibling were already quite old, and viruses probably had many 
mutations. This could explain the large phylogenetic distance o f these viruses and why 
they did not cluster together in the larger tree (see Figures 20 and 21).
162
1831KA YIN28FAntlEmotfam219
1349JUMASARAKOT036FNEGmotherfam89
13S3JUMASARABA 17FEfam89
1482JUMASARABA 10MEfam89
---------------------  1828MACCA11MEslbfam219
r
152SKAR TONGISMEfam 137
1 S22DARSUMA29FNEGmotherfam 137
1524KARTONG10MEfam137
11S9SARESILU 26MEfam36
1162S55FSA RES1UJSSFMothfam36
Figure 25. ML tree o f sequences from families with a HBsAg positive mother and their 
children. Families are marked with different colours.
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6.7 Sequences from the village Manduar.
16 sequences altogether were obtained from the village Manduar. These patients were not 
genetically related, although most of them were from families with multiple carriers. 
Persons bled in Manduar very often were older than 20 years and their viral load was 
apparently very low, therefore it was very difficult to get a larger number of PCR positive 
samples for sequencing. Though sequences did not represent relatives and not even the 
same compounds, most of the sequences were part of several distinct clusters in the 
phylogenetic trees, mimicking family clusters
Several clusters are well pronounced in the phylogenetic tree in figure 26. Most of them 
have bootstrap support higher then 50% and even 75%, what indicates that clustering is 
really significant and viruses within the village are evolutionaiy distinct. See more 
comments on clustering in village Manduar under analysis of Figure 20.
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Figure 26. ML tree with bootstrap node values on pre-core, core sequences from the village 
Manduar. Taxon descriptions include sample number, village o f birth, E antigen status (E 
and E neg), and compound o f birth.
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6.8 Statistical analysis of the clustering in families and villages
A ML approach was also used to determine whether sequences were clustered by family 
and village more than might be expected by chance alone. First, for each of the four data 
sets, 200 random tree topologies were constructed. The log likelihood of each of these 
replicate trees was then estimated, again using empirical Ts/Tv and a  values. As these 
trees represent random assortments of the data, they effectively constitute a null 
distribution of log likelihoods. Next three “model” trees, representing clustering at 
different levels of population structure, were constructed using the Tree View programme: 
(I) one in which only sequences from the same family were grouped together, with all 
other branches left unresolved, (the “family” tree) (II) one in which only sequences from 
the same village were grouped together, with all other branches left unresolved and 
ignoring what family they came from (the “village” tree) and (III) one in which sequences 
from the same family and village were grouped together (the “family+village” tree). The 
log likelihoods of these model trees were then estimated under the data as before. If these 
likelihoods fall outside the null distribution then we could conclude that the HBV sequence 
data shows more clustering by family and village than might be expected by chance. It 
should be noted that this randomisation test is highly conservative because most branches 
are left unresolved, particularly when the data is only partitioned by family, and therefore 
ignores any other phylogenetic signal in the data.
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Figure 27. Example o f how the maximum likelihood tree from HBeAg positives was 
transformed to a model tree with combined family+village clustering.
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The maximum likelihood randomisation test also provided strong evidence that viruses 
tend to be related according to the family and/or village they were sampled from (see Table 
32). In the case of both the complete A and E genotype data sets the log likelihoods for all 
three model trees fell outside the null distribution provided by the random topologies, 
strongly suggesting that there is more clustering by these variable than might be expected 
by chance. In the case of the large genotype E data set, the combined family+village tree 
also had a much higher likelihood than either component tree suggesting that these two 
levels of population structure contain the most information. All three model trees also fell 
outside of the null distribution of log likelihoods in the analysis of the HBeAg positive 
genotype E sequences, but not in the HBeAg negative sequences. The latter may be 
caused by common immunological selection pressures, which increase the extent of 
convergent evolution.
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Genotype n Null Distribution Family Tree Village Tree Village + 
Family Tree
A 14 -1328.12351 to 
-1389.84444
-1323.49993 -1306.50274 -1306.50274
E 99 -4038.09955 to 
-4197.28073
-3851.96791 -3816.84344 -3731.26169
E, E antigen + 53 -2202.85834 to 
-2394.42865
-2188.84172 -2155.96565 -2129.27292
E, E antigen - 30 -2131.48652 to 
-2213.21954
-2162.7006 -2139.66302 -2139.66302
Table 31. Log likelihoods for three different “model” phylogenetic relationships of HBV 
sequences (family, village and village+family) and a null distribution constructed using 
random tree topologies. (See Appendix VIII)
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6.9 Discussion
The exact mechanism of HBV transmission in The Gambia is unclear. Significant family 
clustering of chronic HBV infection has been reported before and this study supported 
this observation. Analysis of HBV sequences in different family members provided an 
insight into the transmission of HBV within the family and yielded new information for 
further epidemiological or anthropological studies.
A large data set of surface, pre-core and core gene sequences was obtained for 
phylogenetic analysis, representing different families, villages and geographical areas. The 
use of phylogenetic analysis for confirmation of epidemiological hypotheses is a relatively 
new approach.
The data collection was designed to run concurrently with collection of human DNA 
samples for genetic studies. Some of the siblings from multiply affected families were 
missing at the time of the bleeding. Many were not PCR positive and it was not possible to 
obtain viral sequences. Another important factor was that the vaccination program was 
introduced 11 years ago and many siblings from affected families were already vaccinated 
and therefore most likely HBsAg negative and not tested. In younger siblings we would 
normally expect higher viral loads and less evolutionary changes. This could make 
establishment of the source of infection easier.
After a time period of more than 10 years viral sequences were expected to change 
significantly, especially in HBeAg negative samples. These changes could possibly alter 
the construction of the right phylogenetic tree and give some samples different location.
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Initially, I was interested in three levels of possible clustering: geographical area, village 
and family, because it was not known how much evolutionary change the viruses had 
undergone, because even approximate information on the variability of the sequences was 
not available.
Sequences of the surface gene fragment did not seem to provide the necessary information, 
because 12 sequences from different families, villages and geographical areas were 
completely identical. The S gene fragments from family 125 seemed to cluster separately. 
Probably these samples could represent some different local variant. A clear differences 
between genotypes A and E were seen (see Figure 19) but otherwise the phylogenetic tree 
did not seem to provide the necessary information and sequencing of the rest of the S gene 
products was abandoned.
Phylogenetic tree obtained on the pre-core/core sequences was more informative, because 
of a larger variability of nucleotide sequences.
Differences between the NJ tree and the ML tree were minimal. This finding supported 
assumption that the NJ method could be succesfully used for creating reliable phylogenetic 
trees and saving a lot of calculation time. For more detailed analysis, the maximum 
likelihood tree and bootstrap analysis were considered necessary. Genotypes A and E were 
very easily distinguishable in the phylogenetic trees (see Figure 20). Thus phylogenetic 
analysis not only of surface gene sequences but also of precore/core ones can be used 
succesfully for genotype detection.
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Overall, pre-core/core gene sequences in The Gambia were very similar. At the 
geographical area level, it was impossible to see any significant clustering of the 
sequences. Sequences from completely different villages and geographical areas were 
sometimes are identical. The phylogenetic distance between the sequences was very small 
and no clear evolutionary pattern emerged. If one could assume that HBV infection arrived 
in The Gambia relatively recently and spread from one part of the country to the rest, then 
it would be possible to see certain consistency in its distribution. The phylogenetic tree 
however, gives more impression that the infection has been present in this area for quite a 
long time and it is moving in different directions without significant sequence changes. 
Genotype A seemed to have been introduced later or had some selection disadvantage, 
which would explain its lower prevalence and limited spread in the country.
One other explanation for this homogenity of the sequences could be that the number of 
possible mutations with similar survival capacity due to the overlapping reading frames is 
rather low and sequences get saturated very quickly. Reverse mutations may take place 
which further complicates any evolutionary phylogenetic analysis.
In some families (51, 81, 174, 217, 231) sequences in the siblings remained completely 
identical over the period since their presumed infection. This is consistant with previous 
observations by other authors (Hannoun, 2000), where children were known to be infected 
perinatally from their mothers and immune tolerance was caused by HBeAg. In this study 
some sequences from non-relatives within villages were also found to be completely 
identical, what has never been previously described. In the Gambian situation, as it was 
shown by numerous epidemiological studies (Whitlle, 1983 and 1990; Vail Mayens, 1990), 
actual infection obviously occurred during early childhood. All patients with identical
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sequences were HBeAg positive, which is consistent with previous observations, that 
before seroconvertion to anti-HBe sequence mutations are rare. The fact, that children from 
different families, but from the same village of birth carry the same viral sequence, is very 
strongly suggestive that they got infected horizontally from a common source or from 
each other.
During the design of the study, it was expected that viral sequences from different 
families would develop certain family specific mutations due to different genetic 
backgrounds and immune pressures. However, the observations on the transmission of 
HBV in the village did not always support this hypothesis. Another explanation for this 
apparent similarity after a long period of time could be the fact that population in Gambian 
villages are relatively inbred and have very similar genetic backgrounds.
In many families and villages the sequences formed clusters which were supported by high 
bootstrap value (>50% or even >70%), widely accepted as reliable criteria for the 
evaluation of the phylogenetic trees. Interestingly , some of the village and family clusters 
were extremely similar. For example, in the cluster from the village Kaiaf, sequences from 
families 79 and 80 were clustered together and these clusters were indistinguishable from 
each other, giving the impression that members of these families got infected from each 
other or from other common sources in the village. Both families were unrelated but 
inhabited the same compound.
16 sequences from non related subjects were obtained from the village of Manduar and it 
was obvious that they represented different phylogenetic clusters. The majority of
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sequences were from children from families with multiple carriers, but unfortunately it was 
impossible to obtain more than one sequence from one or each family. These clusters are 
nearly indistinguishable by their size and phylogenetic distances from family clusters in 
other phylogenetic trees, and many of them have significant bootstrap support (>70%) in 
separate phylogenetic trees from this particular village (see Figure 26), indicating that 
individuals got infected from different sources. Clusters were representing children from 
approximately the same age group, but one has to admit, that nearly all persons bled were 
from the same age group. The village is rather small (500 inhabitants) and isolated from 
the main roads. Most of the people in The Gambia live in housholds called compounds. 
Knowing that, the most probable assumption would be that children get infected 
horizontally from other siblings or compound neighbours, because that is the place where 
they spend most of the time. Information about compounds of birth of the children in this 
village was available. Surprisingly, clusters in the village Manduar did not support this 
assumption. Most of the individuals were from different compounds and still carried very 
similar viruses.
Other findings from this study are similar to findings in Manduar. In village Baniakang 
two non-related subjects from different compounds had very similar sequences (see Figure 
20). In village Damphakunda three samples formed part of a family cluster, but other 
sequences from the village were phylogeneticly very distant (see Figure 21). Village 
Kumbija had a family cluster and two other sequences were very distant (see Figure 20).
The similarities of sequences between several mothers and their children could indicate 
that mother to child transmission occur in The Gambia, though it is not widespread. 
Perinatal transmission has been excluded by multiple epidemiological studies (see 2.3.1.4)
so apparently horizontal transmission or transmission through mother’s milk is more likely 
to take place. If an infection is acquired from the mother, then it happens in an early 
childhood and therefore the virus in mothers since the actual time of infection can have 
more mutations then in their children, especially in HBeAg negatives. This could explain 
why sequences from mothers 1522 and 1349 are evolutionary more distant than those of 
their siblings. They probably shared the same viral strain at the time of infection, but then 
the virus from the mothers underwent more changes, because mothers were of later became 
HBeAg negative.
From these limited data one could assume that there is a clear division between different 
viruses within the village not always reflecting division in families or compounds.
The PAUP 4.0 programme package provides the tools for random simulation. 200 hundred 
random trees were simulated on each of the four data sets and model trees with all 
sequences organised according to village and family clusters, and their maximum 
likelihood log values were obtained. If there was no clustering in the tree, then artificial 
improvement of the tree according to the rules of clustering would just deform the tree and 
make it even more similar to any of the random trees, so it would be impossible to tell the 
difference. In contrast, data sets of the log likelihoods for three model trees fell well 
outside the null distribution provided by the random topologies. The only tree which fitted 
within the random topologies was the tree constructed from HBeAg negative genotype E 
samples. In the case of the E genotype set, the combined family+ village tree had much 
higher likelihood values than either component tree, suggesting that these two levels of 
population structure contain the most information. This statistical analysis is supporting the 
idea that actual clustering is somewhere higher than simple family clustering.
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In conclusion, it is clear that phylogenetic analysis can be a very effective tool for 
epidemiological HBV transmission studies and in addition can raise additional questions 
for further epidemiological exploration.
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7 General Discussion
Only a few studies on HBV transmission within the families have been published so far. 
Nucleotide sequence comparisons have been used previously to demonstrate transmission 
of HBV from mother to infant, but also in common source outbreaks of infection in 
different epidemiological settings (Barlet et al, 1994; Acarca et al, 1994; Santantonio et al, 
1997; Ho, 1995).
The availability of a large number of specimens of all ages from the Gambian families with 
multiple HBV chronic carriers has provided unique opportunity to apply human and 
molecular epidemiological methods for the analysis of transmission of the virus within the 
families.
The original aim of the sample collection for this study consisted in the accumulation of 
human DNA probes from multiple affected siblings for further human genetic studies. 
Overall, 142 families with multiple HBsAg carriers were identified. Although I have tried 
to get as many carriers as possible from each family, several factors reduced the number of 
samples available. A large proportion of the siblings were not bled because they were not 
present at the time of the bleeding or refused to take part in the study. The Gambia is one 
of a few African countries where mass vaccination has been introduced in 1986, and 
vaccination coverage was thought to be higher than 90%, so, the children under 
approximately 9 years of age were most likely protected against chronic infection (Viviani 
et al, 1999; Inskip et al, 1991) and therefore not bled. The extent of mother to child 
transmission could not be established, because the HBsAg and HBeAg status of mothers at 
the time of delivery could not be known. Considering all these factors, the subjects of this
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study represent only a part of the families with multiple HBV earners, making a full 
human epidemiological analysis incomplete. However, one could try to characterise the 
course of the chronic carriage and give an insight into epidemiology of HBV infection 
within the families. Fortunately, several human epidemiological studies were performed in 
The Gambia previously (Whittle et al, 1983; Whittle et al, 1990) and had provided some of 
the missing information about the clustering of HBV infection in Gambian families.
Although a large number of samples have provided good material for molecular 
epidemiology studies, certain insufficiencies in the original design made the data set 
incomplete for this particular study. The possibility of using phylogenetic methods for the 
current molecular study was not considered at the time of the data collection. Patients were 
recruited from all around the country and in many cases only one family represented the 
whole village. Ideally, for molecular epidemiology studies of this kind, a large number of 
samples from a single village would be required in order to better answer questions on 
HBV transmission patterns in the Gambian households.
Many samples were PCR negative and it was not possible to obtain viral sequences. That 
reduced the number of families having multiple carriers with available nucleotide 
sequences to 32. In very young children we would normally expect them being HBeAg 
positives with higher viral loads and less evolutionary changes in viral sequences, what 
would make the sample size bigger and transmission study easier. In my subject group, 
because of the mass vaccination programme, all siblings were older than 9 years and some 
time after infection could undergo significant changes, especially in HBeAg negative 
individuals, making analysis of transmission more difficult.
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Another problem with this study is its retrospective nature. The data collection took place 
in The Gambia, but this current analysis was done in the UK and it was not possible to go 
back and test one or other hypotheses or get more precise information on certain family 
clusters or related epidemiological information. The amount of blood in the samples was 
sometimes insufficient for doing all the necessary serology tests due to the difficulties of 
bleeding in the field surroundings. For these reasons, several samples were not tested, for 
example, on the HBeAg or aminotransferase activity.
Nevertheless, the large sample size, the unique opportunity for a long term follow up of 
chronic HBV earners, the limited information on Gambian and West African sequences in 
general, and the use of novel and experimental phylogenetic methods provided a new and 
interesting information on previously unknown molecular aspects of HBV epidemiology in 
the Gambian families and villages. The detailed phylogenetic approach was shown for the 
first time to be a very effective tool for the analysis of HBV transmission within families 
even being used long time (10-30 years) after the actual time infection.
Overall, the prevalence of HBsAg chronic carnage in The Gambia was previously reported 
to be around 10-15% (Whittle et al, 1983; Viviani et al, 1999; Inskip et al, 1991). The 
prevalence of HBsAg carriage in my study was 37 % in sisters and 57% in brothers of 
chronic carriers, that is, well above usual. The risk that the first sibling of the chronic 
carrier bled would become a carrier in this study was calculated to be 45%. This shows 
clearly, that the infection is more likely to cluster in families, as already suggested in 
previous studies in The Gambia (Whittle, 1990), where the chance of the youngest child in 
household being a earner of HBsAg was strongly related to the number of antigen-positive
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siblings. This cannot be attributed to the increased risk of exposure, because the 
prevalence of HBV infection (anti-HBc positive) in The Gambia is very high (>90%) and 
nearly everybody gets exposed to the virus in early childhood. Based on findings of this 
and previous studies, we can assume that most of the carriers in The Gambia are members 
of carrier families. That would mean that, the overall prevalence of the carriage (10-15%) 
does not really depict the real situation in the population. Those at risk of developing 
serious complications as cirrhosis and HCC are most likely members of these families. 
Identifying these families at risk would be an important measure for better targeting of 
therapeutic interventions.
Remarkable differences in carriage rates were found between brothers and sisters of the 
chronic HBV carriers and between males and females in general. That could mean that 
brothers of the carrier are in higher risk of becoming carriers. This difference could be 
explained by different X chromosome encoded genetic predisposition or hormonal 
differences. Also, if boys would get infected in earlier age than girls, that could lead to 
higher carriage rates. All boys get circumcised in The Gambia and different urination 
habits can also be discussed.
Birth order has been suggested previously as an important risk factor for developing 
chronic HBsAg carriage and hepatocellular carcinoma (Whittle, 1983; Ryder, 1992; Hsieh,
1992). This study confirms previous observations that younger siblings in the families with 
older sibling carriers are at high risk to become carriers. This trend was found to be 
significant in families where mothers were known to be HBsAg negatives or their HBsAg 
status was unknown. They apparently got infected earlier in life from their siblings and 
therefore a higher proportion of them developed chronic carriage. In families with HBsAg
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positive mothers, the higher prevalence of carriage in younger siblings was not observed. It 
seams that in such cases older siblings got infected from their mothers. Possible 
mechanisms for that will be discussed later in this chapter.
There is one very important aspect, which was not considered at the time of the study 
design. Younger vaccinated siblings in families with multiple carriers apparently were 
exposed to infection from the very early childhood. Therefore, they could be potential 
carriers of the vaccine escape mutants that could have far reaching epidemiological 
implications. That is one of the reasons why families with multiple carriers should be 
closely monitored in the future.
The HBeAg carriage and PCR positivity are associated with increased HBV replication 
and higher viremia levels. Therefore, HBeAg and PCR positive patients are more likely to 
be infectious. Prevalence of HBeAg positives in persons older than twenty years in this 
study was found to be significantly lower than in children and adolescents. Therefore one 
can safely assume that if a horizontal transmission is the main route of infection in The 
Gambia than the main sources of infection are children and adolescents. That in all 
respects supports hypothesis on intrafamilial transmission between siblings.
Prevalence of HBeAg and PCR positives is significantly higher in males than in females 
and that could indicate that the virus has more active replication in men. This difference 
was very obvious in the 15-19 age group, suggesting that boys clear viremia later than girls 
and therefore remain as a potential source of infection longer. This observation can lead 
to speculation that boys during their lifetime infect more younger siblings or other children
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than girls. That would be nearly impossible to prove by conventional methods and a new 
cohort study had to be designed.
10% of the carriers followed up for a 6 to 10 year period cleared the HBsAg carriage that is 
consistent with previous reports (McMahon et al, 1990). In elderly this clearance was even 
more common. I cannot say whether these individuals completely cleared the virus from 
their liver and blood because more detailed investigations on samples were not performed. 
Most likely viral replication diminished over the time period and HBsAg became 
undetectable. Possibility that these individuals could develop mutants that could escape the 
conventional HBsAg detection tests could also be considered and PCR on samples 
performed.
Only three genotype E sequences from West Africa have been published so far (Norder,
1993) and information provided by this study was very useful in assessing the predominant 
strains of the HBV and the molecular epidemiology of the virus in Gambian chronic 
carriers. Two genotypes of HBV were identified in The Gambia by this study. Genotype E 
was found to be predominant in the country. The primary_structure of the genotype E HBV 
C and S genes was quite similar to the sequence of the previously published isolate from 
Senegal (Norder et al, 1993). Sequences from this genotype were obtained from samples 
all over The Gambia. Isolates of genotype A represented only 14% of the total number of 
sequenced samples. The primary structure of genotype A representatives was very close to 
a genotype A sequence from Cameroon (Norder et al, 1993). However, HBV genomes 
belonging to genotype A were found only in Eastern parts of the country (see Figure 14). A 
possible explanation for these differences could be that genotype E is older and endemic in 
the area, whilst genotype A was brought in later and that is why it is spread predominantly
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along the coastal area, where main trading routes are located and migration of people is 
historically greater.
Sequencing provided very important information about predominant nucleotide and amino 
acid variations in the HBV genomes occurring in the Gambian population. Core promoter, 
pre-core, and core sequences of HBV have never been obtained from The Gambia and 
therefore the prevalence of previously reported important amino acid substitutions was 
unknown. The double mutations at nt 1762 from A to T and at nt 1764 from G to A in the 
part of the ORF X that covers the core promoter was previously associated with more 
active liver disease (Okamoto et al, 1994; Hannoun et al, 1997). 7% of Gambian carriers 
were found to carry this mutation and 66% (4/6) of them had elevated aminotransferase 
levels. A mother and her child were found to share this mutation, which could indicate 
possible transmission or simply common genetic background.
The pre-core stop codon mutation has been thoroughly studied and was known to be quite 
common in Southern European populations. This mutation has not been reported 
previously in HBV genomes of genotype E and in West African population. In this study, 
14 pre-core mutants were detected out of 141 sequences (10%), which is considerably 
lower than in some parts of the world (Southern Europe, Asia). The overall prevalence of 
the HBV pre-core mutants may be even lower, since two mutants were found in the mother 
and her child, three mutants were found in three siblings from the same family and two 
mutants were in samples from one village. Sequences from these viruses were 
phylogenetically very similar and that could indicate transmission of the mutant viruses. 
Therefore, family clustering of pre-core variants of HBV genomes was obvious. 
Transmission of pre-core variants, even in childhood, was previously associated with
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development of fulminant hepatitis in neonates (Stemeck et al, 1998). In Gambian 
situation, it was very unlikely, that children could develop severe hepatitis and survive, so 
most likely they did not develop clinical disease, if they were infected by the HBV variant 
with pre-core stop codon. Unfortunately, my sample collection was prepared 10-15 years 
after the actual time of infection and more detailed retrospective investigation is 
impossible. Pre-core variants of HBV genomes were found only in isolates belonging to 
genotype E. It was previously suggested that these mutants are observed quite rarely in 
genotype A and no variant was found in our samples.
Most of the HBV samples sequenced did not contain any amino acid substitutions. In the 
core gene, mutations were distributed over the entire gene without an apparent 
concentration in certain regions. Substitutions occured significantly more frequently in the 
HBeAg negative than in HBeAg positive samples. The stage-dependent mutation rate in 
chronic hepatitis B, with few mutations in the HBeAg positive tolerance phase and 
increased number of mutations in the anti-HBe phase, has been previously demonstrated in 
several cross-sectional studies (Akarca et al, 1997; Karasawa et al, 1997).
Interestingly, amino acid substitutions in the HBV core gene in position 64 from E to D, 69 
from T to S and 146 from N to T were much more common in the anti-HBe positive 
samples with the pre-core stop codon mutation. All these substitutions have been 
previously reported as normal in consensus sequences from other genotypes. Why these 
particular transformations occur mainly in the anti-HBe positive patients is not clear. 
Similar transformations to amino acids characteristic for other genotypes were reported in 
another study, but little attention was paid to them (Carman et al, 1995). This can be a 
topic for speculation that perhaps the patients with these mutations are more likely to
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develop the pre-core stop codon mutation or that the pre-core stop codon mutation is 
somehow associated with these mutations
Although many families were bled, only a few of the siblings were found to have the same 
amino acid substitution in the HBV core protein. Family clustering was only significant in 
patients with the pre-core stop codon mutation in a sense, that they shared this mutation. At 
the time of the study design, I expected that siblings will often carry the same amino acid 
substitution because possible similarity of immune pressure and HLA structure and it will 
be very easy to recognise members of different families by typical amino acid mutations in 
B and T cell epitopes. This was not found during the analysis of sequences, despite most 
of them were phylogenetically very close and children obviously got infected with the 
same viral strain.
In the surface gene, only one amino acid mutation 123 T to A was found, which could 
potentially affect the structure of the first loop of the a determinant of the HBsAg 
molecule, but it has never been associated with any clinical significance. The previously 
published vaccine escape mutation at HBsAg amino acid position 141 in The Gambia 
(Karthigeasu, 1994) was not observed in the chronic carriers studied here. This indicates 
that, if this mutation occurs, its prevalence is not high in the normal population. In four 
samples, HBsAg amino acid substitutions characteristic of other genotypes were observed. 
All these samples were anti-HBe positive. These observations are similar to the findings of 
this study in the HBV core gene and it is not clear why these substitutions occur and 
whether they have any clinical importance. Double infection with HBV genomes of two 
genotypes cannot be excluded, because only direct sequencing of PCR products was
performed. Cloning of these PCR products and subsequent sequencing would probably 
provide more information, why these variants occur.
Premature termination codons at position 216 of the S region of the HBV surface gene, 
preventing expression of full length HBsAg protein, previously described only in 
immunosuppressed patients (Preikschat et al, 1999), were found in three Gambian samples. 
There are many factors, which could cause immunosuppresion in the Gambian population. 
Malnutrition, HIV infection and malaria infection are all know to facilitate 
immunodeficiency. The actual pathogenetic importance of this mutation is entirely unclear. 
These mutations did not change the amino acid sequence in the overlapping open reading 
frame of the polymerase gene. The expression of most important immunogenic parts of 
HBsAg protein cannot be influenced by this premature termination codon.
Nucleotide sequence comparisons have been used in the past not only to demonstrate 
transmission of the virus from mother to infant, but also to describe common source 
outbreaks of infection in different epidemiological settings. The presence of similar 
nucleotide sequences, or of well characterised variants of the virus, such as the pre-core 
stop codon and surface variants, or viruses with deletions, have been reliable indicators of 
transmission from one person to another (Hannoun et al, 1997; Lin et al, 1990; Bozkaya et 
al, 1996; McIntosh et al, 1998). Striking similarities of sequences of the pre-core/core 
genes were found in siblings and their mothers (Bozkaya et al, 1997). Some of the 
sequences remained identical over a period of twenty years. No data were available on 
families infected horizontally, or under other circumstances, or about HBV sequences in 
The Gambia. So, at the time of the study design it was very difficult to predict, what the 
findings would be. It was suggested previously that the children most likely get infected
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from their siblings (Whittle et al, 1983) and it was decided to focus mainly on intrafamilial 
transmission, and to study gene sequences from two HBV genome fragments - the pre­
core/core and surface genes. In the present study, I have attempted to address this question 
using rigorous phylogenetic analysis of sequences obtained from the surface and pre- 
core/core region of the virus, from family members and other chronic carriers.
Sequences of the surface gene fragments did not seem to provide the necessary 
information, since many of them were completely identical and therefore could only 
confirm that similar HBV strains were present in the families. However, phylogenetic 
analysis on surface gene was found to be an excellent tool for determining HBV 
genotypes, but not subtypes. Therefore one could speculate that from the evolutionary 
point of view distribution of HBV genomes into genotypes is more feasible than into 
subtypes.
Phylogenetic analysis of pre-core/core gene sequences provided more detailed information 
about the clustering of HBV infection in Gambian families and villages. Despite 
phylogenetic distances being very short, a clear evolutionary pattern emerged. Several 
clusters of viral strains were reported and some of them were supported with high 
bootstrap values (>70%).
At the geographical area level, it was not possible to see any significant clustering of pre­
core/core sequences, because sequences from completely different villages and 
geographical areas were sometimes identical. This could suggest that extensive mixing of 
strains occurs at this level, most likely caused by the movement of infected individuals
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among villages. If one could assume that HBV infection arrived in The Gambia relatively 
recently and spread from one part of the country to the rest, then it would be possible to see 
certain consistency in its distribution. However, the phylogenetic tree gives more 
impression that the infection has been present in this area for quite a long time and it is 
moving in different directions without significant sequence changes. This assumption 
would be against the theory, that HBV infection arrived relatively recently in Africa from 
the New World, suggested previously by phylogenetic analysis of different HBV strains 
(Bollyky et al, 1997 and 1999). Another explanation for this homogeneity of the HBV 
sequences could be that the number of possible mutations with similar survival capacity 
due to the overlapping reading frames is rather low and sequences get saturated very 
quickly. Reverse mutations may take place, thus complicating further evolutionary 
analysis of HBV genomes.
Both HBV genotypes A and E were clearly distinguishable in the phylogenetic trees. Thus, 
phylogenetic analysis can be used successfully for genotype detection not only on surface 
gene, but also on pre-core/core gene sequences. Distribution of both genotypes in the 
phylogenetic tree indicated that genotype A was introduced later and had less evolutionary 
changes (shorter evolutionary distance) or had some selection disadvantages, which could 
also explain its lower prevalence and limited spread within the country.
In some families pre-core/core gene sequences remained completely identical in the 
siblings over the period since their presumed infection. This is reminiscent of previous 
observations in the families, where children were known to be infected with HBV 
perinatally (Hannoun et al, 2000; Bozkaya et al, 1997). In addition, some sequences from 
the same Gambian village, but non-related subjects, remained completely identical for at
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least ten year period, which as far as one could judge, has never been described previously. 
All patients with identical sequences were HBeAg positive. This is consistent with 
previous observations, that before seroconversion to anti-HBe mutations are rare (Bozkaya 
et al, 1996; Carman et al, 1995). The fact that children from different families, but from the 
same village carry the same viral sequence very strongly suggests that they get infected 
horizontally from a common source or from each other. Explanation for this surprising 
similarity of nucleotide sequences in non-related subjects after a long period of time could 
be the fact that population in the Gambian villages was relatively inbred and had very 
similar genetic backgrounds and therefore immune pressures were quite similar.
In many families and villages the sequences formed clusters, which were supported by 
high bootstrap value (>70%), widely accepted as reliable criteria for the evaluation of the 
phylogenetic trees. Interestingly, some of the village and family clusters were very similar. 
For example, in the cluster from the village Kaiaf, sequences from families 79 and 80 were 
clustered together and these clusters were indistinguishable from each other, giving the 
impression that siblings from these families were infected from each other or from another 
common source in the village. Both families were unrelated, but inhabited the same 
compound.
16 HBV pre-core/core sequences from non related subjects in village Manduar were 
grouped in different phylogenetic clusters. These clusters were nearly indistinguishable by 
their size and phylogenetic distances from the family clusters in other phylogenetic trees. 
This could indicate that the routes of HBV transmission within families and within groups 
of children in the villages are similar. Interestingly, these clusters within the village were 
not related to compounds of birth. Most of the individuals were from different compounds
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and still carried similar HBV genomes. Another less likely explanation could be that 
because of different genetic backgrounds these different groups within the village became 
carriers by being particularly susceptible to one specific strain of HBV out of the several 
strains circulating within the village.
Findings in other villages were similar to findings in Manduar, but only a small number of 
sequences were available from each village. Different small clusters from villages 
Baniakang, Kumbija, Damphakunda did not group together according to the village of 
birth, but were located in very different positions.
From these limited data we can assume that there is a clear distribution between different 
viruses within the village, but this distribution does not necessarily mean distribution 
according to families or compounds. It can be speculated that this distribution can be age 
related, but I cannot express a certain opionion on this matter as some age groups were 
under-represented in this study. To answer the question, more HBV sequences and relevant 
epidemiological or anthropological information has to be obtained from Manduar and 
other villages.
There were families, where HBV sequences definitely did not show any signs of clustering 
and were positioned all over the phylogenetic tree. By using genetic markers from host 
DNA, it was established that they were undoubtedly children from the same parents as 
their siblings. Unfortunately, information on whether the children grew up with their 
families, was not available. Traditionally, many families in The Gambia send their 
youngest children to their grandparents or other relatives in distant villages. That could 
certainly happen in early childhood or even during the weaning period, when the risk of
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becoming a carrier is assumed to be the highest and therefore the possibility that these 
children with completely different sequences were infected in another place from the 
village of their birth could not be excluded. It is also very common, that children from 
one or even several compounds were kept together and handled by different mothers, 
increasing the risk of getting infected from other sources.
The importance of mother to child transmission in The Gambia was always uncertain from 
the previous studies (Whittle et al, 1983; Hall, personal communication). Studies in 
Manduar and Keneba showed no significant difference between the prevalence of HBsAg 
antigenemia in mothers of the children, who became chronic earners compared with 
mothers of children, who did not become chronic carriers, but there was the trend (8 
mothers of 35 chronic carriers and 3 mothers of 31 noncarriers were HBsAg- positive) 
(Whittle, 1990). In E- study, the prevalence of HBV carriage was significantly higher in 
children of HBeAg positive women (54%), than in HBeAg negative (26%) and non- 
carriers (19%) (Hall A, personal communication). This difference was not seen with 
HBsAg positive fathers. My study also showed higher prevalence (Vail et al, 1994) of the 
HBsAg antigenemia in the mothers of the carriers, than in the fathers. Prevalence of 
carriage in mothers was higher than average prevalence in Gambian women (10%). The 
phylogenetic analysis on HBV pre-core/core sequences in four mother and child pairs was 
performed. In three of them, mothers had very similar HBV sequences to their children, 
which clustered together in the phylogenetic tree. I consider this information in addition to 
epidemiological data about higher prevalence of HBsAg carriage in mothers sufficient to 
suggest that the mother to child transmission occurs in The Gambia, but it is definitely not 
the predominant route of transmission. When the actual mother to child transmission 
occurs is not clear. It was shown previously that in African population perinatal
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transmission did not occur even in the HBeAg mothers (Marinier et al, 1985). Horizontal 
transmission or transmission via mothers milk most likely takes place.
A different statistical approach was designed in order to better characterise the clustering 
within villages and compounds, because bootstrap analysis could not provide enough 
statistical support for all clusters apparent by eye in the phylogenetic tree. Firstly, samples 
were divided according to their HBeAg status in positives and negatives, since it was 
shown that the HBeAg negatives had many more mutations over the time and this could 
diminish the accuracy of phylogenetic analysis. Secondly, both HBV genotypes A and E 
were analysed separately. In the genotype E samples, combined family + village tree, had 
much higher likelihood values, than either component tree, suggesting that these two levels 
of population structure contain most of the information. This statistical analysis supported 
the idea, that actual clustering is somewhere higher, than simple family clustering.
Therefore, based on epidemiological observations, phylogenetic trees and statistical 
analysis, a model of transmission of HBV in the Gambian population can be proposed. 
Children can get infected horizontally from their siblings, mothers, other compound 
members and even children outside the compounds, but that does not mean that all the 
children, even in the small villages, were infected from the same source or shared the same 
virus strain. Transmission seems to be multi-factorial and associated with the close contact 
between children. They could become infected through close contact when playing, 
sharing the same bed, or through other activities. How this transmission actually happens 
and what factors facilitate it, is still not clear and merits further anthropological 
investigation. The establishment of the single predominant risk factor is very unlikely.
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8 Future plans
Epidemiology.
To go back and find more detailed epidemiological information about the siblings whose 
sequences were analysed in order to find out exactly where they were at the presumed time 
of the infection.
To bleed more people from the subjects of the same compounds and villages and 
vaccinated children of the families with multiple carriers in order to see whether they have 
got vaccine breakthrough infections.
To try to carry out a similar study to this in the country, where mass vaccination has not 
been introduced and all children in the families get exposed to infection in order to find the 
exact route of transmission by collecting anthropological and epidemiological information.
To use the similar combined approach to investigate an outbreak of the HBV and HCV 
infections in approximately fifty Latvian paediatric patients with acute leukemia who were 
infected during the chemotherapy in the ward over the period of two years.
Molecular biology
To obtain full genome HBV sequences from both Gambian genotypes A and E and try to 
use these sequences for the phylogenetic analysis of the evolution of the virus.
To clone some pre-core/core sequences in order to find quasispecies in different patients 
according to HBeAg status
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To analyse further human genetic data from siblings or village inhabitants who carry 
related virus in order to see whether genetic background determines development of certain 
amino acid substitutions in the viral sequences.
Clinical interventions
To get more detailed information about the clinical features 
carriers, involved in this study: e.g.liver biopsy in order to 
disease.
To try to deliver the treatment currently available in The Gambia for those for whom it is 
necessary and to apply new treatments designed on the basis of this study.
Moral obligations
To keep an active follow up of the chronic HBV carriers identified during this study.
of the HBV infection in the 
establish the activity of the
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9 Appendices
Appendix I. Consent form
We are trying to find out why some people in The Gambia get infected with 
a virus (a very small infecting agent) called Hepatitis B, which then stays in their 
blood for a long time. This is a very common infection in The Gambia but only a 
few people carry the virus for a long time. We first need to test you, and your 
brothers and sisters, to see if you are carrying this virus. To do this, we need to take 
2mls (half a teaspoon) of blood (show syringe) that will be taken back to MRC for 
testing. We will return to your compound to tell you the results. If you and one of 
your brothers or sisters are positive for the test, we will ask you for some more 
blood (lOmls, two teaspoons), (show syringe) and will ask your parents if they will 
give the same amount of blood. These second specimens of blood will be carefully 
analysed to see if we can find out why you and your brother or sister has been 
carrying this infection. The knowledge gained from this research will help us 
understand more about this common infection in The Gambia and may help us to 
find a new treatment for this infection, which in some cases may cause damage to 
the liver.
Person’s name 
Field worker
Date / /
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A p p e n d ix  II. Family tree questionnaire
Surname Name Age Vaccination Sex
Father
Mother
Children
1
2
3
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Appendix III. Field questionnaire
Name Surname FCNO
IDNO
Date of interview / / PIDNO
Date of birth I I I DATES / /
Sex SEX
Age in years AGE
Village of birth VILLB
Village of current residence VILLC
Compound COMP
Name of the compound owner NCOMP
Name of the farther Surname FATHN
Name of the mother Surname MOTHN
Ethnic group ETNIC / /
l.Mandinka 5. Fula
2. Aku 6. Sarahule
3. W ollof 7. Other
4. Jola
Ethnic group of father? ETNICF / /
1. Mandinka 5. Fula
2. Aku 6. Sarahule
3. W ollof 7. Other
4. Jola
Ethnic group of mother? ETNICM / /
1. Mandinka 5. Fula
2. Aku 6. Sarahule
3. W ollof 7. Other
4. Jola
How many sisters and brothers index has
with the same father and mother? F AMS / _ /
How many brothers and sisters from the same parents
are older than the index? BORD/ /
What are family relationships with the index? REL / /
I- Index C- Child
P- Parent F- Half sibling from father 
S- Sibling M- Half sibling from mother
First sample brady number SPNO 1
Second sample brady number SPN02
Date of first sample I I I SPDATE1 / /
Date of second sample I I I SPDATE2 / /
Directions to reach the house HBSAG/ /
Interviewer
HBeAG / / 
HBCAB/ / 
AST/ / 
ALT/ /
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A p p e n d ix  IV . Example o f  the result form
Dear parents,
Members of your family have been included in Chronic Hepatitis B and C family study. 
This is study was designed to find out why some of your family members become carriers 
o f hepatitis virus. First tests showed hepatitis B status of your family members.
Manama Camara- HBsAg negative 
Ebrima Camara- HBsAg positive 
Saidou Camara- HBsAg negative 
Amadou Camara- HBsAg negative
You may be invited to take part in other studies.
MRC, Fajara 
Dr.Dumpis
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Appendix V. Main serological markers and age from the family members o f the 
previously known HBV chronic carriers
■
1 N neg +M I7E +F12 +M11 V
2 N N N +F18E N +M9E V V
5 + neg M20 F14 +F12E +M 10E V V V
II N + M19 +M17 F16 M I4 +FI1E V V VV
12 N + +M17 F13 +F11E V
14 N N F31 N F27 N N +F20 N +FI0
17 N neg N + 13F -13M + 10M V V V
18 neg N +M20 N +F14 +M11 +F9 +M 7E V V V
20 neg neg +M15 +M13 N +FI0E
21 neg neg +F13 N +M 10 V V V
22 neg neg F20 N N + M 11 +F9 V
24 N + +M17 F15 +F10 V
28 neg neg N M 20 N +M15 +F12 +M12
29 + + +FI4 N +M 10 V
30 N N +M14 +M 10E
31 N neg +M30 N N F22 M19 +M 17E +F12 +M 10E
33 + neg +M16E +M 13E +M 10 +M 8 V
34 neg neg M18 +M15 +M 13 +M 10E
35 neg N +M31 +M 28 +M 25E N N +M12 N
40 neg N N F16 F14 +M 12E +F10E
41 neg + +M18 +M 16E +M 14 +M10
42 N neg +M12E +M 10E
44 N neg N F19 +M 16 M13 +F10
47 neg neg M20 M 14 +F12 +M 10 V
49 neg neg N N N +M16 N +F10 V v ,  v
53 neg + +M16E +M 13E +M 11E
57 neg neg +M18 N N +M13 FI 1 V V
59 N neg F26 M 24 N +F18 N +M13 F10
61 N + +F19E +F17E +M 13E +M 11E V
69 neg N M20 +F17 F14 +F11 V V V
72 neg neg F27 N F23 F18 +M 16E N +M 12
80 neg neg +M18E F15 +F12E
81 neg +F14 +M 11E +M 9E N N
82 N neg +M12E +F10E V V V
86 neg neg F30 F21 M 19 N +M15 M13 +M11
93 neg neg F26 +M 20 +M 17 F12 +M 10
95 N + +F18 F12 +M 10
96 neg neg F21 F18 +F16 N F12 +F10 V V
97 N neg F15 +M 13E +F10 V V V
99 N neg +M12 +M 10E V V
100 N neg +F30 +F28 +M 26 +F21 M 18 +F12
101 neg neg F20 17M +F15 F13 +M11 V V
106 N neg N M 20 F18 N +M 14 +M12 +F10 V V
108 neg neg M23 F21 F18 M15 +F15 +M 10 V
111 N neg 23F +20M F15 M13 +F11 +F9
114 N neg M19 +M 16 +F14 V V
116 neg neg N +M 16E +M 13 M il V V V
117 neg + E F24 +M 18 N M15 +M13 V
120 N neg N +M 13 +M11 V V V
125 neg neg N +M 16 +M11 V V
126 +E N +F16 N +F11
127 N + +F12 +F10 V V
133 neg neg N N +F13 +M 12E V V
135 neg N F20 +M 17 F15 F12 +M 10E V V
137 N + N +M 15E +M 12 +M 10E V V V
139 N + N +M21 +F17 N F12 +F12 +F10 V
140 neg neg N +F15 +M 12
141 + neg +M21 +F15E +M 13E
142 neg neg +M21 +M 14 V
150 N N M50 M 48 +F46 +F44
153 + . neg +M13E +F11 +M 10E
154 neg neg +F19 +M 16 M 14 M12 N V V V
158 N + +F12 +M 10 V V V V
162 N + N F20 + 14M M12 +M 10 V V V V
165 N neg M15 +M 13 +M 10 V V V
168 neg N F22 M 19 +F13 +F10 V V
169 neg neg N N F21 N +M 16 +F12 V
172 neg +E F13 +F11E +F10E V V
173 neg neg M2 8 +M21 +M21 F18 F18 +M14 +M 10
174 N neg +F24 N +M 19 N +F14E +F12 +F10E V V
176 N neg F16 +M 14 +M 10 V
181 N neg +FI4 +M 12 +F10E
182 N neg M19 +M 12E +M 10 V V V
184 neg + +M 13E +M 10 V V V V
187 N neg +M13 +M 10E V V V
192 neg + F15 +M 13 +F10 V V
200
199 neg N +M I3 +M10 V V V
202 neg neg N N N +FI3 + M 10
203 neg + F39 +M37 +F29 N +FI8 N M I3
205 + + +F30 +M28 +F22 N N
207 N + +F38 +M28 M27 F24
214 neg neg +F17 +FI4E + M IIE V V V V
217 neg N +F21 +FI9E +FI5E +F11E V V
218 neg N +M25 N +M20 N N N +M I1E V
220 neg neg +M I8 M 16 +M11E V
222 neg neg +F23 F21 FI8 M16 +M14 +F11 V V
223 N neg +M20 +M I5E +M13 N N N
225 neg neg M15 +M 13E +F11 V V V V
226 neg neg + FI8 +M20 +M I6E
231 N neg +F29 N +M24 +F22 +M19E FI 7 +F15
233 N + +F3I +F29
234 neg + +F27 N N +M12
237 N N +M24 +F23 N N N N N
238 N neg F22 +M 20E +M16 +F14 V V V
245 neg neg +M45 N F40 +F38 F35 F32 N N
246 N N +F36 F34 M28 +M23 N N
255 N N +F39 +F32 N N F22 N
260 N N +M35 N N +M20 N N
261 N N +F50 N N M38 N +F32
263 N N +F28 +M25 N +F21
264 N neg +F36 N +F26 N
266 neg neg +M31 +F29 F23 +M20
268 N + N +F35 N F23 +M23
272 N neg M48 N M3 8 N +F30 +F27
273 neg neg M30 +F27 N +F22 F19 +M17 N V I
276 N N +F45 +F42 +F39 Not known
277 N + N N +M13 +M14 +M15
This table does not include families, were HBsAg status was already known for all family 
members or data on birth order were not available. Information about how many in the 
family were bled, how many were vaccinated and how many were not available at the time 
of the bleeding or refused to be bled is included in this picture. Age, sex, HBsAg, HBeAg 
status is also shown.
Abbreviations used in the table:
N - Not available at the time of bleeding or refused
+ - HBsAg positive, Neg - HBsAg negative, E - HBeAg positive
V- vaccinated
M- male, F- female
Numerical values - age
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A p p e n d ix  V I. Example o f  the FASTA sequence alignment format
Alignment o f the fragments o f surface genes.
> 1 0 0 3
A G G A T C A T C A A C C A C C A G T A C G G G A C C C T G C C G A A C C T G C A C G A C T C T T G C T C A A G G A
A C C T C T A T G T T T C C C T C A T G T T G C T G T T C A A A A C C T T C G G A C G G A A A T T G C A C T T G T A T T
C C C A T C C C A T C A T C A T G G G C T T T C G G A A A A T T C C T A T G G G A G T G G G C C T C A G C C C G T T T
C T C C T G G C T C A G T T T A C T A G T G C C A T T T G T T C A G T G G T T C G C C G G G C T T T C C C C C A T T G T
C T G G C T T T T A G T T A T A T G G A T G A T G T G G T A T T G G G G G C C A A G T C T G T A C A A C A T C T T G A
G T C C C T T T A T A C C T C T G T T A C C A A T T T T C T T T T G T C T C T G G G
> 1 0 7 3
A G G A T C A T C A A C C A C C A G T A C G G G A C C C T G T C G A A C C T G C A C G A C T C T T G C T C A A G G A
A C C T C T A T G T T T C C C T C A T G T T G C T G T T C A A A A C C T T C G G A C G G A A A T T G C A C T T G T A T T
C C C A T C C C A T C A T C A T G G G C T T T C G G A A A A T T C C T A T G G G A G T G G G C C T C A G C C C G T T T
C T C C T G G C T C A G T T T A C T A G T G C C A T T T G T T C A G T G G T T C G C C G G G C T T T C C C C C A C T G T
C T G G C T T T C A G T T A T A T G G A T G A T G T G G T A T T G G G G G C C A A G T C T G T A C A A C A T C T T G A
G T C C C T T T A T A C C T C T G T T A C C A A T T T T C T T T T G T C T C T G G G
> 1 1 1 2
A G G A T C A T C A A C C A C C A G T A C G G G A C C C T G C C G A A C C T G C A C G A C T C T T G C T C A A G G A
A C C T C T A T G T T T C C C T C A T G T T G C T G T T C A A A A C C C T C G G A C G G A A A T T G C A C T T G T A T T
C C C A T C C C A T C A T C A T G G G C T T T C G G A A A A T T C C T A T G G G A G T G G G C C T C A G C C C G T T T
C T C C T G G C T C A G T T T A C T A G T G C C A T T T G T T C A G T G G T T C G C C G G G C T T T C C C C C A C T G T
C T G G C T T T C A G T T A T A T G G A T G A T G T G G T A T T G G G G G C C A A G T C T G T A C A A C A T C T T G A
G T C C C T T T A T A C C T C T G T T A C C A A T T T T C T T T T G T C T C T G G G
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A p p e n d ix  VII. Example of the NEXUS sequence alignment format
Three S gene fragments aligned.
# N E X U S
b e g in  ta x a ;
d im e n s io n s  n ta x = 3 ;  
t a x la b e l s
1 0 0 3
1 0 7 3
1 1 1 2
e n d ;
b e g in  c h a r a c te r s ;
d im e n s io n s  n c h a r = 3 3 8 ;
f o rm a t  d a t a ty p e = d n a  m i s s in g = N  g a p = - ;
m a t r ix
1 0 0 3
A G G A T C A T C A A C C A C C A G T A C G G G A C C C T G C C G A A C C T G C A C G A C T C T T G C T C A
A G G A A C C T C T A T G T T T C C C T C A T G T T G C T G T T C A A A A C C T T C G G A C
G G A A A T T G C A C T T G T A T T C C C A T C C C A T C A T C A T G G G C T T T C G G A A A A T T C C T A T
G G G A G T G G G C C T C A G C C C G T T T C T C C T G G C T C A G T T T A C T A G T G C
C A T T T G T T C A G T G G T T C G C C G G G C T T T C C C C C A T T G T C T G G C T T T T A G T T A T A T G G
A T G A T G T G G T A T T G G G G G C C A A G T C T G T A C A A C A T C T T G A G T C C
C T T T  A T A C C T C T G T T  A C C  A A T T T T C T T T T G T C T C T G G G
1 0 7 3
A G G A T C A T C A A C C A C C A G T A C G G G A C C C T G T C G A A C C T G C A C G A C T C T T G C T C A
A G G A A C C T C T A T G T T T C C C T C A T G T T G C T G T T C A A A A C C T T C G G A C
G G A A A T T G C A C T T G T A T T C C C A T C C C A T C A T C A T G G G C T T T C G G A A A A T T C C T A T
G G G A G T G G G C C T C A G C C C G T T T C T C C T G G C T C A G T T T A C T A G T G C
C A T T T G T T C A G T G G T T C G C C G G G C T T T C C C C C A C T G T C T G G C T T T C A G T T A T A T G G
A T G A T G T G G T A T T G G G G G C C A A G T C T G T A C A A C A T C T T G A G T C C
C T T T A T A C C T C T G T T A C C A A T T T T C T T T T G T C T C T G G G
1112
A G G A T C A T C A A C C A C C A G T A C G G G A C C C T G C C G A A C C T G C A C G A C T C T T G C T C A
A G G A A C C T C T A T G T T T C C C T C A T G T T G C T G T T C A A A A C C C T C G G A C
G G A A A T T G C A C T T G T A T T C C C A T C C C A T C A T C A T G G G C T T T C G G A A A A T T C C T A T
G G G A G T G G G C C T C A G C C C G T T T C T C C T G G C T C A G T T T A C T A G T G C
C A T T T G T T C A G T G G T T C G C C G G G C T T T C C C C C A C T G T C T G G C T T T C A G T T A T A T G G
A T G A T G T G G T A T T G G G G G C C A A G T C T G T A C A A C A T C T T G A G T C C
C T T T A T A C C T C T G T T A C C A A T T T T C T T T T G T C T C T G G G
e n d ;
b e g in  a s s u m p t io n s ;
o p t io n s  d e f ty p e ^ u n o r d ;
e n d
2 0 3
Appendix VIII. Example of the log likelihood values for different simulated trees.
A genotype E genotype E genotype + E genotype -
1328.12351 4038.09955 2202.85834 2131.48652
1333.4022 4057.57856 2238.27601 2140.69623
1336.97262 4080.44199 2268.61499 2144.87388
1337.2344 4088.87029 2282.8356 2146.43568
1339.89177 4091.42291 2285.38313 2147.89057
1341.37216 4091.95588 2286.43333 2150.09192
1344.0894 4093.08889 2294.32565 2153.06828
1345.10937 4096.42593 2302.09836 2153.32655
1346.28133 4096.48561 2306.17203 2153.45337
1348.19634 4098.51506 2307.21418 2154.05657
1349.84544 4100.65528 2311.09594 2154.25969
1350.13365 4101.4206 2314.9414 2154.94216
1350.20741 4103.95066 2315.04484 2155.09812
1352.01386 4105.33086 2317.17566 2155.77713
1352.31168 4105.48262 2318.33198 2156.05399
1353.79807 4106.32019 2320.21062 2156.39449
1354.23763 4106.97241 2320.74375 2158.91489
1354.79677 4107.73848 2321.84423 2159.52539
1356.31449 4108.72278 2322.31391 2159.74605
1356.52652 4110.27801 2323.25974 2160.31109
1356.8736 4110.2912 2323.46774 2160.60057
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